A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma
Phase: PHASE3
Conditions: Soft Tissue Sarcoma
Sponsor: Eli Lilly and Company

Protocol (d) I5B-MC-JGDJ 
 
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus 
Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft 
Tissue Sarcoma 
 
NCT02451943 
 
Approval Date: 12-Jan-2017 
 
 
 

I5B-MC-JGDJ(d) Clinical Protocol
Page 1
LY3012207
1.
Protocol I5B-MC-JGDJ(d)
A Randomized, Double-Blind, Placebo-Controlled, 
Phase 3 Trial of Doxorubicin plus Olaratumab versus 
Doxorubicin plus Placebo in Patients with Advanced or 
Metastatic Soft Tissue Sarcoma
Confidential Information
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the clinical investigation of 
olaratumab (LY3012207), unless such persons are bound by a confidentiality agreement 
with Eli Lilly and Company or its subsidiaries.  This document and its associated 
attachments are subject to United States Freedom of Information Act Exemption 4.
Olaratumab (LY3012207)
I5B-MC-JGDJ is a global, multicenter, randomized, double-blind, placebo-controlled, 
parallel-group Phase 3 trial that will compare the safety and efficacy in patients with 
advanced or metastatic STS after treatment with doxorubicin (75 mg/m
2 on Day 1) plus 
olaratumab (loading dose of 20 mg/kg on Days 1 and 8 in Cycle 1, followed by 15 mg/kg on 
Days 1 and 8 in subsequent cycles) versus doxorubicin (75 mg/m
2 on Day 1) plus placebo 
(on Days 1 and 8) in a 21-day cycle.  Patients will receive combination treatment for 
8 cycles, followed by monotherapy olaratumab or placebo until evidence of progressive 
disease (PD), unacceptable toxicity, death, or other withdrawal criteria are met.
Eli Lilly and Company
Indianapolis, Indiana USA 46285
Protocol Electronically Signed and Approved by Lilly on 29-Jan-2015.
Amendment (a) Electronically Signed and Approved by Lilly on 27-May-2015.
Amendment (b) Electronically Signed and Approved by Lilly on 04-Jan-2016.
Amendment (c) Electronically Signed and Approved by Lilly on 22-Jan-2016.
Amendment (d) Electronically Signed and Approved by Lilly on approval date provided 
below.
Approval Date: 12-Jan-2017 GMT

I5B-MC-JGDJ(d) Clinical Protocol
Page 2
LY3012207
2.
Synopsis
Study Rationale
This Phase 3 study is a global, multicenter, randomized, double-blind, placebo-controlled,
parallel-group study in which patients with metastatic or locally advanced soft tissue sarcoma 
(STS) who are not amenable to treatment with surgery or radiotherapy with curative intent will 
be treated with doxorubicin plus olaratumab versus doxorubicin plus placebo intravenously for 
8 cycles.  Patients without disease progression will be allowed to continue olaratumab or placebo 
monotherapy for >8 cycles.
Clinical Protocol Synopsis:  Study I5B-MC-JGDJ
Name of Investigational Product:  Olaratumab (LY3012207)
Title of Study:  A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab 
versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma
Number of Planned Patients:
Entered/Screened: Approximately 600
Enrolled/Randomized: Approximately 460
Completed (number of patients who will complete the overall 
survival [OS] endpoint): Approximately 322
Phase of Development:  3
Length of Study:  Approximately 4 years 
First patient visit:  14-Sep-2015
Planned last patient visit (excluding the continued access period):  3Q2019
Planned interim analysis:  60% (at least 194 overall survival [OS] events from the intention-to-treat [ITT] 
population)
Objectives:  The primary objective is to compare doxorubicin plus olaratumab versus doxorubicin plus placebo with 
respect to OS in 2 populations:
(1) Patients with advanced or metastatic soft tissue sarcoma (STS) not amenable to treatment with surgery or 
radiotherapy with curative intent
(2) Patients with advanced or metastatic leiomyosarcoma (LMS) not amenable to treatment with surgery or 
radiotherapy with curative intent
The secondary objectives of the study are to compare doxorubicin plus olaratumab versus doxorubicin plus placebo 
with respect to:

Progression-free survival (PFS)

Objective response rate (ORR) (complete response [CR] + partial response [PR])

Disease control rate (DCR; CR + PR + stable disease [SD])

Patient-reported outcomes (PROs):  Pain, Health-related Quality of Life (HRQoL), and health status 

Duration of response (DoR)

Duration of disease control (DDC)

Safety and tolerability

Pharmacokinetics (PK) and immunogenicity
Additional prespecified objectives include, but are not limited to:

Assessment of the association between biomarkers and clinical outcomes

Assessment of the association between clinical variables, such as histological subtypes, and clinical outcomes
Study Design:  Study I5B-MC-JGDJ is a global, multicenter, randomized, double-blind, placebo-controlled, 
parallel-group Phase 3 trial that will compare the efficacy and safety in patients with advanced or metastatic STS 
treated with doxorubicin (75 mg/m2 on Day 1) plus olaratumab (loading dose of 20 mg/kg on Days 1 and 8 in 
Cycle 1, followed by 15 mg/kg on Days 1 and 8 in subsequent cycles) versus doxorubicin (75 mg/m2 on Day 1) plus 
placebo (on Days 1 and 8) in a 21-day cycle.  Eligible patients will be randomized 1:1 into the 2 treatment options
and stratified as follows:

Number of prior systemic therapies for advanced/metastatic disease (0 versus ≥1)
Note: Any therapy administered in the adjuvant/neoadjuvant setting will not be considered as a prior line of 

I5B-MC-JGDJ(d) Clinical Protocol
Page 3
LY3012207
therapy here.

Histological tumor type (leiomyosarcoma versus liposarcoma versus undifferentiated pleomorphic versus other 
STS types)

Eastern Cooperative Oncology Group performance status (ECOG PS) (0 versus 1)

Region (North America versus Europe versus Rest of World [ROW])
Patients will receive combination treatment for 8 cycles followed by monotherapy olaratumab or placebo until 
evidence of progressive disease (PD), unacceptable toxicity, death, or other withdrawal criteria are met.  No 
crossover will be permitted.
Diagnosis and Main Criteria for Inclusion and Exclusions: Patients at least 18 years of age, ECOG PS 0 to 1, 
anthracycline naïve, with histologically confirmed, advanced or metastatic STS, and not amenable to treatment with 
surgical resection or radiotherapy with curative intent. Patients with gastrointestinal stromal tumor (GIST) or 
Kaposi’s sarcoma will be excluded.
Test Product, Dosage, and Mode of Administration:  Olaratumab: injection for intravenous (IV) use, supplied in 
single-use 500 mg/50 mL vials containing 10 mg/mL of product in histidine buffer, administered to patients as an IV
infusion at a loading dose of 20 mg/kg on Days 1 and 8 in Cycle 1, followed by 15 mg/kg on Days 1 and 8 in 
subsequent cycles. Cycles are 21 days in length.
Reference Therapy, Dose, and Mode of Administration:  Placebo:  injection for IV use, supplied in single-use 
vials, administered to patients as an IV infusion on Days 1 and 8. Doxorubicin:  commercial formulations will be 
used and administered intravenously.  Doxorubicin (75 mg/m2) is to be administered on Day 1 of each 21-day cycle, 
for 8 cycles.  Dexrazoxane: Commercially available dexrazoxane may be administered starting at Cycle 1 at a 10:1 
ratio (dexrazoxane:doxorubicin) at the investigator’s discretion, prior to the doxorubicin infusion for the prevention 
of cardiotoxicity and its use is recommended in patients receiving 5 or more cycles of doxorubicin. Dexrazoxane
should be administered after completion of the olaratumab/placebo infusion, prior to administration of doxorubicin.  
Doxorubicin should be administered within 30 minutes of receiving dexrazoxane.
Planned Duration of Treatment:  Treatment continues until there is evidence of disease progression, death, 
intolerable toxicity, or other withdrawal criteria are met.  Doxorubicin plus olaratumab/placebo will be administered
for 8 cycles, or until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria 
are met.  Patients who discontinue doxorubicin due to unacceptable toxicity prior to the completion of the planned 
8 cycles, may continue receiving single-agent olaratumab/placebo until there is evidence of disease progression, 
death, intolerable toxicity, or other withdrawal criteria are met.  Patients who complete 8 cycles of combination 
treatment will continue to receive olaratumab/placebo monotherapy at the same dose and schedule until there is 
documentation of disease progression, death, intolerable toxicity, or other discontinuation criteria are met.
Short-term follow-up (postdiscontinuation):  30 days (±7 days)
Long-term follow-up (postdiscontinuation): Patients who discontinue study treatment for reasons other than 
progression will be followed every 6 weeks (±7 days) until PD, thereafter every 2 months (±7 days) for the first 
2 years, then every 6 months (±14 days) until the patient’s death or overall study completion.
Continued access:  After study completion, patients on study treatment who continue to experience clinical benefit 
and no undue risks, in the opinion of the investigator, may continue to receive study treatment until one of the 
criteria for discontinuation is met.  A continued access follow-up visit will occur 30 days (±7 days) after 
discontinuation.
Criteria for Evaluation:
Efficacy:  Overall survival (time from randomization to death) is the primary per-patient measure for efficacy.
Radiographic assessments will be performed according to Response Evaluation Criteria in Solid Tumors (Response 
Evaluation Criteria in Solid Tumors [RECIST], Version 1.1) criteria every 6 weeks (±7 days) until radiographic 
documentation of PD.
The following additional efficacy measures will be determined for each patient, with planned statistical analyses 
specified in Section 12 and in the statistical analysis plan (SAP; a separate document). Specific definitions of each 
of these measures (such as defining events and censoring for each time to event endpoint) will be provided in the 
SAP.

Progression-free survival (PFS)

Objective Response Rate (ORR) 

Disease Control Rate (DCR)

I5B-MC-JGDJ(d) Clinical Protocol
Page 4
LY3012207

Time to first worsening of the mBPI-sf (Brief Pain Inventory Short Form Modified) “worst pain” score

Duration of response (DoR)

Duration of disease control (DDC)

Time to any progression (censoring for death without progression)

Time to any new metastases (censoring for death and for other type of PD)

New-metastases-free survival (nMFS)

Time to any progression based solely on increased sum of target lesions

Time to first worsening of the QLQ-C30 scale scores (for example, Global Health Status / Quality of Life 
score, Physical Functioning score, and Role Functioning score)

Time to first worsening of ECOG performance status 

Second PFS (PFS2) after end of study treatment while on subsequent anticancer therapy
Safety:  Safety will be evaluated based on reported adverse events (AEs), physical examinations, vital signs,
laboratory tests, electrocardiograms (ECGs), and results from echocardiograms (ECHOs) or multigated acquisition 
(MUGA) scans. Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRATM) 
and graded using the National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE), 
Version 4.0. Clinical laboratory toxicity will be graded using NCI-CTCAE criteria, Version 4.0.
Patient-Reported Outcomes (PROs): Pain will be assessed with the Brief Pain Inventory Short Form Modified 
[mBPI-sf], HRQoL will be assessed with The European Organization for Research and Treatment of Cancer Quality 
of Life Questionnaire Core 30 version 3.0 [EORTC QLQ-C30] and health state will be assessed with the 
EuroQol 5-Dimension 5-Level [EQ-5D-5L]. Patients will complete the instruments on Day 1 of every cycle and at
the 30-day short-term follow-up visit.  A full due diligence will be taken to collect PRO measures during long-term 
follow-up (every 6 weeks [±7 days] until PD, thereafter every 3 months [±2 weeks] for the first year, every 6 months 
[±2 weeks] the second year, then annually [±2 weeks] thereafter until the patient’s death or overall study 
completion).
Immunogenicity:  Blood samples will be collected to determine olaratumab antibodies in serum at baseline, during 
the study, and in the event of an olaratumab/placebo infusion-related reaction (IRR) serum will be collected as soon 
as possible after the onset, at the resolution, and 30 days (±3 days) after the IRR.
Pharmacokinetics:  Blood samples will be collected to assess the serum concentrations of olaratumab and the plasma 
concentration of doxorubicin. Serum concentrations of olaratumab will be assayed using a validated enzyme-linked 
immunosorbent assay (ELISA) method.  Doxorubicin concentrations in plasma will be analyzed using a validated 
liquid chromatography with tandem mass spectrometry (LC/MS/MS) assay.
Biomarkers:  Samples will be collected and analyses will be performed on biomarkers relevant to pathways 
associated with STS, the mechanism of action of olaratumab or doxorubicin, and/or cancer-related conditions, and 
may also be used for related research methods.  The evaluation of the samples may involve analysis of DNA, RNA, 
and/or proteins.
Statistical Methods:
The primary objective of this study is to compare doxorubicin plus olaratumab (investigational arm) versus 
doxorubicin plus placebo (control arm) with respect to OS in 2 populations:
(1)
Patients with advanced or metastatic STS not amenable to treatment with surgery or radiotherapy with 
curative intent (referred to below as the ITT population)
(2)
Patients with advanced or metastatic LMS not amenable to treatment with surgery or radiotherapy with 
curative intent
The study will be considered positive if either the ITT or LMS populations (or both) show a statistically significant 
improvement in OS.
Investigative sites will screen approximately 600 patients to enroll 460 patients in 1:1 randomization (230 patients in 
the investigational arm and 230 patients in the control arm).  Enrollment will be conducted so that approximately 
200 patients with LMS and 260 patients with other (non-leiomyosarcoma) histology will be randomized.  The final 
analysis will occur only after both a minimum of 131 OS events have been observed in randomized patients with 
LMS, and a minimum of 322 OS events have been observed in randomized patients overall.
The statistical analysis will be conducted using a statistical testing plan according to the graphical method of Maurer 
and Bretz (2013).  Under this testing scheme, the primary analysis for OS can be tested in both the LMS population 

I5B-MC-JGDJ(d) Clinical Protocol
Page 5
LY3012207
and in the full ITT population, splitting and sharing alpha so as to control the family-wise type 1 error rate across 
these 2 populations, across interim and final analyses, and also across a prespecified sequence of endpoints (OS and 
selected secondary endpoints).
The Lan-DeMets form of the O’Brien-Fleming alpha-spending function will be applied for OS and each selected 
secondary endpoint.
The final total of 131 OS events in the LMS population provides 80% statistical power for a one-sided log-rank test 
at a 0.005 alpha level, assuming the true OS hazard ratio (HR) in LMS patients is 0.55.
The final total of 322 OS events in the ITT population provides 80% statistical power for a one-sided log-rank test at 
a 0.02 significance level, assuming the true OS HR in STS patients is 0.723.
An interim efficacy analysis for OS is planned after 194 OS events (60% of the final OS events) have been observed
in the ITT population.  Time to event analyses at the interim and final analysis time points will be based on the 
stratified log-rank test, stratified by the randomization strata: number of prior systemic therapies for 
advanced/metastatic disease (0 versus ≥1), histological tumor type (leiomyosarcoma versus liposarcoma versus 
undifferentiated pleomorphic versus other STS types), and ECOG PS (0 versus 1).  The exact testing boundaries will
depend on the exact number of events and will be determined using an O’Brien-Fleming alpha spending function.  
OS survival curves, the median with 95% CI and survival rates at various time points for each treatment group will 
be estimated using Kaplan-Meier method (Kaplan and Meier 1958).  The HR will be estimated using a stratified Cox 
regression model, stratified by randomization strata).  All randomized patients, according to the ITT principle, will 
be included in the analysis of this endpoint.
The interim analysis will be performed by an independent Data Monitoring Committee (iDMC).  The iDMC Charter 
(a separate document) will provide detailed guidance for the conduct of the interim analysis. 
Safety:  Safety analyses will be performed on the safety population (that is, all randomized patients who received at 
least 1 dose, including a partial dose, of any study treatment, and will include summaries of incidences of 
treatment-emergent adverse events (TEAEs) by maximum CTCAE grade that occurred during the study treatment 
period or within approximately 30 days after the decision is made to discontinue study treatment.  Additionally, the 
following (but not limited to) safety-related outcomes will be summarized:  study treatment discontinuation due to 
TEAEs, deaths during the study treatment period or within 30 days after the decision is made to discontinue study 
treatment, treatment-emergent serious adverse events (SAEs) during the study treatment period or within 30 days 
after the decision is made to discontinue study treatment, hospitalizations, and transfusions during the study 
treatment period or within 30 days after the decision is made to discontinue study treatment.
Adverse events (AEs), including TEAEs, will be listed and summarized in frequency tables using MedDRA.  
Severity of AEs will be graded using CTCAE version 4.0.  Other safety data, such as laboratory tests, ECGs, 
echocardiogram (ECHO) or MUGA scans, and vital signs will be listed and summarized, if appropriate.
Patient-Reported Outcomes (PROs): For each instrument (mBPI-sf, EORTC QLQ-C30, and EQ-5D-5L), 
percentage compliance will be calculated as the number of completed assessments divided by the number of 
expected assessments (that is, patients still on study and alive). Data will be separately summarized by treatment 
and time point using descriptive statistics. Analyses of time to first worsening of pain as well as HRQoL domains 
and sub-domains will be conducted.
Immunogenicity:  Incidence of anti-olaratumab antibodies will be tabulated. Correlation to olaratumab drug level, 
activity, and safety will be assessed, as appropriate.
Pharmacokinetics:  The PK parameters of olaratumab will be computed by nonlinear mixed effect modelling using 
.  PK data collected for doxorubicin will be analyzed using descriptive methods.
Biomarkers: Analyses will be performed on biomarkers relevant to pathways associated with STS, the mechanism of 
action of olaratumab or doxorubicin, and/or cancer-related conditions.  Assay results will be summarized and 
correlated with clinical outcomes.

I5B-MC-JGDJ(d) Clinical Protocol
Page 6
LY3012207
3.
Table of Contents
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 
Trial of Doxorubicin plus Olaratumab versus Doxorubicin 
plus Placebo in Patients with Advanced or Metastatic Soft 
Tissue Sarcoma
Section
Page
1.
Protocol I5B-MC-JGDJ(d)  A Randomized, Double-Blind, Placebo-
Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus 
Doxorubicin plus Placebo in Patients with Advanced or Metastatic 
Soft Tissue Sarcoma............................................................................................................1
2.
Synopsis .............................................................................................................................2
3.
Table of Contents................................................................................................................6
4.
Abbreviations and Definitions...........................................................................................13
5.
Introduction ......................................................................................................................19
5.1.
Soft Tissue Sarcoma.....................................................................................................19
5.2.
Olaratumab Background...............................................................................................20
5.3.
Study Rationale............................................................................................................20
5.3.1.
Olaratumab Dose Rationale..................................................................................21
5.4.
Rationale for Amendments...........................................................................................22
5.4.1.
Rationale for Amendment (a)...............................................................................22
5.4.2.
Rationale for Amendment (b)...............................................................................22
5.4.3.
Rationale for Amendment (c)...............................................................................23
5.4.4.
Rationale for Amendment (d)...............................................................................23
6.
Objectives.........................................................................................................................24
6.1.
Primary Objective ........................................................................................................24
6.2.
Secondary Objectives...................................................................................................24
6.3.
Additional Prespecified Objectives...............................................................................24
7.
Study Population...............................................................................................................25
7.1.
Inclusion Criteria..........................................................................................................25
7.2.
Exclusion Criteria ........................................................................................................27
7.2.1.
Rationale for Exclusion of Certain Study Candidates ...........................................29
7.3.
Discontinuation............................................................................................................29
7.3.1.
Discontinuation of Inadvertently Enrolled Patients...............................................29
7.3.2.
Discontinuation of Patients...................................................................................29
7.3.3.
Patients who are Lost to Follow-Up .....................................................................30
7.3.4.
Discontinuation of Study Sites .............................................................................30

I5B-MC-JGDJ(d) Clinical Protocol
Page 7
LY3012207
7.3.5.
Discontinuation of the Study................................................................................31
8.
Investigational Plan...........................................................................................................32
8.1.
Summary of Study Design............................................................................................32
8.1.1.
Baseline and Study Treatment Period Assessments ..............................................34
8.1.2.
Postdiscontinuation Follow-Up Period Assessments.............................................36
8.1.3.
Study Completion and End of Trial......................................................................36
8.1.4.
Continued Access Period......................................................................................37
8.1.5.
Committees..........................................................................................................38
8.1.6.
Study Duration.....................................................................................................39
8.2.
Discussion of Design and Control ................................................................................39
9.
Treatment..........................................................................................................................40
9.1.
Treatments Administered .............................................................................................40
9.1.1.
Premedication ......................................................................................................42
9.2.
Materials and Supplies .................................................................................................42
9.2.1.
Olaratumab/Placebo .............................................................................................43
9.2.2.
Doxorubicin.........................................................................................................43
9.3.
Method of Assignment to Treatment ............................................................................44
9.4.
Selection and Timing of Doses.....................................................................................44
9.4.1.
Special Treatment Considerations ........................................................................45
9.4.1.1.
Dose Delays, Modifications, and Discontinuations .........................................45
9.4.1.1.1.
Olaratumab/Placebo..................................................................................47
9.4.1.1.1.1.
Infusion-Related Reactions .................................................................47
9.4.1.1.1.2.
Hematologic Toxicity..........................................................................48
9.4.1.1.1.3.
Nonhematologic Toxicity....................................................................48
9.4.1.1.2.
Doxorubicin..............................................................................................49
9.4.1.1.2.1.
Hematologic Toxicity..........................................................................49
9.4.1.1.2.2.
Cardiovascular Toxicity......................................................................50
9.4.1.1.2.3.
Hepatic Impairment.............................................................................50
9.4.1.1.2.4.
Nonhematologic Toxicity....................................................................50
9.5.
Blinding .......................................................................................................................51
9.5.1.
Emergency Unblinding ........................................................................................51
9.5.2.
Inadvertent Unblinding ........................................................................................51
9.6.
Concomitant Therapy...................................................................................................52
9.6.1.
Supportive Care ...................................................................................................52
9.6.1.1.
Dexrazoxane...................................................................................................52
9.6.1.2.
Granulocyte-Colony Stimulating Factors and Erythroid 
Growth Factors...............................................................................................53
9.6.1.3.
Transfusion of Blood Products........................................................................53

I5B-MC-JGDJ(d) Clinical Protocol
Page 8
LY3012207
9.6.1.4.
Anti-emetic Therapy.......................................................................................53
9.6.2.
Prohibited Therapies ............................................................................................53
9.6.2.1.
Effect of CYP3A4, CYP2D6, and P-gp Inhibitors and 
Inducers on Doxorubicin ................................................................................53
9.7.
Treatment Compliance .................................................................................................53
10.
Efficacy, Patient Reported Outcomes, Safety Evaluations, Sample 
Collection and Testing, and Appropriateness of Measurements .........................................55
10.1. Efficacy Measures........................................................................................................55
10.1.1.
Radiographic Assessments at Baseline and during Study 
Treatment.............................................................................................................55
10.1.2.
Radiographic Assessments during the Study Period 
Postdiscontinuation Follow-Up ............................................................................55
10.1.3.
Primary Efficacy Measure....................................................................................56
10.1.4.
Additional Efficacy Measures ..............................................................................56
10.2. Patient-Reported Outcomes/Resource Utilization .........................................................57
10.2.1.
mBPI-sf ...............................................................................................................57
10.2.2.
EORTC QLQ-C30 ...............................................................................................58
10.2.3.
EQ-5D-5L............................................................................................................59
10.2.4.
Resource Utilization.............................................................................................59
10.3. Safety Evaluations........................................................................................................59
10.3.1.
Adverse Events ....................................................................................................60
10.3.1.1.
Serious Adverse Events ..................................................................................61
10.3.1.2.
Suspected Unexpected Serious Adverse Reactions..........................................62
10.3.1.3.
Adverse Events of Special Interest (AESI)......................................................62
10.3.2.
Other Safety Measures .........................................................................................63
10.3.2.1.
Electrocardiograms.........................................................................................63
10.3.2.2.
Echocardiograms/MUGA Scans .....................................................................64
10.3.3.
Safety Monitoring ................................................................................................64
10.3.3.1.
Cardiac Events of Special Interest...................................................................65
10.3.4.
Complaint Handling.............................................................................................65
10.4. Sample Collection and Testing.....................................................................................66
10.4.1.
Samples for Study Qualification and Health Monitoring.......................................66
10.4.2.
Samples for Central Pathology Review and Translational 
Research ..............................................................................................................66
10.4.2.1.
Blood Samples for Plasma Collection.............................................................67
10.4.2.2.
Whole Blood Samples for DNA Collection.....................................................67
10.4.2.3.
Mandatory Tumor Tissue Samples..................................................................68
10.4.3.
Samples for Immunogenicity Research.................................................................68

I5B-MC-JGDJ(d) Clinical Protocol
Page 9
LY3012207
10.4.4.
Samples for Drug Concentration Measurements 
Pharmacokinetics .................................................................................................69
10.5. Appropriateness of Measurements................................................................................69
11.
Data Quality Assurance.....................................................................................................70
11.1. Data Capture System....................................................................................................70
12.
Sample Size and Statistical Methods .................................................................................71
12.1. Determination of Sample Size ......................................................................................71
12.2. Statistical and Analytical Plans.....................................................................................73
12.2.1.
General Considerations ........................................................................................73
12.2.1.1.
Analysis Populations ......................................................................................73
12.2.2.
Patient Disposition...............................................................................................73
12.2.3.
Patient Characteristics..........................................................................................74
12.2.4.
Concomitant Therapy...........................................................................................74
12.2.4.1.
Postdiscontinuation Therapy...........................................................................74
12.2.5.
Treatment Compliance .........................................................................................74
12.2.6.
Primary Outcome and Methodology.....................................................................74
12.2.7.
Other Analyses of Efficacy ..................................................................................74
12.2.7.1.
Progression-Free Survival...............................................................................74
12.2.7.2.
Additional Efficacy Analyses .........................................................................75
12.2.8.
Pharmacokinetic and Immunogenicity Analyses...................................................75
12.2.9.
Translational Research Analyses..........................................................................76
12.2.10. Analyses of Patient-Reported Outcomes (PROs) ..................................................76
12.2.11. Safety Analyses....................................................................................................76
12.2.12. Subgroup Analyses ..............................................................................................77
12.2.13. Interim Analyses..................................................................................................77
13.
Informed Consent, Ethical Review, and Regulatory Considerations ..................................78
13.1. Informed Consent.........................................................................................................78
13.2. Ethical Review.............................................................................................................78
13.3. Regulatory Considerations ...........................................................................................78
13.3.1.
Country-Specific Protocol Addenda .....................................................................79
13.3.2.
Investigator Information.......................................................................................79
13.3.3.
Protocol Signatures ..............................................................................................79
13.3.4.
Final Report Signature .........................................................................................79
14.
References ........................................................................................................................80

I5B-MC-JGDJ(d) Clinical Protocol
Page 10
LY3012207
List of Tables
Table
Page
Table JGDJ.1.
Treatment Regimens/Dosing Schedule ...................................................41
Table JGDJ.2.
General Guidelines for Olaratumab/Placebo Dose Modification 
Due to Hematologic Toxicity Deemed Related to 
Olaratumab/Placebo ...............................................................................48
Table JGDJ.3.
General Guidelines for Dose Modification Due to Nonhematologic 
Toxicities Related to Olaratumab/Placebo ..............................................49
Table JGDJ.4.
General Guidelines for Doxorubicin Dose Modification Due to 
Neutropenia............................................................................................50
Table JGDJ.5.
World Health Organization Pain Scale....................................................58
Table JGDJ.6.
Adverse Event and Serious Adverse Event Reporting Guidelines ...........60
Table JGDJ.7.
Bazett’s QT Heart Rate Correction Formula ...........................................63

I5B-MC-JGDJ(d) Clinical Protocol
Page 11
LY3012207
List of Figures
Figure
Page
Figure JGDJ.1.
Illustration of study design......................................................................33
Figure JGDJ.2.
Study period and continued access diagram. ...........................................37
Figure JGDJ.3.
Graphical representation of testing sequence...........................................72

I5B-MC-JGDJ(d) Clinical Protocol
Page 12
LY3012207
List of Attachments
Attachment
Page
Attachment 1.
Protocol JGDJ Study Schedule ...............................................................83
Attachment 2.
Protocol JGDJ Clinical Laboratory Tests................................................92
Attachment 3.
Protocol JGDJ Hepatic Monitoring Tests for Treatment-Emergent 
Abnormality ...........................................................................................94
Attachment 4.
Protocol JGDJ ECOG Performance Status..............................................95
Attachment 5.
Protocol JGDJ Creatinine Clearance Formula.........................................96
Attachment 6.
Protocol JGDJ RECIST Criteria 1.1........................................................97
Attachment 7.
Protocol JGDJ Pharmacokinetic, Immunogenicity, and 
Translational Research Sampling Schedule...........................................104
Attachment 8.
Protocol JGDJ CYP3A4, CYP2D6, and P-gp Inhibitors and 
Inducers of Doxorubicin.......................................................................106
Attachment 9.
Protocol JGDJ Amendment (d) Summary
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial 
of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo 
in Patients with Advanced or Metastatic Soft Tissue Sarcoma ..............108

I5B-MC-JGDJ(d) Clinical Protocol
Page 13
LY3012207
4.
Abbreviations and Definitions
Term
Definition
AC
Assessment Committee
AE
adverse event
Any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product and that does not necessarily have a causal 
relationship with this treatment.  An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
AESI
adverse event of special interest
ALT
alanine aminotransferase
ANC
absolute neutrophil count
ASCO
American Society of Clinical Oncology
AST
aspartate aminotransferase
AUC
area under the curve
audit
A systematic and independent examination of the trial-related activities and documents 
to determine whether the evaluated trial-related activities were conducted, and the data 
were recorded, analyzed, and accurately reported according to the protocol, applicable 
standard operating procedures (SOPs), good clinical practice (GCP), and the applicable 
regulatory requirement(s).
β-HCG
beta human chorionic gonadotropin
blinding
A procedure in which one or more parties to the trial are kept unaware of the treatment 
assignment(s).  Unless otherwise specified, blinding will remain in effect until final 
database lock.
A single-blind study is one in which the investigator and/or his staff are aware of the 
treatment but the patient is not, or vice versa, or when the Sponsor is aware of the 
treatment but the investigator and/his staff and the patient are not.  
A double-blind study is one in which neither the patient nor any of the investigator or 
Sponsor staff who are involved in the treatment or clinical evaluation of the patients are 
aware of the treatment received.
BSA
body surface area
BSC
best supportive care
CBR
clinical benefit rate
CI
confidence interval
CNS
central nervous system

I5B-MC-JGDJ(d) Clinical Protocol
Page 14
LY3012207
collection database
A computer database where clinical trial data are entered and validated.
companion diagnostic
An in vitro diagnostic device (assay or test) that provides information that is essential 
for the safe and effective use of a corresponding therapeutic product
complaint
A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance
Adherence to all the trial-related requirements, good clinical practice (GCP) 
requirements, and the applicable regulatory requirements.
continued access 
period
The period between study completion and end of trial during which patients on 
olaratumab who continue to experience clinical benefit and no undue risks may 
continue to receive olaratumab until one of the criteria for discontinuation is met. 
CR
complete response
CrCl
creatinine clearance
CRF/eCRF
case report form/electronic case report form
Sometimes referred to as clinical report form:  A printed or electronic form for 
recording study participants’ data during a clinical study, as required by the protocol.
CRP
clinical research physician
Individual responsible for the medical conduct of the study.  Responsibilities of the 
CRP may be performed by a physician, clinical research scientist, global safety 
physician, or other medical officer.
CSFs
colony-stimulating factors
CT
computed tomography
CTCAE
Common Terminology Criteria for Adverse Events
CTS
change in tumor size
A measure of tumor dynamics from which tumor response is derived.  Tumor size is the 
sum of tumor measurements across all target tumors at a given evaluation (RECIST 
criteria).
DCR
disease control rate
DDC
duration of disease control
DoR
duration of response
DNA
deoxyribonucleic acid
ECG
electrocardiogram
ECHO
Echocardiogram

I5B-MC-JGDJ(d) Clinical Protocol
Page 15
LY3012207
ECOG
Eastern Cooperative Oncology Group
end of trial
End of trial is the date of the last visit or last scheduled procedure for the last patient.
enroll
The act of assigning a patient to a treatment.  Patients who are enrolled in the trial are 
those who have been assigned to a treatment.
enter
Patients entered into a trial are those who sign the informed consent form directly or 
through their legally acceptable representatives.
EORTC QLQ-C30
The European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire Core 30
EQ 5D-5L
EuroQol 5-Dimension 5-Level
ERB/IRB
ethical review board/institutional review board
A board or committee (institutional, regional, or national) composed of medical and 
nonmedical members whose responsibility is to verify that the safety, welfare, and 
human rights of the patients participating in a clinical trial are protected.
ESAs
erythropoiesis-stimulating agents
evaluable patients
Patients must have received at least 1 dose of study therapy and have either started 
treatment in Cycle 3 or discontinued all study treatment prior to Cycle 3 due to any 
reasons.  This population applies only to the safety interim analyses.
FDA
Food and Drug Administration
FFPE
formalin-fixed paraffin embedded
FSH
follicle-stimulating hormone
GCP
good clinical practice
GIST
gastrointestinal stromal tumors
GnRH
gonadotropin-releasing hormone
H0
null hypothesis
Ha
alternative hypothesis
HIV
human immunodeficiency virus
HR
hazard ratio
HRQoL
Health Related Quality of Life
IB
Investigator’s Brochure
ICF
informed consent form
ICH
International Conference on Harmonisation

I5B-MC-JGDJ(d) Clinical Protocol
Page 16
LY3012207
IDMC
independent data monitoring committee
IG/IK
Immunogenicity
IgG1
immunoglobulin G, subclass 1
IND
Investigational New Drug application
informed consent
A process by which a patient voluntarily confirms his or her willingness to participate 
in a particular trial, after having been informed of all aspects of the trial that are relevant 
to the patient’s decision to participate.  Informed consent is documented by means of a 
written, signed, and dated informed consent form.  
INR
International Normalized Ratio
interim analysis
An interim analysis is an analysis of clinical trial data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
investigational 
product (IP)
A pharmaceutical form of an active ingredient substance or placebo being tested, or 
used as a reference, in a clinical trial.  Investigational product (IP) includes a product 
with a marketing authorization when:
1.
used or assembled (formulated or packaged) in a way different from the 
authorized form,
2.
used for an unauthorized indication, or 
3.
used to gain further information about the authorized form.
investigator
A person responsible for the conduct of the clinical trial at a trial site.  If a trial is 
conducted by a team of individuals at a trial site, the investigator is the responsible 
leader of the team and may be called the principal investigator.
IRB
Institutional Review Board
IRR
infusion-related reaction
ITT
intention-to-treat
The principle that asserts that the effect of a treatment policy can be best assessed by 
evaluating on the basis of the intention to treat a patient (that is, the planned treatment 
regimen) rather than the actual treatment given.  It has the consequence that patients 
allocated to a treatment group should be followed up, assessed, and analyzed as 
members of that group irrespective of their compliance to the planned course of 
treatment.
IV
Intravenous
IWRS
interactive web-response system
legal representative
An individual, judicial, or other body authorized under applicable law to consent on 
behalf of a prospective patient to the patient’s participation in the clinical study.
Lilly Safety System
Global safety database that tracks and reports serious adverse and spontaneous events 
occurring while using a drug/drug delivery system.

I5B-MC-JGDJ(d) Clinical Protocol
Page 17
LY3012207
LLN
Lower Level of Normal
LMS
leiomyosarcoma
mBPI-SF
Brief Pain Inventory Short Form Modified
MedDRA
Medical Dictionary for Regulatory Activities
MRI
magnetic resonance imaging
MUGA
multigated acquisition
NCI
National Cancer Institute
ORR
objective response rate
OS
overall survival
patient
A study participant who has the disease or condition for which the investigational 
product is targeted.
PD
progressive disease
PDA
personal data assistant
PDGF
platelet-derived growth factor
PDGFRα
platelet-derived growth factor receptor alpha
PDGFRβ
platelet-derived growth factor receptor beta
PET
positron emission tomography
PFS
progression-free survival
PK
pharmacokinetics
PPS
per protocol set
The set of data generated by the subset of patients who sufficiently complied with the 
protocol to ensure that these data would be likely to exhibit the effects of treatment, 
according to the underlying scientific model.
PR
partial response
PRO
patient-reported outcome
PS
performance status
PT
Preferred Term or prothrombin time
PTT
partial thromboplastin time
QTc
corrected QT interval

I5B-MC-JGDJ(d) Clinical Protocol
Page 18
LY3012207
randomize
the process of assigning patients to an investigational group on a random basis
RECIST
Response Evaluation Criteria in Solid Tumors
reporting database
A point-in-time copy of the collection database.  The final reporting database is used to 
produce the analyses and output reports for interim or final analyses of data.
re-screen
to screen a patient who was previously declared a screen failure for the same study
ROW
rest of the world
SAE
serious adverse event
SAP
Statistical Analysis Plan
screen
The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study.  In this study, 
screening involves invasive or diagnostic procedures and/or tests (for example, 
diagnostic psychological tests, x-rays, blood draws).  For this type of screening, 
informed consent for these screening procedures and/or tests shall be obtained; this 
consent may be separate from obtaining consent for the study.
screen failure
patient who does not meet one or more criteria required for participation in a trial
SD
stable disease
SOC
System Organ Class
STS
soft tissue sarcoma
Study completion
This study will be considered complete after the final analysis/evaluation of overall 
survival is performed.  
SUSARs
suspected unexpected serious adverse reactions 
TEAE
treatment-emergent adverse event
Any untoward medical occurrence that either occurs or worsens at any time after 
treatment baseline and that does not necessarily have to have a causal relationship with 
this treatment.
TPO
third-party organization
TTP
time to progression
UK
United Kingdom
ULN
upper limit of normal
US
United States
VEGF
vascular endothelial growth factor
VEGFR2
vascular endothelial growth factor receptor-2

I5B-MC-JGDJ(d) Clinical Protocol
Page 19
LY3012207
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 
Trial of Doxorubicin plus Olaratumab versus Doxorubicin 
plus Placebo in Patients with Advanced or Metastatic Soft 
Tissue Sarcoma
5.
Introduction
5.1.
Soft Tissue Sarcoma
Soft tissue sarcoma (STS) is a heterogeneous group of tumors that arise mainly from embryonic 
mesoderm, with some neuroectodermal contribution and differentiation to non-epithelial 
extraskeletal tissue including muscle, fat, and fibrous tissue (D’Angelo et al. 2014).  There are 
approximately 50 tumor subtypes of STS (Sharma et al. 2013) and they can be located anywhere 
in the body. This is a rare tumor group that comprises approximately 1% of adult cancers with 
an annual incidence of the disease in the United Kingdom (UK) and United States (US), 
respectively, of 3300 (ESMO 2014) and 10,000 (ACS 2014).  Soft tissue sarcoma is best treated 
by multidisciplinary teams specialized in the management of these tumors (Linch et al. 2014).
When the disease is localized, it is usually treated with curative intent using surgical resection 
with or without radiotherapy and chemotherapy. Unfortunately, STS recurs frequently as locally 
inoperable or metastatic disease, at which point systemic therapy plays a prominent role in the 
multidisciplinary management of this tumor.
Cytotoxic chemotherapy has been the mainstay therapy for treating advanced stage STS, 
providing overall response rates of about 25% in the first-line setting (Linch et al. 2014).
Despite the use of chemotherapy, advanced-stage STS is almost invariably fatal and there is a 
clear need to find novel and effective therapies.
For many decades, anthracycline based chemotherapy has been the standard first-line option for 
patients with metastatic STS. A recent Phase 3 trial performed by the European Organization for 
the Research and Treatment of Cancer (EORTC) randomized patients with STS to receive 
doxorubicin with or without ifosfamide (Judson et al. 2014). Patients treated with the 
combination achieved a significantly higher response rate and progression-free survival (PFS) 
compared with those randomized to single agent doxorubicin. However, there was no significant 
difference in overall survival (OS) between the 2 treatment arms. In view of these findings, 
single-agent doxorubicin is considered the standard treatment option for many patients with 
metastatic STS (NCCN 2011; ESMO 2014; Schöffski et al. 2014). Doxorubicin and ifosfamide 
are often reserved for patients with symptomatic disease or for those in whom down staging 
could result in surgical resection.
A number of randomized Phase 3 trials have demonstrated that dexrazoxane significantly 
reduces the risk of anthracycline-associated cardiotoxicity, with no effect on PFS or OS (Jones 
2008).

I5B-MC-JGDJ(d) Clinical Protocol
Page 20
LY3012207
5.2.
Olaratumab Background
Olaratumab is a recombinant human immunoglobulin G subclass 1 (IgG1)-type monoclonal 
antibody that binds to platelet-derived growth factor receptor alpha (PDGFRα).  This antibody
possesses high affinity binding for PDGFRα and blocks platelet-derived growth factor 
(PDGF)-AA, -BB, and -CC from binding to the receptor. In addition to blocking ligand-induced 
cell mitogenesis and receptor autophosphorylation, olaratumab inhibits ligand-induced
phosphorylation of the downstream signaling molecules Akt and mitogen-activated protein
kinase (MAPK).
PDGF/PDGFRα signaling plays a role in both organ and tissue development, as well as in 
pathogenesis of nonmalignant diseases (for example, pulmonary fibrosis) and malignant cancers.  
Many cancer types have been shown to consistently express PDGFRα on tumor tissues, 
including osteosarcoma, chondrosarcoma, prostate cancer, breast cancer, ovarian cancer, and 
others.  In malignant disease, the PDGF/PDGFRα axis is effective in promoting tumor growth 
and proliferation through both autocrine and paracrine mechanisms.  PDGFRα is expressed on 
stromal cells, as well as the cancer cells themselves, within certain tumors.  Furthermore, studies 
have shown that PDGF/PDGFRα signaling affects tumor vasculature through paracrine 
mediation of vascular endothelial growth factor (VEGF) production (Shah et al. 2010).
5.3.
Study Rationale
Previously reported data support the molecule being advanced in human trials, including the 
Sponsor’s Phase 1b/2 trial (Study I5B-MC-JGDG [JGDG]), titled ‘A Phase 1b/2 Randomized 
Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα 
Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma.’ The 
investigational Arm A received olaratumab (15 mg/kg) on Day 1 and Day 8 plus doxorubicin 
(75 mg/m²) on Day 1 of each 21-day cycle for up to 8 cycles. The control Arm B received 
doxorubicin (75 mg/m²) on Day 1 of each 21-day cycle for up to 8 cycles.  As of a data cutoff 
date of 16 May 2015, the combination of olaratumab and doxorubicin in this trial showed a
statistically significant and clinically meaningful improvement in median OS (11.8-month 
improvement; hazard ratio [HR]=0.463; p=0.0003) over doxorubicin alone.  Furthermore, in the 
primary analysis (using the intention-to-treat [ITT] population based on investigator assessment), 
the study met the protocol-defined final significance level for PFS (2-sided alpha=0.1999). The 
combination of olaratumab and doxorubicin improved median PFS by 2.5 months over 
doxorubicin alone (stratified HR=0.672 [95% confidence interval (CI): 0.442, 1.021]; p=0.0615), 
corresponding to a 32.8% reduction in the risk of progression or death.  Grade ≥3 treatment-
emergent adverse events (TEAEs) were reported in 79.7% of patients in the investigational Arm 
A and 69.2% of patients in the control Arm B.  Grade ≥3 adverse events (AEs) occurring in at 
least 10% of patients in Arm A included neutropenia (consolidated term), anemia (consolidated 
term), and febrile neutropenia.  In Arm B, the Grade ≥3 AEs occurring in at least 10% of patients 
included febrile neutropenia and neutropenia (consolidated term).  The safety profile of the 
combination of olaratumab and doxorubicin was consistent with the known toxicities of 
doxorubicin.  

I5B-MC-JGDJ(d) Clinical Protocol
Page 21
LY3012207
The proposed study is a Phase 3 trial of the efficacy and safety of olaratumab in combination 
with doxorubicin for the treatment of advanced or metastatic STS that is not amenable to 
treatment with surgical resection or radiotherapy with curative intent.
More information about the known and expected benefits, risks and reasonably anticipated AEs 
of olaratumab may be found in the Investigator’s Brochure (IB).  Information on AEs expected 
to be related to olaratumab may be found in Section 7 (Development Core Safety Information) of 
the IB.  Information on serious adverse events (SAEs) expected in the study population 
independent of drug exposure and that will be assessed by the Sponsor in aggregate, periodically 
during the course of the study, may be found in Section 6 (Effects in Humans) of the IB.
5.3.1. Olaratumab Dose Rationale
The current dose-selection strategy for Phase 3 Study JGDJ is based on the integrated safety, 
efficacy, and PK data for olaratumab across previous Phase 1 and Phase 2 studies.
In 2 Phase 1 dose-escalation trials (JGDC and JGDF) and in the 2 Phase 2 monotherapy studies 
(JGDE and JGDH), single-agent olaratumab has consistently been well tolerated, with no 
dose-limiting toxicities observed up to a dose of 20 mg/kg administered every 2 weeks and up to 
a dose of 15 mg/kg administered of Day 1 and Day 8 of a 21-day cycle.  When used in 
combination with liposomal doxorubicin in Study JGDA (olaratumab dose of 20 mg/kg every 
2 weeks), and with paclitaxel/carboplatin in Study JGDB (olaratumab dose of 15 mg/kg Day 1 
and Day 8 every 3 weeks), a higher rate of toxicities such as neutropenia and infections was
observed versus the comparator agents.  In Study JGDG, an increase in neutropenia and 
mucositis, but not in neutropenic sepsis or febrile neutropenia, has been observed compared to 
single-agent doxorubicin.  Overall, these toxicities are consistent with the toxicity profile of the 
combination agents used, and are considered monitorable and acceptable for the patient 
populations studied.
Interim survival data from Study JGDG show the combination of olaratumab 15 mg/kg with 
doxorubicin 75 mg/m2 provides a significant benefit compared to single-agent doxorubicin in 
patients with advanced metastatic STS without an increase in serious toxicity.  A matched 
case-control analysis per exposure quartiles based on the trough olaratumab serum concentration 
at the end of Cycle 1 (Cmin,1 < 61 µg/mL, N=15) tend to experience disease progression within 
the first 2 cycles of treatment, and unlike the other quartiles, did not show PFS or OS 
improvement.  Interim results from a population PK (PopPK) model performed on PK data from 
4 studies (JGDB, JGDE, JGDG, and JGDH) indicate that steady-state olaratumab serum levels 
are not achieved until Cycle 3.  Together, these findings suggest that clinical outcome for the 
lowest exposure quartile could be improved if patients were able to achieve therapeutic 
steady-state serum concentration levels (Cmin,1 ≥ 61 µg/mL) of olaratumab earlier in treatment, 
before disease progression.
Simulations performed with the current PK model indicate that loading doses of 20 mg/kg 
administered on Day 1 and Day 8 of Cycle 1 would allow steady-state olaratumab serum levels
to be achieved with the first administration and would minimize the number of patients whose 
Cmin,1 falls below 61 µg/mL during the first 2 cycles.  Additionally, a dose of 20 mg/kg 

I5B-MC-JGDJ(d) Clinical Protocol
Page 22
LY3012207
olaratumab administered on Day 1 and Day 8 during the first cycle, followed by 15 mg/kg 
administered on Day 1 and Day 8 of all the subsequent cycles, is predicted to yield maximum 
serum concentrations within the overall range observed in Study JGDG.  Therefore, olaratumab 
safety risks related to high serum concentrations or exposure using this loading dose approach 
are expected to be similar to those in Study JGDG.
The dosing strategy adopted for Study JGDJ therefore consists of a loading cycle wherein a dose 
of 20 mg/kg will be administered on Day 1 and Day 8, followed by 15 mg/kg administered on 
Day 1 and Day 8 of every subsequent cycle.  This dosing strategy is expected to minimize the 
number of patients exposed to sub-therapeutic olaratumab serum levels without an increased risk 
of toxicity, thereby optimizing the benefit-risk ratio.
5.4.
Rationale for Amendments
5.4.1. Rationale for Amendment (a)
The rationale for amendment (a) was based on feedback received from global regulatory 
authorities and compliance with local regulatory requirements for submissions.  Major changes 
for amendment (a) included the following:  

Leiomyosarcoma (LMS) was added as a specific population to be tested within the 
primary objective, and is now co-primary with the STS (ITT) population.

Pleomorphic was added to the stratifications factors

Due to regional/institutional differences dexrazoxane dosing was modified

PFS2 was added to the efficacy endpoints

Cardiovascular monitoring was increased

Gatekeeping methods have been included for OS, PFS, ORR, and DoR

Grade 1 liposarcoma patients are now included under certain conditions

The olaratumab dosing regimen was modified

Management of infusion-related reactions was modified

Single interim analysis will be performed based on 60% of overall OS events (194) in the 
ITT population and 72 events from the LMS

Analysis of OS will be based on the stratified log-rank test analyzed by the randomization 
strata, excluding region.
5.4.2. Rationale for Amendment (b)
The rationale for amendment (b) was based on global regulatory authority feedback, regulatory 
guidance and compliance with local regulatory requirements for submissions.  Additional 
changes were made by the sponsor to address issues of subject safety and to improve the 
efficiency of study implementation and conduct.  Major changes for amendment (b) included the 
following:  

Exclusion criteria were deleted

Grade 4 nonhematologic toxicity as related to study therapy is now considered a basis for 
study drug discontinuation

I5B-MC-JGDJ(d) Clinical Protocol
Page 23
LY3012207

Duration of Response was deleted from secondary objectives.

O’Brien-Fleming alpha spending will now be used for all efficacy boundaries

bisphosphonate osteoclast inhibitors are now allowed, denosumab is still not permited.
5.4.3. Rationale for Amendment (c)
The rationale for amendment (c) was based on global regulatory authority feedback, regulatory 
guidance and compliance with local regulatory requirements for submissions.  Additional 
changes were made by the sponsor to address issues of subject safety and to improve the 
efficiency of study implementation and conduct.  Major changes for amendment (c) included the 
following:  

Germany was directed to refer to Addendum (7)
5.4.4. Rationale for Amendment (d)
The rationale for amendment (d) was to increase subject safety and to improve the efficiency of 
study implementation and conduct.  Major changes for amendment (d) included the following:  

Patients receiving anticoagulants are now eligible to participate

Long-term follow-up for survival and patient reported outcome collection were updated 
so that these events are concurrent with the collection of ECG data

Efficacy interim stopping rules were removed from the protocol plan, as the intention is 
to continue the study until the final analysis with the sponsor remaining blinded to 
aggregate data by study arm until the final analysis.

Urine protein creatinine ratio of spot urine can now be used in place of 24-hour urine 
protein excretion
See Attachment 9 for more details.

I5B-MC-JGDJ(d) Clinical Protocol
Page 24
LY3012207
6.
Objectives
6.1.
Primary Objective
The primary objective is to compare doxorubicin plus olaratumab versus doxorubicin plus 
placebo with respect to OS in 2 populations:
(1) Patients with advanced or metastatic STS not amenable to treatment with surgery or 
radiotherapy with curative intent
(2) Patients with advanced or metastatic leiomyosarcoma (LMS) not amenable to treatment 
with surgery or radiotherapy with curative intent
6.2.
Secondary Objectives
The secondary objectives of the study are to compare doxorubicin plus olaratumab versus 
doxorubicin plus placebo as follows:

PFS

Objective response rate (ORR) (complete response [CR] + partial response [PR])

Disease control rate (DCR) (CR + PR + stable disease [SD])

Patient-reported Outcomes (PROs): Pain, Health-related Quality of Life (HRQoL), and 
health status

Duration of response (DoR)

Duration of disease control (DDC)

Safety and tolerability

PK and immunogenicity
6.3.
Additional Prespecified Objectives

Assessment of the association between biomarkers and clinical outcomes

Assessment of clinical variables, such as histological subtypes, and clinical outcomes

I5B-MC-JGDJ(d) Clinical Protocol
Page 25
LY3012207
7.
Study Population
Eligible patients will have a histological diagnosis by local pathology review of advanced or 
metastatic STS, not amenable to treatment with surgical resection or radiotherapy with curative 
intent.
All patients meeting the eligibility requirements will be considered for enrollment regardless of 
race, religion, or gender.  The investigator or the Sponsor will not grant exceptions to eligibility 
criteria.  The duration of the screening period is 14 days for the majority of procedures 
(Attachment 1); certain noted procedures may be performed within 28 days of randomization.  
Individuals who do not meet the criteria for participation in this study within the extended 
28-day screening period (screen failure) may be re-screened.  Note that repeating laboratory tests 
during the 28-day screening period does not constitute re-screening.  Screening laboratory tests 
may not be repeated more than once to meet eligibility during the 28-day screening period.  If a 
repeat screening laboratory value meets eligibility, it is recommended that the test is rechecked 
to confirm stability.
Patients may be considered for re-screening after discussion with the Lilly study physician or 
designee.  Patients may be re-screened up to 1 time.  The interval between re-screenings should 
be at least 28 days.  Patients who will be re-screened must sign a new informed consent form 
(ICF) and will be assigned a new identification number.
Prospective approval of protocol deviations to recruitment and enrollment criteria (also known as 
protocol waivers or exemptions) is not permitted.
7.1.
Inclusion Criteria
Patients are eligible to be included in the study only if they meet all of the following criteria:
[1]
The patient signed an ICF and authorization for release of health information for
research prior to any study-specific procedures being performed.
[2]
The patient is aged ≥18 years at study entry.
[3]
The patient has histologically confirmed diagnosis of locally advanced unresectable or 
metastatic STS not amenable to curative treatment with surgery or radiotherapy.  
Patients with a diagnosis of Grade 1 liposarcoma are eligible if there is histological or 
radiographic evidence of evolution to more aggressive disease.  Patients with Kaposi’s 
sarcoma and gastrointestinal stromal tumors (GIST) will be excluded.
Note: Evidence of disease progression is required for patients that are not newly 
diagnosed. 
[4]
The patient has measurable or nonmeasurable but evaluable disease as defined by the 
Response Evaluation Criteria in Solid Tumors (RECIST 1.1, Eisenhauer et al. 2009; 
refer to Attachment 6).  Tumors within a previously irradiated field will be designated 
as “nontarget” lesions unless progression is documented or a biopsy is obtained to 
confirm persistence at least 90 days following completion of radiotherapy.

I5B-MC-JGDJ(d) Clinical Protocol
Page 26
LY3012207
[5]
The patient has a performance status 0-1 on the Eastern Cooperative Oncology Group 
(ECOG) scale (refer to Attachment 4).
[6]
The patient has not received any previous treatment with anthracyclines.
[7]
The patient may have had any number of prior systemic cytotoxic therapies for 
advanced/metastatic disease and are considered appropriate candidates for 
anthracycline therapy. All previous anticancer treatments must be completed ≥3 weeks 
(21 days) prior to first dose of study drug.
[8]
The patient has resolution of adverse events and of all clinically significant toxic effects 
of prior locoregional therapy, surgery, radiotherapy, or systemic anticancer therapy to 
≤Grade 1, by National Cancer Institute - Common Terminology Criteria for Adverse 
Events (NCI-CTCAE) Version 4.0.
[9]
Availability of tumor tissue is mandatory for study eligibility. The patient must have 
consented to provide archived formalin-fixed paraffin embedded (FFPE) tumor tissue 
or be subject to a pre-treatment re-biopsy of primary or metastatic tumor tissue for 
future central pathology review and translational research (if archived tissue is 
unavailable) (refer to Section 10.4.2.3 regarding tissue collection parameters).
[10] The patient has adequate hematologic, organ, and coagulation function within 2 weeks 
(14 days) prior to randomization:

Absolute neutrophil count (ANC) ≥1.5 x 109/L.  Granulocyte colony-stimulating 
factor (G-CSF) cannot be administered within 2 weeks (14 days) prior to 
randomization.

Platelet count ≥100 x 109/L

Hemoglobin ≥9.0 g/dL.  No transfusions are allowed within 2 weeks (14 days)
prior to randomization.

The creatinine clearance is ≥45 mL/min (refer to Attachment 5 for the 
Cockcroft-Gault formula)

Proteinuria ≤1000 mg in 24 hours (if routine urinalysis indicates ≥2+ proteinuria)

Total bilirubin below upper limit of normal (ULN) (except for patients with
Gilbert’s Syndrome, who must have a total bilirubin <3 mg/dL)

Alanine aminotransferase/aspartate aminotransferase (AST/ALT) ≤3.0 × ULN; if 
the liver has tumor involvement, AST and ALT ≤5.0 × ULN are acceptable.

The patient has an adequate coagulation function as defined by International 
Normalized Ratio (INR) or prothrombin time (PT) ≤1.5 x ULN, and partial 
thromboplastin time (PTT or aPTT) ≤1.5 x ULN if not receiving anticoagulation 
therapy. For patients receiving anticoagulants, exceptions to these coagulation 
parameters are allowed if they are within the intended or expected range for their 
therapeutic use. Patients must have no history of active bleeding (defined as 
within 14 days of first dose of study drug) or pathological condition that carries a 

I5B-MC-JGDJ(d) Clinical Protocol
Page 27
LY3012207
high risk of bleeding (for example, tumor involving major vessels or known 
esophageal varices).
[11] The patient has left ventricular ejection fraction (LVEF) ≥50% assessed within 28 days 
prior to randomization.
[12] Females of child-bearing potential must have a negative serum pregnancy test within 
7 days prior to randomization.
(a) Exceptions: Females not of child-bearing potential due to surgical 
sterilization (at least 6 weeks following surgical bilateral oophorectomy 
with or without hysterectomy or tubal ligation) confirmed by medical 
history or menopause.
A “postmenopausal woman” is a woman meeting either of the following criteria:

spontaneous amenorrhea for at least 12 months, not induced by a medical 
condition such as anorexia nervosa and not taking medications during the 
amenorrhea that induced the amenorrhea (for example, oral contraceptives, 
hormones, gonadotropin releasing hormone, antiestrogens, selective estrogen 
receptor modulators (SERMs), or chemotherapy

spontaneous amenorrhea for 6 to 12 months and a follicle-stimulating hormone 
(FSH) level >40 mIU/mL
[13] Females of child-bearing potential and males and must agree to use highly effective
contraceptive precautions during the trial and up to 6 months following the last dose of 
study drug.  A highly effective method of birth control is defined as one that results in a 
low failure rate (that is, <1% per year) when used consistently and correctly, such as 
implants, injectables, combined oral contraceptives, some intrauterine contraceptive 
devices (IUDs), sexual abstinence, or a vasectomized partner.
[14] The patient has, in the opinion of the investigator, a life expectancy of at least 
3 months.
7.2.
Exclusion Criteria
Patients will be excluded from the study if they meet any of the following criteria:
[15] The patient is diagnosed with GIST or Kaposi sarcoma.
[16] The patient has active central nervous system (CNS) or leptomeningeal metastasis 
(brain metastasis) at the time of randomization. Patients with a history of a CNS 
metastasis previously treated with curative intent (for example, stereotactic radiation or 
surgery) that have not progressed on follow-up imaging, have been asymptomatic for at
least 60 days and are not receiving systemic corticosteroids and or/anticonvulsants, are 
eligible. Patients with signs or symptoms of neurological compromise should have 
appropriate radiographic imaging performed before randomization to rule out brain 
metastasis.

I5B-MC-JGDJ(d) Clinical Protocol
Page 28
LY3012207
[17] The patient has received prior treatment with doxorubicin, epirubicin, idarubicin, and/or 
other anthracyclines or anthracenediones; the patient has received treatment with 
olaratumab or has participated in a prior olaratumab trial. 
[18] The patient had prior radiotherapy of the mediastinal/pericardial area or whole pelvis 
radiation.
[19] The patient has history of another primary cancer, with the exception of a) curatively 
treated non-melanomatous skin cancer, b) curatively treated cervical carcinoma in situ, 
c) other primary nonhematologic malignancies or solid tumor treated with curative 
intent, no known active disease and no treatment administered during the last 3 years 
prior to randomization.
[20] The patient has electively planned or will require major surgery during the course of the 
study.
[21] The patient has uncontrolled intercurrent illness including, but not limited to, an 
ongoing/active infection requiring parenteral antibiotics, symptomatic congestive heart 
failure (CHF), left ventricular dysfunction (LVEF <50%), severe myocardial 
insufficiency, cardiac arrhythmia, cardiomyopathy, or a psychiatric illness/social 
situation that would limit compliance with study requirements.
[22] The patient has unstable angina pectoris, angioplasty, cardiac stenting, or myocardial 
infarction within 6 months of randomization.
[23] Exclusion criterion [23] has been deleted.
[24] The patient has a QTcB interval of >450 msec for males and >470 msec for females on 
screening electrocardiogram (ECG) utilizing Bazett’s correction (refer to formula in
Table JGDJ.7).
[25] Females who are pregnant or breastfeeding.
[26] The patient has a known allergy to any of the treatment components including a history 
of allergic reactions attributed to compounds of chemical or biological composition 
similar to olaratumab.
[27] The patient is enrolled in, or discontinued study treatment from another trial involving 
an investigational agent or use of non-approved drug or device within 28 days of being 
randomized in this trial, or concurrent enrollment in any other type of medical research 
judged scientifically or medically incompatible with this trial. Patients participating in 
surveys or observational studies are eligible to participate in this study.
[28] Exclusion criterion [28] has been deleted.
[29] The patient has a known investigator-assessed active fungal, bacterial, or viral infection 
including human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis 
(screening is not required).  

I5B-MC-JGDJ(d) Clinical Protocol
Page 29
LY3012207
7.2.1. Rationale for Exclusion of Certain Study Candidates
The exclusion criteria have been carefully selected by the Sponsor to ensure their ethical and 
scientific acceptability, and to help establish specificity of the patient population for both 
efficacy and safety analyses.
7.3.
Discontinuation
The reason for discontinuation and the date of discontinuation will be collected for all patients.  
All randomized patients who discontinue, regardless of whether or not they received study 
treatment, will have procedures performed as shown in the Study Schedule (Attachment 1).
Patients who are discontinued from the study treatment early will have follow-up procedures 
performed as shown in the Study Schedule (Attachment 1).
If a patient withdraws informed consent, he or she must not be contacted unless he or she has 
explicitly provided permission and consent.  Lilly may continue to use previously collected 
medical research data prior to the withdrawal consistent with the original authorization.
7.3.1. Discontinuation of Inadvertently Enrolled Patients
For sites in Germany: this section is replaced by Section 7.3.1 as laid down in protocol 
addendum, I5B-MC-JGDJ(7), dated 04 November 2015 in Annex to this protocol.  
The criteria for enrollment must be followed explicitly. If the investigator site identifies a patient 
who did not meet enrollment criteria and who was inadvertently enrolled, the Sponsor must be 
notified.  If the Sponsor identifies a patient who did not meet enrollment criteria and who was 
inadvertently enrolled, the investigator site will be notified.  A discussion must occur between 
the Lilly CRP and the investigator to determine whether the patient may continue in the study, 
with or without study treatment.
The patient may continue to receive study drugs if all of the following conditions are met:

In the opinion of the investigator, the patient is receiving benefit

The Lilly CRP or clinical research scientist (CRS) and the investigator determines that no 
effective alternative therapy exists

The Lilly CRP/CRS and the investigator agree there is no safety concern meriting 
discontinuation of study drugs
The investigator must obtain documented approval from the Lilly CRP/CRS to allow the 
inadvertently enrolled patient to continue in the study with or without study treatment.
7.3.2. Discontinuation of Patients
In addition, patients will be discontinued from the study drug and/or from the study in the
following circumstances:

enrollment in any other clinical trial involving an investigational product or enrollment in 
any other type of medical research judged not to be scientifically or medically compatible 
with this study

I5B-MC-JGDJ(d) Clinical Protocol
Page 30
LY3012207

investigator/physician or Sponsor decision
o
the investigator/physician or Lilly, for any reason, but considering the rights, 
safety, and well-being of the patients(s) and in accordance with International 
Conference on Harmonisation (ICH) / Good Clinical Practices (GCP) guidelines 
and local regulations, stops the study or stops the patient’s participation in the 
study
o
if the patient, for any reason, requires treatment with another therapeutic agent or 
procedure that has been demonstrated to be effective for treatment of the study 
indication, discontinuation from the study drugs occurs prior to introduction of the 
other agent

patient decision
o
the patient requests to be discontinued from the study or study drug

evidence of progressive disease

unacceptable toxicity

pregnancy

significant noncompliance with study procedures and/or treatment
The discontinuation reason and date will be collected for all patients.  The date of 
discontinuation (for any of the above reasons) from study treatment is to be reported on the case 
report form (CRF).  Patients who discontinue will have follow-up procedures performed as 
shown in the Study Schedule (Attachment 1).
7.3.3. Patients who are Lost to Follow-Up
A patient will be considered lost to follow-up if he or she repeatedly fails to return for scheduled 
visits and is unable to be contacted by the study site.  Site personnel are expected to make 
diligent attempts to contact patients (for example, by phone calls, certified letters, etc.) who fail 
to return for a scheduled visit or who the site is otherwise unable to follow.
Site personnel, or an independent third party, will attempt to collect the vital status (that is, alive 
or dead) for all enrolled patients who are lost to follow-up, including enrolled patients who do 
not receive study treatment, within legal and ethical boundaries.  Site personnel, or an 
independent third party, may search public sources for vital status information.  If the patient's 
vital status is determined, the vital status will be documented and the patient will not be 
considered lost to follow-up.
Lilly personnel will not be involved in any attempts to collect vital status information.
7.3.4. Discontinuation of Study Sites
Study site participation may be discontinued if Lilly, the investigator, or the ethical review board 
(ERB) or institutional review board (IRB) of the study site judges discontinuation of study site 

I5B-MC-JGDJ(d) Clinical Protocol
Page 31
LY3012207
participation necessary for medical, safety, regulatory, ethical, or other reasons consistent with 
applicable laws, regulations, and GCP.
7.3.5. Discontinuation of the Study
The study will be discontinued if Lilly judges discontinuation of the study necessary for medical, 
safety, regulatory, ethical, or other reasons consistent with applicable laws, regulations, and 
GCP.  Prior to discontinuation, the ERB (which approved the trial) will be notified according to 
local regulation.

I5B-MC-JGDJ(d) Clinical Protocol
Page 32
LY3012207
8.
Investigational Plan
8.1.
Summary of Study Design
Study I5B-MC-JGDJ is a global, multicenter, randomized, double-blind, placebo-controlled,
parallel-group, Phase 3 trial in patients with advanced or metastatic STS who are doxorubicin 
naïve but who may have had any number of prior systemic cytotoxic therapies.  Previous therapy 
must be completed ≥3 weeks (21 days) prior to randomization.
Eligible patients will be randomized 1:1 into 1 of 2 treatment options (olaratumab plus 
doxorubicin or placebo plus doxorubicin).  Randomization will be stratified by:

Number of prior systemic therapies for advanced/metastatic disease (0 versus ≥1)
NOTE: Any therapy administered in the adjuvant/neoadjuvant setting will not be 
considered as a prior line of therapy here.

Histological tumor type (leiomyosarcoma versus liposarcoma versus undifferentiated 
pleomorphic sarcoma versus other STS types)

ECOG performance status (0 versus 1)

Region (North America versus Europe versus Rest of World [ROW])
Patients assigned to the investigational arm will receive 2 loading doses of olaratumab at 
20 mg/kg on Days 1 and 8 in Cycle 1 followed by doxorubicin 75 mg/m2 IV on Day 1 of a 
21-day cycle, then 15 mg/kg IV on Days 1 and 8 followed by doxorubicin 75 mg/m2 IV on Day 1
of a 21-day cycle in all subsequent cycles.  Patients assigned to the control arm will receive 
placebo (equivalent volume) IV on Days 1 and 8 followed by doxorubicin 75 mg/m2 IV on Day 1
of a 21-day cycle.
Patients will receive combination treatment for 8 cycles, followed by monotherapy olaratumab or 
placebo until evidence of progressive disease (PD), unacceptable toxicity, death, or other 
withdrawal criteria are met.  No crossover will be permitted.
Starting with Cycle 1, the use of dexrazoxane (in a 10:1 ratio versus doxorubicin dose) to 
mitigate cardiotoxicity during treatment with doxorubicin is allowed at the investigator’s 
discretion and is recommended for all patients receiving 5 or more cycles of doxorubicin.
Figure JGDJ.1 illustrates the study design.

I5B-MC-JGDJ(d) Clinical Protocol
Page 33
LY3012207
Abbreviations: C1 = Cycle 1; C2+ = Cycle 2 and beyond; D = day; 
ECOG PS = Eastern Cooperative Oncology Group Performance Status;
IV = intravenous, N = number of randomized patients; PD = progressive disease; 
STS = soft tissue sarcoma.
Figure JGDJ.1.
Illustration of study design.
Terms used to describe the periods during the study are defined below:

Baseline:  begins when the ICF is signed (study entry) and ends at the first study 
treatment (or at discontinuation, if no treatment is given).

Study Period:  begins at the first study treatment and ends at study completion.
o
Study Treatment Period:  begins at the first study treatment and ends when the 
patient and the investigator agree that the patient will no longer continue study 
treatment.  The date of this agreement is to be reported on the electronic case 
report form (eCRF) as the Date of Discontinuation from study treatment.
o
Post discontinuation Follow-Up:  begins the day after the patient and the 
investigator agree that the patient will no longer continue study treatment.

Short-term follow-up begins the day after the patient and the investigator 
agree that the patient will no longer continue study treatment and lasts 
approximately 30 days (±7 days).  The short-term follow-up visit occurs at 
or near the end of the short-term follow-up period (±7 days).

Long-term follow-up begins the day after short-term follow-up is 
completed.
Follow-up for progression - Patients that discontinue study 
treatment for reasons other than progression will be assessed for 
progression every 6 weeks (±7 days) until PD.
Follow-up for survival - Patients will be followed every 3 months 
(±2 weeks) for the first year, every 6 months (±2 weeks) the 
second year, then annually [±2 weeks] thereafter until the patient’s 
death or overall study completion.

Continued Access Period:  begins after study completion and ends at the end of trial.  
During the continued access period, patients on study treatment who continue to 
experience clinical benefit and no undue risks may continue to receive olaratumab
treatment until one of the criteria for discontinuation is met.  The continued access period 
includes continued access follow-up.  Refer to Section 8.1.4 for more details.

I5B-MC-JGDJ(d) Clinical Protocol
Page 34
LY3012207
o
Continued access follow-up:  begins the day after the patient and the investigator 
agree that the patient will no longer continue treatment in the continued access 
period and lasts approximately 30 days (±7 days).  The continued access
follow-up visit occurs at or near the end of the continued access follow-up period.
8.1.1. Baseline and Study Treatment Period Assessments
Baseline radiographic assessment of disease will be performed within 28 days prior to 
randomization; scans performed prior to the date of consent may be used provided they are 
within 28 days of randomization.
Imaging and tumor assessment will be performed every 6 weeks (±7 days), irrespective of 
treatment cycles, as calculated from randomization.  Imaging requirements include CT scan or 
magnetic resonance imaging (MRI) of chest, abdomen, and pelvis. Other areas may be scanned,
when clinically indicated.  Digital images are to be sent to a third-party organization (TPO) for 
storage. It is recommended that CT imaging of the abdomen/pelvis be performed with IV
contrast, whenever possible.  If this is not feasible/advisable secondary to hypersensitivity or 
other conditions, then gadolinium-enhanced MRI is preferred.  For patients with known serious 
allergic reactions to CT contrast material, a CT of the chest without contrast and contrast-
enhanced MRI of the abdomen/pelvis are encouraged.
The patient’s first treatment will be administered within 72 hours (3 days) following 
randomization.  Patients in both arms will receive any necessary premedication if needed (see 
Section 9.1.1) prior to the infusion of study therapy at each treatment cycle.
A treatment cycle will be defined as 3 weeks (21 days ± 3 days).  The start of study treatment 
will be considered Cycle 1 Day 1 (C1D1).
Patients in the investigational Arm A will receive:

Olaratumab on Day 1 and Day 8 of every 3-week cycle as an IV infusion over 
approximately 60 minutes, followed by a 1-hour observation period for the first 
2 cycles.  If there is no evidence of an infusion-related reaction (IRR) after the D1 
and D8 infusions of olaratumab in the first 2 cycles, no observation period is 
required for subsequent treatment cycles. In the event that a Grade 1 or 2 IRR
occurs after Cycle 2, the 1-hour observation period will be reinstituted for a 
minimum of 2 cycles.  The reinstituted observation period may be suspended after
2 cycles if the patient shows no further signs or symptoms of an IRR.

I5B-MC-JGDJ(d) Clinical Protocol
Page 35
LY3012207

Doxorubicin (after the olaratumab administration and 1-hour observation period, 
if instituted) on Day 1 of every 3-week cycle administered according to 
institutional guidelines and/or clinical practice, as an IV injection or as an 
infusion to be administered in less than 60 minutes for 8 cycles.  Starting with 
Cycle 1, dexrazoxane may be administered at a 10:1 ratio 
(dexrazoxane:doxorubicin) at the investigator’s discretion according to
instructions provided in the Pharmacy Manual for this study, beginning within
30 minutes prior to each doxorubicin infusion for the prevention of cardiotoxicity.  
It is recommended that all patients receiving 5 or more cycles of doxorubicin
receive dexrazoxane.
Patients in the control Arm B will receive:

Placebo on Day 1 and Day 8 of every 3-week cycle as an IV infusion over 
approximately 60 minutes, followed by a 1-hour observation period for the first 
2 cycles.  If there is no evidence of an IRR after the D1 and D8 infusions of 
placebo during the first 2 cycles, no observation period is required for subsequent 
treatment cycles.  In the event that a Grade 1 or 2 IRR occurs after Cycle 2, the 1-
hour observation period will be reinstituted for a minimum of 2 cycles.  The 
reinstituted observation period may be suspended after 2 cycles if the patient 
shows no further signs or symptoms of an IRR.

Doxorubicin (after the placebo administration and 1-hour observation period, if 
instituted) on Day 1 of every 3-week cycle administered according to institutional 
guidelines and/or clinical practice, as an IV injection or as an infusion to be 
administered in less than 60 minutes for 8 cycles.  Starting with Cycle 1, 
dexrazoxane may be administered IV at a 10:1 ratio (dexrazoxane:doxorubicin) at 
the investigator’s discretion according to instructions provided in the Pharmacy 
Manual for this study, beginning within 30 minutes prior to each doxorubicin 
infusion for the prevention of cardiotoxicity.  It is recommended that all patients 
receiving 5 or more cycles of doxorubicin receive dexrazoxane.
Administration and dosing of all therapeutic products will occur as described in Section 9.1.
Criteria for starting the next cycle are defined in Section 9.4.1.1.  Dose reductions for 
olaratumab/placebo will be made in the event of specific treatment-related AEs, as described in 
Section 9.4.1.1.1.  Supportive care guidelines are detailed in Section 9.6.1.  No dose escalations 
or re-escalations are permitted.
Patients will undergo radiographic assessment of disease status (CT or MRI) according to 
RECIST v. 1.1), every 6 weeks (±7 days), as calculated from randomization, until there is 
radiographic documentation of PD.
Patients in both arms will be treated until there is documented radiological PD, toxicity requiring 
cessation of treatment, withdrawal of consent, or until other withdrawal criteria are met.  In the 
event there is symptomatic deterioration resulting in treatment discontinuation, radiographic 
confirmation should be performed.  For patients who discontinue treatment for any reason other 
than radiographically documented PD (for example, symptomatic deterioration), radiographic 

I5B-MC-JGDJ(d) Clinical Protocol
Page 36
LY3012207
assessments should continue as scheduled every 6 weeks (±7 days) as calculated from 
randomization until objective radiographic evidence of PD.
8.1.2. Postdiscontinuation Follow-Up Period Assessments
Postdiscontinuation short-term and long-term follow-up assessments will be conducted as 
described in the Study Schedule (Attachment 1).  Adverse event (AE) information will be 
collected until at least 30 days after the last dose of study treatment.  After the 30-day short-term 
follow-up visit, only new and ongoing SAEs deemed related to study treatment will be collected.
Long-term follow-up will continue as long as the patient is alive and has not withdrawn consent 
to follow-up or the study has completed (as defined in Section 8.1.3).
For patients who discontinue study treatment for any reason without objectively measured PD, 
imaging studies and tumor assessments are obtained every 6 weeks (±7 days), irrespective of 
treatment cycles as calculated from randomization, until documented progression.
For patients that discontinue study treatment after objectively measured PD, the following 
information will be collected every 2 months (±7 days) for the first 2 years, then every 6 months 
(±14 days) until the patient’s death, or overall study completion:

details on all subsequent anticancer treatment (start/stop dates and treatments 
administered)

first post-study treatment disease progression date

survival status
8.1.3. Study Completion and End of Trial
Figure JGDJ.2 is a diagram of the study period and continued access period.  Section 12.2.13
provides the details on the interim analyses.  This study will be considered complete (that is, the 
scientific evaluation will be complete [study completion]) once it has been determined by Lilly 
that the evaluation of efficacy and safety are sufficient and complete.  Investigators will continue 
to follow the study schedule for all patients until notified by Lilly that study completion has 
occurred.  
Upon study completion, investigators and patients may be unblinded to study treatment
assignment. Patients receiving olaratumab and experiencing ongoing clinical benefit and no 
undue risks may continue to receive olaratumab in the continued access period. The continued 
access period begins after study completion and will continue until the end of trial.
“End of trial” refers to the date of the last visit or last scheduled procedure for the last patient.
The end of trial occurs after study completion and after the last patient has discontinued 
olaratumab treatment and completed any applicable continued access follow-up.

I5B-MC-JGDJ(d) Clinical Protocol
Page 37
LY3012207
Abbreviations:  iDMC = independent Data Monitoring Committee; pts = patients; OS = 
overall survival.
a
Or discontinued all study treatment due to any reasons prior to Day 8 in Cycle 2.
b
Lilly will notify sites when this begins and ends.
Figure JGDJ.2.
Study period and continued access diagram.
8.1.4. Continued Access Period
Lilly will notify investigators when the continued access period begins and ends.
The continued access period will apply to this study only if at least 1 patient is still on 
olaratumab treatment when study completion occurs.
After study completion, all patients who are on study treatment and who are eligible for 
continued access will be unblinded.  Patients receiving olaratumab and experiencing ongoing 
clinical benefit and no undue risks may continue to receive olaratumab in the continued access 
period until one of the criteria for discontinuation is met (see Section 7.3).  Patients receiving 
placebo will be discontinued from study treatment.  
Patients who are in short-term follow-up when the continued access period begins will continue 
in short-term follow-up until the 30-day short-term follow-up visit is completed.  Long-term 
follow-up does not apply.
End of 
Trial
Study 
Completion
Patients 
on 
Treatment
Patient on Study Treatment
Study Period
Continued 
Access Periodb
Patient on 
Study 
Treatment
Short-Term 
Follow-Up 
Patient 
Discontinues 
Study 
Treatment
Continued 
Accesss 
Follow-Up
Interim OS 
Analysis at 
60% of OS 
Events
Evaluation of 
Final OS Data 
and Additional 
Endpoints
Patient on 
Study 
Treatment
Long-Term Follow-Up
Short-Term 
Follow-Up 
Patient 
Discontinues 
Study 
Treatment
Last visit/
scheduled 
procedure for 
last patient
Patient 
Discontinues 
Study 
Treatment
iDMC Interim 
Safety 
Analysis after 
40 pts in both 
arms receive 
2 cyclesa
iDMC Ongoing Safety Analyses

I5B-MC-JGDJ(d) Clinical Protocol
Page 38
LY3012207
Patients who are in long-term follow-up when the continued access period begins will be 
discontinued from long-term follow-up.
During the continued access period, concomitant medication, AEs, SAEs, and olaratumab
exposure will be reported on the CRF.  Serious adverse events will also be reported to Lilly 
Global Patient Safety (see Section 10.3.1).  In the event that an SAE occurs, Lilly may request 
additional information (such as local laboratory results, concomitant medications, and 
hospitalizations) in order to evaluate the reported SAE. Blood samples for PK and 
immunogenicity analysis will be collected only in the event of an infusion-related reaction.
Investigators will perform any other standard procedures and tests needed to treat and evaluate 
patients; however, the choice and timing of the tests will be at the investigator’s discretion.  Lilly
will not routinely collect the results of these assessments.
8.1.5. Committees
The following committees will be established to evaluate patients’ safety and/or efficacy of the 
study treatment.  There will be charters for these committees to follow.
Independent Data Monitoring Committee (iDMC)
The independent Data Monitoring Committee (iDMC) will be established to conduct interim 
efficacy and safety analyses as specified in Section 12.2.13 and will follow an approved iDMC 
charter. The iDMC may initiate a consultation with an appropriate expert (such as cardiac) if 
additional expertise is needed regarding evaluation of any safety signals.  The iDMC will 
communicate back to Lilly Senior Management Designee (SMD) about their assessment.
The iDMC will also review adverse events of special interest (AESIs), including:

myocardial failure, dysfunction

myocardial ischemia or infarction

arrhythmias

cardiovascular insufficiency

IRRs
The first iDMC meeting to review interim data for monitoring the loading dose will occur when 
approximately 80 patients (approximately 40 patients from each arm) have received 2 cycles of 
treatment or discontinued all study treatment due to any reasons prior to Day 8 in Cycle 2.
Subsequent iDMC meetings will occur approximately every 6 months thereafter.  Enrollment 
and treatment will continue during the iDMC safety assessments.  In the event a safety signal is 
detected, additional meetings may occur as needed.  See Section 12.2.13 for additional details.
Independent Review Committee (IRC)
An Independent Review Committee (IRC) may review the CT scans and MRI scans for tumor 
assessments from selected patients if necessary (for example, based on inquiries from regulatory
authorities).

I5B-MC-JGDJ(d) Clinical Protocol
Page 39
LY3012207
8.1.6.
Study Duration
From first patient visit to last patient visit, the estimated study duration is 4 years.
8.2.
Discussion of Design and Control
A randomized, controlled design is being used in this study.  Randomization minimizes 
systematic bias in the selection and assignment of patients to study treatment and provides 
justification for inferential statistical methods to be used on data from this study.  Using an 
appropriate concurrent control arm enables direct statistical estimation of benefits and harms due 
to study treatment and minimizes bias in the assessment and interpretation of observed treatment 
effects. Patients will be stratified for differences in factors thought to be associated with clinical 
outcomes to further reduce the potential for bias and improve the power of the analyses. 
Assessment of bias is further minimized by the use of a double blind and placebo control.
Investigational treatment administration in this study is double-blind; that is, patients, 
investigational sites, and the Sponsor study team do not have immediate access to treatment 
assignments for any patients.  This design feature minimizes potential bias due to knowledge of 
patient’s treatment during evaluation of study endpoints, at the patient level or aggregated across 
patients.

I5B-MC-JGDJ(d) Clinical Protocol
Page 40
LY3012207
9.
Treatment
9.1.
Treatments Administered
The following treatments will be administered in this study every 3-week (21-day) ± 3 day cycle:

Investigational Arm A:  doxorubicin (75 mg/m2 IV infusion) on Day 1 plus olaratumab 
(loading doses of 20 mg/kg IV infusion) on Days 1 and 8 of Cycle 1, followed by 
doxorubicin (75 mg/m2 IV infusion) on Day 1 plus olaratumab (15 mg/kg IV infusion) on 
Days 1 and 8 of Cycles 2 to 8.

Control Arm B:  doxorubicin (75 mg/m2 IV infusion) on Day 1 plus placebo (equivalent 
volume IV infusion) on Days 1 and 8 of Cycles 1 to 8.
Patients who complete 8 cycles of combination treatment will continue to receive 
olaratumab/placebo monotherapy at the same dose and schedule until there is documented
disease progression, unacceptable toxicity, death, or other discontinuation criteria are met. No 
crossover will be permitted.
Table JGDJ.1 shows the treatment regimens.

I5B-MC-JGDJ(d) Clinical Protocol
Page 41
LY3012207
Table JGDJ.1.
Treatment Regimens/Dosing Schedule
Study Drug
Dose
Route
Timing
Olaratumaba
20 mg/kg (C1)
15 mg/kg (C2+)
IV
approximately 1 hour infusion Day 1 and 
Day 8 of each 21-day cycle
ARM A
1-hour (+5 minutes)
Observation Periodb
followed by
initial 2 cycles
Doxorubicinc
75 mg/m2 (C1-C8)
IV
IV injection on Day 1 of each 21-day 
cycle
OR
Placeboa
equivalent volume
(C1+)
IV
approximately 1 hour infusion Day 1 and 
Day 8 of each 21-day cycle
ARM B
1-hour (+5 minutes)
Observation Periodb
followed by
initial 2 cycles
Doxorubicinc
75 mg/m2 (C1-C8)
IV
IV injection on Day 1 of each 21-day 
cycle
Abbreviations: C = Cycle; IRR = infusion-related reaction; IV = intravenous; PO = orally.
a
Premedicate all patients with the following (or equivalent) medications: a histamine H1 antagonist (eg, 
diphenhydramine) and dexamethasone intravenously 30–60 minutes prior to the olaratumab doses on Days 1 and 
8 of Cycle 1.  For subsequent cycles, premedicate all patients with a histamine H1 antagonist (eg, 
diphenhydramine) intravenously 30-60 minutes prior to each dose of olaratumab.  Additional premedication may 
be provided at the investigator’s discretion. Premedication must be provided in the setting of a prior Grade 1-2 
olaratumab/placebo IRR, as detailed in Section 9.4.1.1.1.1.  All premedication administered must be adequately 
documented in the eCRF.
b
A 1-hour (+5 minutes) Observation Period is required after the administration of the initial 2 cycles of 
olaratumab/placebo.  During the Observation Period, collect vital signs 3 times: 1) within 15 minutes (+5 
minutes) prior to olaratumab/placebo infusion, 2) within 1 hour (+5 minutes) after completion of the 
olaratumab/placebo infusion, and 3) within 1 hour (+5 minutes) after completion of the doxorubicin infusion.  
If there is no evidence of an IRR during the initial 2 cycles of olaratumab/placebo, then no observation period is 
required for subsequent treatment cycles.  In the event an IRR occurs thereafter, then the 1-hour observation 
period should be reinstituted, see Section 9.2.1.  Thereafter (Cycles 3+), obtain vital signs 2 times: 1) within 15 
minutes (+5 minutes) prior to olaratumab/placebo infusion and 2) within 1 hour (+5 minutes) after completion of 
the doxorubicin infusion.
c
Administer doxorubicin according to institutional guidelines and/or clinical practice as an IV injection or as an 
infusion in less than 60 minutes. Decrease the rate of doxorubicin administration if erythematous streaking along 
the vein proximal to the site of infusion or facial flushing occur.  Infusion or injection start and end times will 
need to be recorded. Starting with Cycle 1, dexrazoxane may be administered at a 10:1 ratio
(dexrazoxane:doxorubicin) at the investigator’s discretion according to instructions provided in the Pharmacy 
Manual for this study, beginning within 30 minutes prior to the doxorubicin infusion for prevention of 
cardiotoxicity. It is recommended that all patients receiving 5 or more cycles of doxorubicin receive 
dexrazoxane.
Any measurements used to determine dose should be taken at each cycle, and dose should be 
recalculated for each cycle.
The investigator or his/her designee is responsible for the following:

I5B-MC-JGDJ(d) Clinical Protocol
Page 42
LY3012207

explaining the correct use of the drugs and planned duration of each individual’s 
treatment to the patient/site personnel/legal representative,

verifying that instructions are followed properly, 

maintaining accurate records of study drug dispensing and collection, 

and returning all unused medication to Lilly or its designee at the end of the study.
Note: In some cases, sites may destroy the material if, during the investigator site selection, the 
evaluator has verified and documented that the site has appropriate facilities and written 
procedures to dispose clinical trial materials.
Patients will be instructed to contact the investigator as soon as possible if they have a complaint 
or problem with the study drug so that the situation can be assessed.
9.1.1. Premedication
Infusion-related reactions, including Grade 3-5 IRR events, have been observed with 
olaratumab. To date, Grade 3-5 IRR events have primarily occured during the first cycle of 
olaratumab treatment. Therefore, premedicate all patients with the following (or equivalent) 
medications: a histamine H1 antagonist (eg, diphenhydramine) and dexamethasone intravenously 
30–60 minutes prior to the olaratumab/placebo doses on Days 1 and 8 of Cycle 1.   
For subsequent cycles, premedicate all patients with a histamine H1 antagonist (eg, 
diphenhydramine) intravenously 30-60 minutes prior to each dose of olaratumab/placebo.  
Premedication with additional agents may be provided at investigator discretion.
Premedication must be provided in the setting of a prior Grade 1 or 2 olaratumab/placebo IRR, 
as detailed in Section 9.4.1.1.1.1.  All premedication administered must be adequately 
documented in the eCRF.
Given the emetogenic potential of doxorubicin, premedication with antiemetics per institutional 
guidelines is recommended.  Additional premedication may be provided at investigator 
discretion.
If doxorubicin premedication is required prior to the doxorubicin infusion, this must be done 
after the completion of olaratumab/placebo infusion, not before the olaratumab/placebo infusion. 
This premedication may be administered immediately following the end of the observation 
period (if applicable) or after the completion of the olaratumab/placebo infusion.
Starting with Cycle 1, dexrazoxane may be administered IV at a 10:1 ratio 
(dexrazoxane:doxorubicin) at the investigator’s discretion, according to instructions provided in 
the Pharmacy Manual for this study, beginning no later than 30 minutes prior to each 
doxorubicin infusion for the prevention of cardiotoxicity.  It is recommended that all patients 
receiving 5 or more cycles of doxorubicin receive dexrazoxane.
9.2.
Materials and Supplies
Olaratumab and placebo will be provided to the sites by Lilly.

I5B-MC-JGDJ(d) Clinical Protocol
Page 43
LY3012207
Study drug will be supplied as a sterile preservative-free solution for IV infusion in single-use 
vials containing 500 mg/50 mL of olaratumab (10 mg/mL) or placebo. 
Olaratumab/placebo is formulated in 10 mM histidine, 100 mM glycine, 50 mM sodium 
chloride, 75 mM mannitol, and 0.02% polysorbate-20, pH 5.5. All excipients used in the 
formulation of olaratumab/placebo drug product are of pharmacopeia grade.
Where commercially available, doxorubicin hydrochloride will be purchased by the sites.  In the 
event that there are regional restrictions or supply limitations, doxorubicin may be provided to 
the sites by Lilly.
Where commercially available, dexrazoxane will be purchased by the sites.  In the event that 
there are regional restrictions or supply limitations, dexrazoxane may be provided to the sites by 
Lilly.
Clinical study materials will be labeled according to the country’s regulatory requirements.
9.2.1. Olaratumab/Placebo
Olaratumab/Placebo Drug Product: The drug product must be stored under refrigeration at 2°C 
to 8°C (36°F-46°F) with protection from direct light.  Do not freeze and/or shake 
olaratumab/placebo drug product.  Stability studies have demonstrated that the drug product can 
withstand transient excursion to room temperature without adverse effect; however, storage at 
this temperature is not recommended.
Please refer to the pharmacy manual for olaratumab/placebo dosing solution for infusion.
CAUTION: Infusion-related reactions may occur during or following olaratumab/placebo
administration (see Section 9.4.1.1.1.1 for a definition of Grade 3 and 4 IRRs). During the 
administration of olaratumab/placebo, patients should be in an area with resuscitation equipment 
and treatments necessary for advanced life support and cardiopulmonary resuscitation (CPR), 
such as bronchodilators, vasopressor agents (e.g., epinephrine), oxygen, glucocorticoids, 
antihistamines, IV fluids, and so forth. A 1-hour observation period is required after the 
administration of the first and second cycles of olaratumab/placebo. If there is no evidence of an 
IRR during the initial 2 cycles of olaratumab/placebo, then no observation period is required for 
subsequent treatment cycles. In the event that a Grade 1 or 2 IRR occurs after Cycle 2, the 1-
hour observation period will be reinstituted for a minimum of 2 cycles.  The reinstituted 
observation period may be suspended after 2 cycles if the patient shows no further signs or 
symptoms of an IRR.
9.2.2. Doxorubicin
Investigators should consult the approved doxorubicin hydrochloride package insert for complete 
prescribing information (including warnings, precautions, contraindications, adverse reactions, 
and dose modifications) and follow institutional procedures for the administration of 
doxorubicin.  If a patient should have an IRR to doxorubicin, the investigator should follow the
manufacturer’s recommendations and clinical guidelines in the management of the patient.

I5B-MC-JGDJ(d) Clinical Protocol
Page 44
LY3012207
Doxorubicin 75 mg/m2 is administered IV. The dose of doxorubicin should be reconstituted in 
100 mL of normal saline.  Administer doxorubicin as an IV injection or as an infusion in less 
than 60 minutes.  Decrease the rate of doxorubicin administration if erythematous streaking 
along the vein proximal to the site of infusion or facial flushing occur.
Doxorubicin must be reconstituted prior to infusion. The reconstituted solution is stable for 
7 days at room temperature and under normal room light and 15 days under refrigeration (2ºC to 
8ºC). It should be protected from exposure to sunlight.
Parenteral drug products should be inspected visually for particulate matter and discoloration 
prior to administration, whenever solution and container permit.
See Section 9.6.1.1 for dexrazoxane administration.  Dexrazoxane should be started within 
30 minutes prior to the doxorubicin infusion.
9.3.
Method of Assignment to Treatment
Upon completion of all screening evaluations to confirm a patient’s eligibility, the site will 
register the patient by the Interactive Web Response System (IWRS), which is web-based and 
accessible 24 hours a day.  The IWRS registration consists of assigning the patient a unique 
study identification number for all patients randomized into 1 of the 2 treatment arms on a 1:1 
basis.
The IWRS will assign patients to treatment arms according to a stratified method of 
randomization (that is, independent randomization within each of 48 strata or cells), defined by 
the following 4 prognostic factors:

Number of prior systemic therapies for advanced/metastatic disease (0 versus ≥1)
NOTE:  Any therapy administered in the adjuvant/neoadjuvant setting will not be 
considered as a prior line of therapy here.

Histological tumor type (leiomyosarcoma versus liposarcoma versus undifferentiated 
pleomorphic sarcoma versus other STS types)

ECOG performance status (0 versus 1)

Region (North America versus Europe versus ROW)
Once the patient is registered through the IWRS, he/she is considered to be enrolled in the study.  
After randomization, patients should receive their first dose of treatment within 72 hours (3 days) 
whenever possible (up to 3 additional days delay of first dose of treatment will be permitted due 
to holidays, weekends, bad weather, or other unforeseen circumstances and will not count as a 
protocol deviation).
9.4.
Selection and Timing of Doses
A cycle is defined as an interval of 21 days (up to 3 days delay of a cycle will be permitted due 
to holidays, weekends, bad weather, or other unforeseen circumstances and will not count as a 
protocol deviation).
Refer to Section 5.3.1 for the olaratumab dose rationale in this study.

I5B-MC-JGDJ(d) Clinical Protocol
Page 45
LY3012207
The dose of olaratumab/placebo administered will be determined by measuring the patient's 
weight in kilograms on Days 1 and 8 of each cycle. The dose of doxorubicin administered will 
be determined by calculating the patient's body surface area (BSA) at the beginning of each 
cycle. If the patient’s weight does not fluctuate by 10% (increase or decrease) from the weight 
used to calculate the prior dose, the olaratumab/placebo dose will not need to be recalculated. A 
5% variance in the calculated total dose will be allowed for ease of dose administration.
Patients will receive combination treatment with olaratumab/placebo + doxorubcin for 8 cycles, 
followed by olaratumab/placebo as monotherapy until evidence of progressive disease (PD), 
unacceptable toxicity, death, or other withdrawal criteria are met.
9.4.1. Special Treatment Considerations
9.4.1.1.
Dose Delays, Modifications, and Discontinuations
After treatment has been initiated, in order to start the next cycle the following criteria must be 
fulfilled:

ANC ≥1.0 × 103/µL (1000/µL; ≥1.0 × 109/L)
Note that in order to administer single-agent olaratumab/placebo on Day 8, ANC must be 
750/µL; 0.75 × 109/L.  If the ANC is 750/µL, the Day 8 administration of 
olaratumab/placebo may be delayed for a maximum of 7 days.  If the ANC level has not 
increased to 750/µL within 7 days, then the Day 8 olaratumab/placebo dose in that cycle 
should be skipped and dosing resumed on Day 1 of the following cycle if criteria for 
dosing are met. If all dosing criteria are met, a delay or omission of the Day 8 
olaratumab/placebo dose should not result in a delay of the Day 1 olaratumab/placebo 
dose of the following cycle. 

Platelets ≥100 × 103/µL (100,000/µL; ≥100 × 109/L)

Hemoglobin ≥8 g/dL

Creatinine clearance ≥45 mL/min (refer to Attachment 5 for the Cockcroft-Gault 
formula)

Total bilirubin below ULN. In patients with Gilbert’s syndrome, total bilirubin should be 
3 mg/dL.

AST and ALT ≤3.0 x ULN, or ≤5 x ULN if the transaminase elevation is due to liver 
metastases

Nonhematologic toxicity must be less than Grade 2, except for those not deemed 
clinically significant by the investigator, or electrolyte abnormalities (for example, 
potassium, magnesium, phosphate).
Delays:
In general, dose delays of 1 study drug (olaratumab/placebo or doxorubicin) due to toxicity 
guidances outlined in Sections 9.4.1.1.1 and 9.4.1.1.2 will not necessitate delays of the other 
study drug.

I5B-MC-JGDJ(d) Clinical Protocol
Page 46
LY3012207
To maintain a concomitant administration schedule of olaratumab/placebo and doxorubicin on 
Day 1 of the first 8 cycles, a delay in olaratumab/placebo administration will be allowed to 
match the corresponding delay in doxorubicin due to toxicity.  For the same reason, a delay in 
doxorubicin administration will be allowed to match the corresponding delay in 
olaratumab/placebo due to toxicity.  Treatment may be delayed for up to 21 days (1 equivalent 
cycle) to allow a patient sufficient time for recovery from study drug-related toxicity.  If a patient 
does not recover from the toxicity within 42 days (2 equivalent cycles) from last dose, then the 
patient must be discontinued from study therapy.
Dose Modifications:
Any patient who requires a dose reduction will continue to receive the reduced dose for the 
remainder of the study.  Any patient who has had 2 dose reductions and who experiences a 
toxicity that would cause a third dose reduction must be discontinued from study treatment.
Since all investigators are blinded to treatment arms, they will treat all patients as if the patient
received study drug versus placebo and will adjust doses accordingly.
In the event of an alteration in olaratumab/placebo dose due to an olaratumab/placebo-related 
toxicity, doxorubicin need not be altered, and the planned doxorubicin schedule should be 
maintained.
Similarly, olaratumab/placebo therapy need not be altered or discontinued for doxorubicin-
related toxicity. An alteration in doxorubicin dose will always necessitate a corresponding 
change in dexrazoxane dose, if administered, in order to maintain a dosage ratio of 10:1
(dexrazoxane:doxorubicin).
Discontinuations:
In general, discontinuation of 1 study drug (olaratumab/placebo or doxorubicin) will not 
necessitate discontinuation of the other study drug. Any changes in treatments being added to or 
removed from patient care will be recorded on the eCRF.
In the event of discontinuation of olaratumab/placebo therapy due to an olaratumab/placebo-
related toxicity, doxorubicin need not be altered, and the planned doxorubicin schedule should be 
maintained. In the event that olaratumab/placebo treatment is discontinued for reason of 
toxicity, the patient may continue treatment with doxorubicin through Cycle 8 at the discretion of 
the investigator. 
Similarly, olaratumab/placebo therapy should not be discontinued for doxorubicin-related 
toxicity. In the event that doxorubicin is discontinued for reason of toxicity, the patient may 
continue treatment with olaratumab/placebo until one or more discontinuation criteria are met, at 
the discretion of the investigator.
The following information (in this section and the following subsections) pertains to dose 
modifications and delays for and management of AEs of concern, which may or may not be 
associated with olaratumab/placebo therapy, including the following:

I5B-MC-JGDJ(d) Clinical Protocol
Page 47
LY3012207

IRR (see Section 9.4.1.1.1.1)

Hematologic toxicity (see Section 9.4.1.1.1.2)

Nonhematologic toxicity (see Section 9.4.1.1.1.3)
The following information (in this section and the following subsections) pertains to dose 
modifications and delays for and management of AEs of concern, which may or may not be 
associated with doxorubicin therapy, including the following:

Hematologic toxicity (see Section 9.4.1.1.2.1)

Cardiovascular toxicity (see Section 9.4.1.1.2.2)

Hepatic impairment (see Section 9.4.1.1.2.3)

Nonhematologic toxicity (see Section 9.4.1.1.2.4)
9.4.1.1.1. Olaratumab/Placebo
9.4.1.1.1.1.
Infusion-Related Reactions
As with other monoclonal antibodies, hypersensitivity reactions may occur during or following 
olaratumab administration.
Patients treated with olaratumab/placebo should be closely monitored for signs and symptoms 
indicative of an infusion reaction by the medical staff from the start of the infusion until at least 
1 hour after the end of the infusion in an area where emergency medical resuscitation equipment 
and other agents (epinephrine, prednisolone equivalents, etc.) are available.
Olaratumab/placebo infusion reactions will be defined according to the NCI-CTCAE version 4.0 
definition of IRRs.
Symptoms occurring during or following infusion of investigational therapy may also be defined 
according to AE categories such as allergic reaction, anaphylaxis, or cytokine release syndrome 
(NCI-CTCAE version 4.0 section “Immune system disorders”). In the setting of symptoms or 
signs occurring during or following infusion of investigational therapy, investigators are 
encouraged to use the AE terms that best describe the event, and mark “yes” or “no” for 
hypersensitivity/IRR event flag.
For patients who experience a Grade 1 or 2 IRR, the infusion should be stopped and the patient 
treated with the following (or equivalent) medications: a histamine H1 antagonist (eg,
diphenhydramine) and glucocorticoid (eg, dexamethasone) intravenously, acetaminophen, and 
oxygen (as indicated), according to standard medical practices.  After recovery, the infusion rate 
should be decreased 50% for the duration of the infusion.  After a Grade 1 or 2 IRR, patients 
should be premedicated with the following (or equivalent) medications: a histamine H1
antagonist (eg, diphenhydramine) and glucocorticoid (eg, dexamethasone) intravenously, and 
acetaminophen, as appropriate, approximately 30-60 minutes prior to all subsequent 
olaratumab/placebo infusions.
A Grade 3 or 4 IRR will require immediate treatment, including the use of epinephrine, 
bronchodilators, and/or glucocorticoids for symptomatic bronchospasm, IV fluids and/or 

I5B-MC-JGDJ(d) Clinical Protocol
Page 48
LY3012207
pressors for hypotension, and immediate and permanent discontinuation of olaratumab/placebo
with appropriate supportive care.
If a patient experiences an IRR to olaratumab/placebo, all attempts should be made to obtain an 
anti-olaratumab/placebo antibody blood sample as close to the onset of the event as possible, at 
the resolution of the event, and 30 days (±3 days) following the event.  In addition, these same 
samples may be assessed for levels of olaratumab and for pharmacodynamic markers to provide 
information on the nature of the IRR. The procedure for sample collection and handling is 
described in a separate procedural manual.
9.4.1.1.1.2.
Hematologic Toxicity
Table JGDJ.2 summarizes the olaratumab dose modifications required in case of hematological 
toxicities.  
Table JGDJ.2.
General Guidelines for Olaratumab/Placebo Dose Modification Due 
to Hematologic Toxicity Deemed Related to Olaratumab/Placebo
Toxicity
Required Dose Modification
Neutropenia
  ANC Grade 1-3
No dose modification required
  ANC <500 cells/µL (Grade 4)
No treatment administered; treatment cycle delayed
  At retreatment:
  If  ≥Grade 3 neutropenic fever/infection has 
occurred
Withhold dose until ANC is 1000 cells/uL or higher; 
reduce dose to 12 mg/kg (15 mg/kg if toxicity occurs 
during Cycle 1).
  If Grade 4 neutropenia lasting longer than 1 week
has occurred
Withhold dose until ANC is 1000 cells/uL or higher; 
reduce dose to 12mg/kg (15 mg/kg if toxicity occurs 
during Cycle 1).
  Grade 4 ANC without fever/infection
Retreatment with olaratumab/placebo at full dose at
investigator’s discretion with recommended use of 
prophylactic G-CSFs
  Second incidence of either:  
  1) ≥Grade 3 neutropenic fever/infection
  2) Grade 4 neutropenia lasting longer than 1 week
Second dose reduction to 10 mg/kg
Thrombocytopenia
  Platelets <100,000 cells/µL
No treatment administered; treatment delayed until 
resolved to ≥100,000 cells/ µL
Anemia
  Hemoglobin <8 gm/dL
No treatment administered; treatment delayed until 
resolved to ≥8 gm/dL
Abbreviations:  ANC = absolute neutrophil count; G-CSFs = granulocyte colony-stimulating factors.
9.4.1.1.1.3.
Nonhematologic Toxicity
Specific guidelines for dose adjustments in patients who experience olaratumab/placebo IRRs
may be found in Section 9.4.1.1.1.1.

I5B-MC-JGDJ(d) Clinical Protocol
Page 49
LY3012207
General guidelines for dose modification for other nonhematologic toxicities related to 
olaratumab/placebo are shown in Table JGDJ.3.  If more than 2 toxicity-related 
olaratumab/placebo dose reductions are required, treatment with this agent will be permanently 
discontinued.
Table JGDJ.3.
General Guidelines for Dose Modification Due to Nonhematologic 
Toxicities Related to Olaratumab/Placebo
Reaction Grade
Required Dose Modification
Grade 1
No dose modification is required.
Grade 2
At the investigator’s discretion, the patient may continue to receive olaratumab/placebo per 
protocol, provided that the event does not pose a serious health risk or is easily treated.
Grade 3 
For a Grade 3 toxicity not adequately controlled with appropriate supportive care, the dose 
must be withheld until toxicity is ≤ Grade 1 or has returned to pretreatment baseline; then 
treatment may resume at a reduced dose of 12 mg/kg (15 mg/kg if the toxicity occurs during 
Cycle 1).  If toxicity recurs after therapy resumes, a second dose reduction (to 10 mg/kg) is 
permitted.
Grade 4
The dose must be withheld until dose toxicity is ≤ Grade 1 or has returned to baseline.  
Permanent discontinuation should be considered for any patient experiencing Grade 4 
nonhematological toxicity assessed as related to olaratumab/placebo. However, if resumption
of dosing is deemed appropriate by the investigator, treatment may resume only after 
consultation with the Lilly study physician, with the dose reduced to 10 mg/kg (15 mg/kg if 
the toxicity occurs during Cycle 1).  If Grade 4 toxicity recurs after therapy resumes, 
olaratumab/placebo treatment will be discontinued.
9.4.1.1.2. Doxorubicin
9.4.1.1.2.1.
Hematologic Toxicity
Doxorubicin will not be administered after the initial dose if the patient’s ANC is <1000 cells/µL
or if the platelet count is <100,000 cells/µL. When necessary, the next treatment cycle should be 
delayed until the ANC is ≥1000 cells/µL and the platelet count is ≥100,000 cells/µL and 
nonhematologic toxicities have resolved. For patients who experience ≥Grade 3 neutropenic 
fever or infection or Grade 4 neutropenia without fever lasting more than 1 week, doxorubicin 
should be reduced to 75% of the starting dose (that is, to approximately 60 mg/m2).  If a patient 
experiences a second incidence of neutropenic fever/infection or has another episode of Grade 4 
neutropenia lasting >1 week, then a second dose reduction to 45 mg/m2 will be necessary. 
Therapeutic and prophylactic use of Neulasta® (pegfilgrastim) or other G-CSFs will be allowed 
per current American Society of Clinical Oncology (ASCO; Smith et al. 2006) and National 
Comprehensive Cancer Network (NCCN) guidelines (NCCN 2014). For patients with Grade 4 
ANC without fever/infection lasting less than 1 week, retreatment will be allowed at the 
investigator’s discretion with the full dose of doxorubicin (75 mg/m2) with recommended use of 
G-CSFs per current ASCO guidelines (Smith et al. 2006).  See Table JGDJ.4 for doxorubicin 
dose modification for neutropenia.

I5B-MC-JGDJ(d) Clinical Protocol
Page 50
LY3012207
Table JGDJ.4.
General Guidelines for Doxorubicin Dose Modification Due to 
Neutropenia
Toxicity
Required Dose Modification
ANC <1000 cells/µL
No doxorubicin administered; treatment cycle delayed.
At retreatment:
If  ≥Grade 3 neutropenic fever/infection has occurred
Approximately 60 mg/m2 doxorubicin.
If Grade 4 neutropenia lasting longer than 1 week
has occurred 
Approximately 60 mg/m2 doxorubicin.
Grade 4 absolute neutrophil count (ANC) without 
fever/infection
Retreatment with doxorubicin at full dose at
investigator’s discretion with recommended use of 
prophylactic G-CSFs.
Second incidence of either:  
1) ≥Grade 3 neutropenic fever/infection
2) Grade 4 neutropenia lasting longer than 1 week
Second dose reduction to 45 mg/m2.
9.4.1.1.2.2.
Cardiovascular Toxicity
Cardiotoxicity is a recognized risk of doxorubicin that increases with higher cumulative drug
exposure. Cardiac monitoring is conducted by a combination of monitoring of clinical 
parameters, ECG, and echocardiogram (ECHO) / multigated acquisition (MUGA) scan.
ECG changes, arrhythmias, tachycardia, and/or chest pain should be managed according to 
clinical practice based on the specific findings.
Patients will undergo baseline LVEF determination by ECHO or MUGA scan. This evaluation 
may be repeated at any time during the study if clinically indicated. A decrease in LVEF of 
10% and below the lower limit of normal, or an absolute decrease of 20%, or if the absolute 
LVEF decreases to or below 40%, then doxorubicin will be discontinued. Doxorubicin should 
also be discontinued if the patient develops Grade 3 or 4 left ventricular systolic dysfunction 
(symptomatic congestive heart failure).  If doxorubicin is discontinued for the above changes in 
LVEF, the patient may continue on study with olaratumab/placebo, provided that the patient 
meets all other entry criteria (see Section 9.4.1.1).
The diagnostic method used at baseline for cardiovascular assessments (for example ECHO or 
MUGA scans) should be the same method used throughout the study, unless there is clinical or 
instrumental evidence that further investigations are needed.
9.4.1.1.2.3.
Hepatic Impairment
Doxorubicin is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C 
or total serum bilirubin >5.0 mg/dL).  Refer to Section 9.4.1.1 for additional information. 
9.4.1.1.2.4.
Nonhematologic Toxicity
Permanent discontinuation of doxorubicin should be considered for any patient experiencing 
Grade 4 nonhematologic toxicity assessed as related to doxorubicin.  If the investigator feels re-
dosing of doxorubicin is appropriate (except for Grade 4 cardiotoxicities and Grade 4 bilirubin 
increase which require mandatory discontinuation [see Section 9.4.1.1.2.2 and Section 
9.4.1.1.2.3], treatment may only resume after consultation with the Lilly study physician, with 

I5B-MC-JGDJ(d) Clinical Protocol
Page 51
LY3012207
the dose reduced to 60 mg/m² (or less if agreed by the investigator and Lilly physician).  If Grade 
4 toxicity recurs after therapy resumes, doxorubicin treatment will be permanently discontinued.
For appropriate management of cardiac toxicities and hepatic impairment, refer to Section 
9.4.1.1.2.2 and Section 9.4.1.1.2.3.
9.5.
Blinding
This is a double-blind study.
To preserve the blinding of the study, a minimum number of Lilly personnel will see the 
randomization table and treatment assignments before the study is complete.  Individuals (IWRS, 
clinical trials materials management, Global Patient Safety, iDMC, and data management 
personnel) validating the database will not have access to aggregate summary reports or 
statistics.  PK and/or immunogenicity data that could unblind the study will not be reported to 
investigative sites or other blinded study personnel until the study has been unblinded.
Upon overall study completion (see Section 8.1.1), investigators may unblind patients to study 
treatment assignment.
Efficacy information (as outlined in Section 10.1) will not be shared with sites until the study is 
completed (see Section 8.1.3).  Treatment assignment will be scrambled in the reporting database 
until the database lock for data analysis.  This will ensure unblinded aggregate efficacy results 
are not available until the time of final data analysis.
If an investigator, site personnel performing assessments, or patient is unblinded, the patient may
be discontinued from study treatment.  In cases where there are ethical reasons to have the 
patient remain on study treatment, the investigator must obtain specific approval from a Sponsor 
physician or designee for the patient to continue on study treatment.
9.5.1. Emergency Unblinding
In case of an emergency, the investigator has the sole responsibility for determining if unblinding 
of a patient’s treatment assignment is warranted.  Patient safety must always be the first 
consideration in making such a determination.  If the investigator decides that unblinding is 
warranted, the investigator should make every effort to contact the Lilly CRP prior to unblinding 
a patient’s treatment assignment unless this could delay emergency treatment of the patient.  If a 
patient’s treatment assignment is unblinded, Lilly must be notified immediately.
All events resulting in an unblinding event must be recorded and reported through the IWRS. If 
the investigator or patient becomes unblinded in the IWRS, that patient may be discontinued 
from study treatment.
9.5.2. Inadvertent Unblinding
Every effort will be made to blind both the patient and the investigator to the identity of the 
treatment, but the inadvertent unblinding of a patient may occur.  A double-blind study design is 
known to be imperfect in the oncolytic setting because the potential for individual unblinding 
exists due to treatment-related signs and symptoms.  If an investigator, site personnel performing 

I5B-MC-JGDJ(d) Clinical Protocol
Page 52
LY3012207
assessments, or patient is unblinded, the unblinding will not be sufficient cause (in and of itself) 
for that patient to be discontinued from study treatment or excluded from any safety or efficacy 
analyses.
Additionally, there may be ethical reasons to have the patient remain on the study treatment.  For 
patients to continue on study treatment in the event of unblinding, the investigator must obtain 
specific approval from a Lilly CRP for the patient to continue in the study.
9.6.
Concomitant Therapy
All concomitant medications should be recorded throughout the patient’s participation in the 
study.
Concomitant medications and supportive care therapies must also be documented at the time of 
discontinuation and at the 30-day short-term follow-up visit.
With the exceptions listed in the sections below, no other chemotherapy, investigational
medications, other anticancer therapy, immunotherapy, hormonal cancer therapy, radiation, 
surgery for cancer, or investigational medications will be permitted while patients are on study 
treatment.
Biophosphonate osteoclast inhibitors (eg, zoledronic acid or pamidronate) for treatment of bone 
metastases will be permitted while patients are on study treatment. However, the osteoclast 
inhibitor denosumab is a monoclonal antibody and could confound safety analysis in the study if 
the patient experiences a hypersensitivity reaction to denosumab. Therefore, concomitant use of 
denosumab will not be permitted.
Appropriate documentation for all forms of premedications, supportive care, and concomitant 
medications (for example, medications such as sedatives, antibiotics, analgesics, antihistamines, 
corticosteroids, erythropoietin; procedures such as paracentesis, thoracentesis; or blood products 
such as blood cells, platelets, fresh frozen plasma transfusions) must be captured on the eCRF.
If doxorubicin premedication is required prior to the doxorubicin infusion, this must be done 
after the completion of olaratumab/placebo infusion, not before the olaratumab/placebo infusion.
9.6.1. Supportive Care
Patients should receive full supportive care, if necessary.  Patients will receive supportive care as 
judged by their treating physician.  If it is unclear whether a therapy should be regarded as 
supportive care, the investigator should consult the Lilly CRP.  Use of any supportive care 
therapy must be captured on the eCRFs.
9.6.1.1.
Dexrazoxane
Starting with Cycle 1, dexrazoxane may be administered IV at the investigator’s discretion
according to instructions provided in the Pharmacy Manual for this study, beginning within 
30 minutes prior to each doxorubicin infusion for the prevention of cardiotoxicity.  It is 
recommended that all patients receiving 5 or more cycles of doxorubicin receive dexrazoxane.  
Investigators should consult the dexrazoxane information provided in the Pharmacy Manual for 

I5B-MC-JGDJ(d) Clinical Protocol
Page 53
LY3012207
this study for administration information (including warnings, precautions, contraindications, 
adverse reactions, and dose modifications).
Note that as the dose of dexrazoxane administered is dependent on the dose of doxorubicin 
administered, any dose modifications to doxorubicin will require a corresponding dose 
modification to dexrazoxane in order to maintain a dosage ratio of 10:1
(dexrazoxane:doxorubicin).
9.6.1.2.
Granulocyte-Colony Stimulating Factors and Erythroid Growth Factors
Following the first dose of doxorubicin treatment, the use of G-CSFs such as Neulasta®
(pegfilgrastim) and erythroid stimulating factors (for example, erythropoietin) are permitted, 
including prophylactic use, during investigational therapy at the discretion of the investigator, 
according to ASCO guidelines (Smith et al. 2006) and NCCN Guidelines (NCCN 2014).
9.6.1.3.
Transfusion of Blood Products
Transfusions of red blood cells, platelets, or other blood products are permitted at the 
investigator’s discretion, but may not be used to meet hematologic criteria for inclusion in the 
study (refer to Section 7.1, inclusion #10).
9.6.1.4.
Anti-emetic Therapy
Both prophylactic and symptom-directed anti-emetic therapy are recommended and should be 
used in accordance with institutional guidelines (when existent) and/or at investigator’s 
discretion.
9.6.2. Prohibited Therapies
Additional concurrent chemotherapy, radiation therapy, biologic response modifiers, or other 
investigational or approved anticancer agents may not be administered to patients on this study.  
Palliative radiation or surgery to symptomatic sites of disease will not be permitted while on 
study.
9.6.2.1.
Effect of CYP3A4, CYP2D6, and P-gp Inhibitors and Inducers on 
Doxorubicin
Doxorubicin is a major substrate of cytochrome P450 CYP3A4 and CYP2D6, and P-
glycoprotein (P-gp).  Clinically significant interactions have been reported with inhibitors of 
CYP3A4, CYP2D6, and/or P-gp (for example, verapamil), resulting in increased concentration 
and clinical effect of doxorubicin. Inducers of CYP3A4 (for example, phenobarbital, phenytoin, 
St. John’s Wort) and P-gp inducers may decrease the concentration of doxorubicin.  Avoid 
concurrent use of doxorubicin with inhibitors and inducers of CYP3A4, CYP2D6, or P-gp.  
Refer to Attachment 8 for a list.
9.7.
Treatment Compliance
The study medication will be administered only at the investigational sites by the authorized 
study personnel.  As a result, treatment compliance is ensured.  Treatment compliance will be 
monitored by drug accountability records, and treatment administration data are recorded in the 
patient’s medical record and eCRF.  An investigator is required to prepare, maintain, and record 

I5B-MC-JGDJ(d) Clinical Protocol
Page 54
LY3012207
all observations and other data pertinent to the investigation on each individual treated in this 
clinical trial.  All data reported on the eCRF must be derived from source documents and be 
consistent with the source documents.

I5B-MC-JGDJ(d) Clinical Protocol
Page 55
LY3012207
10. Efficacy, Patient Reported Outcomes, Safety Evaluations, 
Sample Collection and Testing, and Appropriateness of 
Measurements
Written informed consent must be obtained prior to any study-specific pretreatment evaluations.
Study procedures related to efficacy, safety, pain, health-related quality of life measures, sample 
collection and testing assessments and their timing are described in the sections below and 
shown in the Study Schedule (Attachment 1).
10.1. Efficacy Measures
10.1.1. Radiographic Assessments at Baseline and during Study 
Treatment
Within 28 days before randomization, baseline tumor measurements will be performed on each 
patient.  Computed tomography (CT), including spiral CT, scans and magnetic resonance 
imaging (MRI) are the preferred methods of measurement.
The CT portion of a PET-CT scan may be used as a method of response assessment if the site 
can document that the CT is of identical diagnostic quality to a diagnostic CT (with intravenous 
and oral contrast). A PET scan alone or as part of a PET-CT may be performed for additional 
analyses but cannot be used to assess response according to RECIST.
The method of assessment used at baseline must be used consistently for tumor assessment and 
will be repeated every 6 weeks (±7 days), as calculated from randomization. Patients will be 
evaluated for response according to RECIST, v 1.1 guidelines (Eisenhauer et al. 2009), as 
outlined in Attachment 6.
After the primary analysis of OS and until study completion, Lilly will continue to collect all 
further anticancer treatment, subsequent disease progression date, and survival data on all 
patients but may reduce data collection for other efficacy data.  The frequency and types of 
efficacy assessments (other than collection of OS data) will be at the discretion of the 
investigator, based on the standard of care.  Lilly will notify investigators when this reduced data 
collection begins and ends.
During the continued access period, efficacy assessments (frequency and type of assessments) 
will be at the discretion of the investigator, based on the standard of care, and these data will not 
be collected or analyzed.
10.1.2. Radiographic Assessments during the Study Period 
Postdiscontinuation Follow-Up
Postdiscontinuation follow-up during the study period will be conducted as described in the 
Study Schedule (Attachment 1).

I5B-MC-JGDJ(d) Clinical Protocol
Page 56
LY3012207
For those patients who discontinue study treatment without objectively measured progressive 
disease (PD), the investigative sites will continue to monitor patients and periodically evaluate 
tumor response every 6 weeks (±7 days) as calculated from randomization by the same method 
used at baseline and throughout the study until the patient has objective disease progression, or 
until the final analysis of overall survival.  After the patient has objective disease progression, 
radiologic tests are no longer required and the patient will be followed approximately every 
2 months (±7 days) for the first 2 years, then every 6 months (±14 days) until the patient’s death 
or overall study completion.
After final analysis of OS, during the Continued Access Period, efficacy assessments (frequency 
and type of assessments) will be at the discretion of the investigator, based on the standard of 
care.
Lilly will continue to collect all further anticancer treatments, initial subsequent disease 
progression date, and survival data through study completion but may reduce data collection for 
other efficacy data.  Lilly will notify investigators when this reduced data collection begins and 
ends.
10.1.3. Primary Efficacy Measure
Overall survival duration is measured from the date of randomization to the date of death due to
any cause.  For each patient, prior to each data analysis, a reasonable effort will be made to 
obtain the most up to date status of the patient (date of death or last date known to be alive). For 
each patient who is not known to have died as of the data-inclusion cutoff date for a particular 
analysis, OS will be censored for that analysis at the date the patient was last known to be alive.  
For any patient who has withdrawn consent for further follow-up of survival data, OS will be 
censored at the last date for which the patient consented to be followed for the study.
10.1.4. Additional Efficacy Measures
The following additional efficacy measures will be determined for each patient, with planned 
statistical analyses specified in Section 12 and in the SAP (a separate document). Specific 
definitions of each of these measures (such as defining events and censoring for each time to 
event endpoint) will be provided in the SAP.

Progression-free survival (PFS)

Objective Response Rate (ORR)

Disease Control Rate (DCR)

Time to first worsening of the mBPI-sf (Brief Pain Inventory Short Form Modified)
“worst pain” score

Duration of Response (DoR)

Duration of Disease Control (DDC)

Time to any progression (censoring for death without progression)

Time to any new metastases (censoring for death and for other type of PD)

New-metastases-free survival (nMFS)

Time to any progression based solely on increased sum of target lesions

I5B-MC-JGDJ(d) Clinical Protocol
Page 57
LY3012207

Time to first worsening of the QLQ-C30 scale scores (for example, Global Health Status 
/ Quality of Life score, Physical Functioning score, and Role Functioning score)

Time to first worsening of ECOG performance status 

Second PFS (PFS2) after end of study treatment while on subsequent anticancer therapies
10.2. Patient-Reported Outcomes/Resource Utilization
Patient-reported pain will be assessed using the mBPI-sf (Cleeland et al. 1991). Health related 
Quality of Life will be assessed with the EORTC QLQ-C30 (Aaronson et al. 1993).  Health 
status will be assessed using the EQ-5D-5L (Janssen et al. 2008).  The PRO measures will be 
collected on Day 1 of every cycle and at the 30-day short term follow-up visit.  A full due 
diligence will be taken to collect PRO measures during long-term follow-up (every 6 weeks 
[±7 days] until PD, thereafter every 3 months [±2 weeks] for the first year, every 6 months [±2
weeks] the second year, then annually [±2 weeks] thereafter until the patient’s death or overall 
study completion).
Paper versions of the questionnaires will be used. It is recommended that the instruments be 
administered together and in sequence order, at the beginning of the visit prior to other study 
procedures, with the mBPI-sf presented first, followed by the EORTC QLQ-C30 and continuing 
with the EQ-5D-5L. Whenever possible, if administration is not possible prior to all other 
procedures, every effort should be made to administer at the same time point in each visit and 
questionnaire must be completed prior to study drug administration.
Patient-reported questionnaires should be completed by patients when a language translation is 
available in which the patient is fluent or literate.
10.2.1. mBPI-sf
The mBPI-sf (Cleeland et al. 1991) is an 11-item instrument used as a multiple-item measure of 
cancer pain intensity.  In addition to pain intensity (4 items), the mBPI-sf is designed for patients 
to record the presence of pain in general, pain relief, and pain interference with function (general 
activity, mood, ability to walk, ability to perform normal work, relations with others, sleep, and 
enjoyment of life).  The mBPI-sf is administered per the Study Schedule (Attachment 1).  The 
recall period is the past 24 hours or previous week and completion time is typically 5 to 
7 minutes.
Responses for the mBPI-sf items are captured through the use of 11-point numeric rating scales 
anchored at 0 (no pain or does not interfere) and ranged through 10 (pain as bad as you can 
imagine or completely interferes).  The focus of the analysis will be on the “worst pain”. “Worst 
pain” intensity has been shown to meaningfully impact patients’ lives as indicated by a strong 
correlation with functional interference scores in various types of cancer (Daut et al. 1983; Serlin 
et al. 1995; Ger et al. 1999; McMillan et al. 2000; Shi et al. 2009). Moreover, a study by Stone 
et al. (2004) suggested that patients’ tendency to focus on the most severe level of pain during a 
recall period may bias average recalled pain. Therefore, the focus of the analysis will be on the 
“worst pain”.

I5B-MC-JGDJ(d) Clinical Protocol
Page 58
LY3012207
Analgesic use will be recorded on the eCRF.  Data on each individual prescription and 
over-the-counter analgesic medication will be recorded on the Concomitant Medications eCRF
including but not limited to drug name and mode of administration.  The use of analgesics should 
be reviewed with the patient during each visit.  Any changes to analgesic use (new or stopped 
analgesics) will be recorded on the eCRF.  Analgesics will be classified into 1 of 6 categories, 
using an analgesic ladder approach with medication category based on a World Health 
Organization scale outlined in Table JGDJ.5.  A therapy category will be assigned according to 
the maximum category of therapy routinely administered based on analgesic data for that cycle.
The mBPI-sf population will include all patients who completed at least 1 baseline (Cycle 1 
Day 1) followed by at least 1 mBPI-sf “worst pain” assessment after 1 cycle of study drug
(Cycle 2 Day 1 or later). Patients with an mBPI-sf “worst-pain baseline score of 8 or more will 
not be included in the analysis.
Table JGDJ.5.
World Health Organization Pain Scale
Code
Description
0
No analgesia
1
Aspirin (for pain, not cardiovascular prophylaxis), acetaminophen, nonsteroidal anti-inflammatory drugs
2
Codeine, hydrocodone, pentazocine, oxycodone
3
Oral morphine, hydromorphone, methadone, transdermal fentanyl
4
Parenteral opiates
5
Neurosurgical procedures (blocks)
10.2.2. EORTC QLQ-C30
Broadly used in cancer trials, validated, and available in over 80 different languages, the EORTC 
QLQ-C30 (Aaronson et al. 1993) is a reliable and validated tool.  The EORTC QLQ-C30 v3.0 is 
a self-administered, cancer-specific questionnaire with multidimensional scales. The EORTC 
QLQ-C30 self-reported general cancer instrument consists of 30 items covered by 1 of 
3 dimensions:

global health status/quality of life (2 items)

functional scales (15 total items addressing either physical, role, emotional, cognitive, or 
social functioning)

symptom scales (13 total items addressing either fatigue, nausea/vomiting, pain, dyspnea, 
insomnia, appetite loss, constipation, diarrhea, or financial impact)
The EORTC QLQ-C30 questionnaire is administered per the Study Schedule (Attachment 1).  
The recall period is the past week, completion time is typically 5 to 7 minutes, and the 
questionnaire will be scored as described by the EORTC scoring manual (Fayers et al. 2001).  
The EORTC population will include all patients who completed at least 1 baseline (Cycle 1 
Day 1) followed by at least 1 EORTC assessment after 1 dose of study drug (Cycle 2 Day 1 or 
later).

I5B-MC-JGDJ(d) Clinical Protocol
Page 59
LY3012207
10.2.3. EQ-5D-5L
The EQ-5D-5L is a standardized instrument for use as a measure of self-reported health status
(Herdman et al. 2011).  Specifically, this questionnaire is included in this trial to evaluate 
health-state utilities associated with advanced STS.  These utility measures are an important 
input for economic evaluations concerning the value of treatment interventions.
The EQ-5D 5L is designed to be used in conjunction with other patient-reported measures.  
Patients will complete the 5-dimension (mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression), 5-level (no problem, slight, moderate, severe, or extreme problem) 
assessment according to the Study Schedule (Attachment 1).  A unique EQ-5D health state is 
defined by combining 1 level from each of the 5 dimensions. Additionally, patients will indicate 
their current health status by marking on a visual analogue scale (VAS) ranging from 100 (best 
imaginable health state) to 0 (worst imaginable health state).
The recall period is “today.”  The EQ-5D-5L is designed for self-completion by respondents and 
is cognitively simple, taking only a few minutes to complete.
The EQ-5D 5L population will include all patients who completed at least 1 baseline assessment 
followed by at least 1 EQ-5D 5L assessment after 1 dose of study drug.
EQ-5D 5L responses may be incorporated into cost utility analyses, but will not be included in 
the clinical study report.
10.2.4. Resource Utilization
Investigators will be asked to document the use of best supportive care (BSC) measures, 
concomitant medications, transfusions, and treatment-related hospitalization days.  Such 
assessments are to be taken throughout the study through the 30-day short-term 
postdiscontinuation follow-up visit.
10.3. Safety Evaluations
Investigators are responsible for monitoring the safety of patients who have entered this study 
and for alerting Lilly or its designee to any event that seems unusual, even if this event may be 
considered an unanticipated benefit to the patient.
The investigator is responsible for the appropriate medical care of patients during the study.
The investigator remains responsible for following, through an appropriate health care option, 
AEs that are serious, considered related to the study, or that caused the patient to discontinue 
before completing the study.  The patient should be followed until the event is resolved or 
explained.  Frequency of follow-up evaluation is left to the discretion of the investigator.
The timing of all safety evaluations is shown in the Study Schedule (Attachment 1).  
Table JGDJ.6 presents a summary of AE and SAE reporting guidelines.  Table JGDJ.6 also 
shows which database or system is used to store AE and SAE data.

I5B-MC-JGDJ(d) Clinical Protocol
Page 60
LY3012207
Table JGDJ.6.
Adverse Event and Serious Adverse Event Reporting Guidelines
Period
Types of AEs/SAEs to be Reported
Collection 
Database
Lilly Safety 
System
Baseline (pretreatment)
Preexisting conditions
x
All AEs
x
SAEs related to protocol procedures
x
x
Study treatment period
All AEs 
x
All SAEs
x
x
30-day short-term 
postdiscontinuation follow-up 
All AEs 
x
All SAEs
x
x
Long-term postdiscontinuation 
follow-up 
All SAEs related to protocol procedures 
or study treatment
x
x
Continued access period
All AEs
x
All SAEs
x
x
Continued access follow-up
All AEs
x
All SAEs
x
x
After the patient is no longer 
participating in the study (that is, no 
longer receiving study treatment and 
no longer in follow-up)
All SAEs related to protocol procedures 
or study treatment that the investigator 
becomes aware of
x
Abbreviations:  AEs = adverse events; SAEs = serious adverse events.
10.3.1. Adverse Events
Lilly has standards for reporting AEs that are to be followed regardless of applicable regulatory 
requirements that may be less stringent.  A clinical study AE is any untoward medical event 
associated with the use of a drug in humans, whether or not it is considered related to that drug.
Lack of drug effect is not an AE in clinical trials, because the purpose of the clinical trial is to 
establish drug effect.
Any clinically significant findings from ECGs, ECHOs/MUGAs, labs, or vital sign 
measurements that result in a diagnosis should be reported to Lilly or its designee.
Cases of pregnancy that occur during maternal or paternal exposures to study drug should be 
reported.  Data on fetal outcome and breast-feeding are collected for regulatory reporting and 
drug safety evaluation.
Study site personnel will record the occurrence and nature of each patient’s preexisting 
conditions, including clinically significant signs and symptoms of the disease under treatment in 
the study.
After the ICF is signed, before the patient receives the first dose of study treatment, site 
personnel will record the occurrence and nature of any AEs and any change in the preexisting 
condition(s).  All AEs and SAEs related to protocol procedures are reported to Lilly or its 
designee via eCRF.
In addition, all AEs occurring after the patient receives the first dose of study treatment must be 
reported to Lilly or its designee via eCRF.

I5B-MC-JGDJ(d) Clinical Protocol
Page 61
LY3012207
Investigators will be instructed to report to Lilly or its designee their assessment of the potential 
relatedness of each AE to protocol procedure or study drugs via eCRF.
Patients will be evaluated for AEs at each visit and will be instructed to call their physician to 
report any AEs between visits.
The National Cancer Institute (NCI)-CTCAE v 4.0 will serve as the reference document for 
choosing appropriate terminology for, and grading the severity of, all AEs and other symptoms.  
For AEs without matching terminology within the NCI-CTCAE v 4.0 criteria, the investigator 
will be responsible for selecting the appropriate system organ class and assessing severity grade 
based on the intensity of the event. 
In addition to collecting the AE verbatim and the CTCAE severity grade, AE verbatim text will 
also be mapped by Lilly or its designee to corresponding terminology within the Medical 
Dictionary for Regulatory Activities (MedDRA) dictionary.
If a patient’s dosage is reduced or treatment is discontinued as a result of an AE, study site 
personnel must clearly report to Lilly or its designee via eCRF the circumstances and data 
leading to any such dosage reduction or discontinuation of treatment.
10.3.1.1. Serious Adverse Events
An SAE is any adverse event from this study that results in one of the following outcomes:

death

a life-threatening experience (that is, immediate risk of dying)

persistent or significant disability/incapacity

initial or prolonged inpatient hospitalization

congenital anomaly/birth defect

considered significant by the investigator for any other reason
Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered serious adverse drug events when, based upon appropriate 
medical judgment, they may jeopardize the patient and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition.
Serious adverse event collection begins after the patient has signed informed consent and has 
received study treatments.  If a patient experiences an SAE after signing informed consent, but 
prior to receiving study treatments, the event will not be reported as serious unless the 
investigator feels the event may have been caused by a protocol procedure.
Data on SAEs that occur before the end of trial will be stored in the collection database and the 
Lilly Safety System.
Study site personnel must alert Lilly or its designee of any serious adverse event (SAE) within 
24 hours of investigator awareness of the event via a Sponsor-approved method.  If study site 
personnel contact Lilly or its designee by telephone regarding an SAE, study site personnel must 
also immediately provide official notification on study-specific SAE forms.

I5B-MC-JGDJ(d) Clinical Protocol
Page 62
LY3012207
This 24-hour notification requirement refers to the initial SAE information and all follow-up 
SAE information.
Planned surgeries should not be reported as SAEs unless the underlying medical condition has 
worsened during the course of the study.
Planned hospitalizations or procedures for preexisting conditions that are already recorded in the 
patient’s medical history at the time of study enrollment should not be considered SAEs.  
Hospitalization or prolongation of hospitalization without a precipitating clinical AE (for 
example, for the administration of study treatment or other protocol-required procedure) should 
not be considered SAEs.
Serious adverse events due to disease progression, including death, should not be reported unless 
the investigator deems them to be possibly related to the study treatments.
The investigator does not need to actively monitor patients for AEs once the trial has ended, 
unless provided otherwise in the protocol; however, if an investigator becomes aware of an SAE 
occurring after the patient’s participation in the trial has ended, and the investigator believes that 
the SAE is related to a protocol procedure or study treatments, the investigator should report the 
SAE to the Sponsor, and the SAE will be entered in the Lilly Safety System.
Information on SAEs expected in the study population independent of drug exposure and that 
will be assessed by the Sponsor in aggregate periodically during the course of the trial may be 
found in the IB.
10.3.1.2. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse reactions (SUSARs) are serious events that are not listed 
in the Development Core Safety Information (DCSI) in the IB and that the investigator identifies 
as related to the study treatments or study procedure.  United States 21 CFR 312.32 and 
European Union Clinical Trial Directive 2001/20/EC and the associated detailed guidances or 
national regulatory requirements in participating countries require the reporting of SUSARs.  
Lilly has procedures that will be followed for the recording and expedited reporting of SUSARs 
that are consistent with global regulations and associated detailed guidances.
10.3.1.3. Adverse Events of Special Interest (AESI)
Adverse events of special interest are events that have been identified as safety signals during 
preclinical or early clinical trials or based on class effects of similar drugs. These events will be 
monitored prospectively in the clinical developmental program. Each event is defined by a
careful assessment and grouping of individual related MedDRA preferred terms. 
AESI for olaratumab/placebo
Infusion-related reactions
AESIs for combination of olaratumab/placebo and doxorubicin
Infusion-related reactions
Cardiac arrhythmias and cardiac dysfunction

I5B-MC-JGDJ(d) Clinical Protocol
Page 63
LY3012207
Refer to Section 9.4.1.1 for special treatment considerations for dose delay, modifications, and 
discontinuations from olaratumab/placebo and doxorubicin, including adverse events of concern 
or special interest.
10.3.2. Other Safety Measures
10.3.2.1. Electrocardiograms
A 12-lead electrocardiogram (ECG) is required within 28 days prior to randomization for all 
patients.  Thereafter, 12-lead ECGs will be performed on Day 1 of Cycle 1 through Cycle 9. 
After Cycle 9, perform ECGs every 3 months (± 2 weeks) the first year, every 6 months (± 2 
weeks) the second year, then annually (± 2 weeks) thereafter as long as the patient is alive and 
has not withdrawn consent to follow-up (refer to Attachment 1). 
Patients who stop doxorubicin prior to Cycle 8 will undergo the same cardiac monitoring 
frequency described above (refer to Attachment 1).
Patients must be supine for approximately 5 to 10 minutes before ECG collection and remain 
supine but awake during ECG collection.
Electrocardiograms may be obtained at additional times, when deemed clinically necessary.  
Collection of more ECGs than expected at a particular time point is allowed when needed to 
ensure high quality records.
Electrocardiograms will be interpreted by a qualified physician (the investigator or qualified 
designee) at the site as soon after the time of ECG collection as possible, and ideally while the 
patient is still present, to determine whether the patient meets entry criteria and for immediate 
patient management, should any clinically relevant findings be identified.  
Table JGDJ.7 provides the Bazett’s QT heart rate correction formula.
Table JGDJ.7.
Bazett’s QT Heart Rate Correction Formula
Formula
Bazett
QTc = QT (HR/60)1/2 = QT (RR)–1/2
Type of formula
Nonlinear
Use
Most commonly used in clinical practice
Unique limitations
Over-corrects QT at fast HRs
Under-corrects QT at low HRs (the risk of TdP which frequently occurs at low HRs, may 
not be evident)
Abbreviations:  QTc = corrected QT interval; HR = heart rate;  RR = duration of ventricular cardiac cycle; 
TdP = torsade de pointes (a polymorphic ventricular tachycardia).
After enrollment, if a clinically significant increase in the QT/corrected QT (QTc) interval from 
baseline, or other clinically significant quantitative or qualitative change from baseline, is 
present, the investigator will assess the patient for symptoms (for example, palpitations, near 
syncope, syncope) and to determine if the patient can continue in the study.  The investigator or 

I5B-MC-JGDJ(d) Clinical Protocol
Page 64
LY3012207
qualified designee is responsible for determining if any change in patient management is needed 
and must document his/her review of the ECG printed at the time of evaluation.
The investigator (or qualified designee) must document his/her review of the ECG printed at the 
time of evaluation.
10.3.2.2. Echocardiograms/MUGA Scans
An ECHO or MUGA scan is required within 28 days prior to randomization for all patients.  
Thereafter, perform ECHO or MUGA scans within 7 days prior to start of treatment in Cycles 5, 
7, and 9.  After Cycle 9 (for patients with resting LVEF 50%), perform ECHO or MUGA scans 
every 3 months (± 2 weeks) the first year, every 6 months (± 2 weeks) the second year, then 
annually (± 2 weeks) thereafter as long as the patient is alive and has not withdrawn consent to
follow-up (refer to Attachment 1).  
Patients who stop doxorubicin prior to Cycle 8 (with resting LVEF 50%) will undergo the same 
cardiac monitoring frequency described above; perform ECHO or MUGA scans every 3 months 
(± 2 weeks) the first year, every 6 months (± 2 weeks) the second year, then annually (± 2 weeks)
thereafter as long as the patient is alive and has not withdrawn consent to follow-up (refer to 
Attachment 1).
For patients with LVEF 50% or other cardiac dysfunction, perform more frequently, if 
clinically indicated.
10.3.3. Safety Monitoring
The Sponsor will monitor blinded safety data throughout the course of the study.
Lilly will review SAEs within time frames mandated by company procedures.  The Lilly CRP
will, as is appropriate, consult with the functionally independent Global Patient Safety 
therapeutic area physician or clinical scientist, and review:

trends in safety data

laboratory analytes

adverse events, including cardiac events such as:
o
myocardial failure, dysfunction
o
myocardial ischemia or infarction
o
arrhythmias
o
cardiovascular insufficiency

adverse events of special interest (as defined in Section 10.3.1.3)
If a patient experiences elevated alanine aminotransferase (ALT) >5× ULN and elevated total 
bilirubin >2× ULN, clinical and laboratory monitoring should be initiated by the investigator. 
For patients entering the study with ALT >3× ULN, monitoring should be triggered at ALT >2×
baseline.  Details for hepatic monitoring depend upon the severity and persistence of observed 
laboratory test abnormalities. To ensure patient safety and comply with regulatory guidance, the 
investigator is to consult with the Lilly CRP regarding collection of specific recommended 
clinical information and follow-up laboratory tests. See Attachment 3.

I5B-MC-JGDJ(d) Clinical Protocol
Page 65
LY3012207
In the event that safety monitoring uncovers an issue that needs to be addressed by unblinding at 
the group level, only members of the data monitoring committee (an advisory group for this 
study formed to protect the integrity of data; refer to Section 12.2.13) can conduct additional 
analyses of the safety data.
For the purpose of this study, in which survival is a primary endpoint, all deaths and SAE reports 
will be reviewed in a blinded manner by Lilly during the clinical trial.  These reports will be 
reviewed to assure completeness and accuracy but will not be unblinded to Lilly during the 
clinical trial.  If a death or other clinical AE is deemed serious, unexpected, and possibly related 
to study treatments, only Lilly Global Patient Safety representatives external to the study team 
will be unblinded for regulatory reporting and safety monitoring purposes.  These measures will 
preserve the integrity of the data collected during this trial and minimize any potential for bias 
while providing for appropriate safety monitoring.
10.3.3.1. Cardiac Events of Special Interest
Patients exposed to doxorubicin are at risk for cardiovascular events.  These events will be 
monitored throughout the JGDJ study as cardiac AESI. Each event is defined by a careful 
assessment and grouping of individual related MedDRA preferred terms.
1. Cardiac dysfunction
2. Arrhythmias
AESI data will be collected for all study treatment arms and monitored throughout the conduct of 
this study and across the development program.  If cardiovascular events are reported, sites will 
be prompted to collect additional information.
10.3.4. Complaint Handling
Lilly collects product complaints on study treatments used in clinical trials in order to ensure the 
safety of study participants, monitor quality, and to facilitate process and product improvements.
Complaints related to unblinded doxorubicin and/or dexrazoxane are reported directly to the 
manufacturers of those drugs in accordance with the package insert.
For blinded studies, all product complaints associated with material packaged, labeled, and 
released by Lilly or its designee will be reported.
The investigator or his/her designee is responsible for handling the following aspects of the 
product complaint process in accordance with the instructions provided for this study:

recording a complete description of the product complaint reported and any associated 
AEs using the study-specific complaint forms provided for this purpose

faxing the completed product complaint form within 24 hours to Lilly or its designee
If the investigator is asked to return the product for investigation, he/she will return a copy of the 
product complaint form with the product.

I5B-MC-JGDJ(d) Clinical Protocol
Page 66
LY3012207
10.4. Sample Collection and Testing
Attachment 1 and Attachment 7 list the schedule for sample collections in this study.
Attachment 2 lists the specific tests that will be performed for this study and whether these will 
be performed at a central or local laboratory.  In the event of a treatment-emergent hepatic 
abnormality, selected tests may be obtained as specified in Attachment 3.
10.4.1. Samples for Study Qualification and Health Monitoring
Blood and urine samples will be collected to determine whether patients meet 
inclusion/exclusion criteria and to monitor patient health.   Eligibility for inclusion in this clinical 
trial will be based on local clinical laboratory results (not transcribed onto eCRFs) and duplicate 
samples will be submitted to the central laboratory.  Treatment decisions may be based upon 
results of tests performed locally. If local laboratory tests are used for this purpose, then a 
duplicate specimen must be submitted to the central laboratory. Discrepancies between local and 
central laboratory that may have an impact on eligibility or treatment decisions will not be 
considered protocol deviations.
Investigators must document their review of each laboratory safety report.
Laboratory/analyte results that could unblind the study will not be reported to investigative sites 
or other blinded personnel until the study has been unblinded.
Samples collected for specified laboratory tests will be destroyed within 60 days of receipt of 
confirmed test results.  Tests are run and confirmed promptly whenever scientifically 
appropriate.  When scientific circumstances warrant, however, it is acceptable to retain samples 
to batch the tests run, or to retain the samples until the end of the study to confirm that the results 
are valid.  Certain samples may be retained for a longer period, if necessary, to comply with 
applicable laws, regulations, or laboratory certification standards.
10.4.2. Samples for Central Pathology Review and Translational 
Research
The following samples for biomarker and pharmacogenetics research are required to be collected 
from all patients in this study:

plasma samples from whole blood (see Section 10.4.2.1)

whole blood sample for DNA collection (see Section 10.4.2.2)

archived tumor tissue or tumor tissue from biopsy (see Section 10.4.2.3)
Samples will be stored and analyses will be performed to assess biomarkers relevant for STS, the 
mechanism of action of olaratumab or doxorubicin and/or cancer-related conditions, and may 
also be used for related research methods.  Samples will be stored until analyzed, as described 
below.
Plasma samples for biomarker research, whole blood samples for DNA, and tumor tissue 
samples will be collected at the times specified in the Study Schedule (Attachment 1 and

I5B-MC-JGDJ(d) Clinical Protocol
Page 67
LY3012207
Attachment 7). Translational research samples will be stored at a facility chosen by the Sponsor 
or designee.
Supplies required for the collection and shipment of the patients’ stored samples will be supplied 
by the central laboratory vendor.  Sample handling and shipment to the central laboratory will 
occur per instructions provided to the study site.
10.4.2.1. Blood Samples for Plasma Collection
Blood samples will be collected at specified time points (Attachment 7) for plasma collection.  
Potential pharmacodynamic and/or circulating markers may include, but are not limited to, 
PDGF, VEGF, PDGFRα, and PDGFRα ligand(s).  The samples will be coded with the patient 
number and stored for up to a maximum 15 years after the last patient visit for the study at a 
facility selected by the Sponsor.
10.4.2.2. Whole Blood Samples for DNA Collection
There is growing evidence that genetic variation may impact a patient’s response to therapy.  
Variable response to therapy may be due to genetic determinants that impact drug absorption, 
distribution, metabolism, and excretion, the mechanism of action of the drug, the disease 
etiology and/or the molecular subtype of the disease being treated.  Therefore, where local 
regulations and ERBs allow, a blood sample will be collected for pharmacogenetic analysis.  
Sampling for such analysis will be a one-time collection, as noted in the Study Schedule 
(Attachment 1).  Variable response to olaratumab and doxorubicin may be due to genetic 
determinants that impact drug absorption, distribution, metabolism and excretion, the mechanism 
of action of the drug, the availability of receptors, the disease etiology and/or the disease subtype 
itself.
Samples will be stored and analyses may be performed on genetic variants/copy number 
variations that are thought to play a role in STS, the mechanism of action of olaratumab or 
doxorubicin, and/or cancer-related conditions.
In the event of an unexpected AE or the observation of an unusual response, the samples may be 
genotyped and analysis may be performed to evaluate genetic association with response to 
olaratumab and/or doxorubicin.  These investigations may include focused candidate gene 
studies or, if appropriate, genome-wide association studies may be performed to identify regions 
of the genome associated with the variability observed in drug response.  Samples will only be 
used for investigations related to disease, cancer-related conditions, and drug under study in the 
context of this clinical program.
They will not be used for broad exploratory unspecified disease or population genetic analysis.  
Pharmacogenetic data will not be provided back to the investigator or the patient except where 
required by local law.
The samples will be coded with the patient number and stored for up to a maximum 15 years 
after the last patient visit for the study at a facility selected by the Sponsor.  The samples and any 
data generated from them can only be linked back to the patient by investigator site personnel.  

I5B-MC-JGDJ(d) Clinical Protocol
Page 68
LY3012207
The duration allows the Sponsor to respond to regulatory requests related to the study treatment.
Samples will be destroyed according to a process consistent with local regulation.
10.4.2.3. Mandatory Tumor Tissue Samples
Previously obtained archived FFPE tissue will be requested both for a central pathology review 
to confirm the diagnosis of STS and histologic subtype, and for exploratory biomarker research. 
In the event that archived tissue is not available at study entry, a pre-treatment tumor biopsy of 
primary or metastatic tissue will be required (treatment can be initiated after tissue collection, 
without the need to wait for availability of tissue analysis results).  The specific tissue amount 
required and processing and shipping instructions are detailed in the Pathology Letter provided 
to each site. A paraffin block (FFPE) is acceptable. Due diligence should be used to make sure 
that tumor specimen (not a normal adjacent or a tumor margin sample) is provided. De-
identified diagnostic pathology reports accompanying archival tissue will also be required.
Mutation profiling, copy number variability, gene expression, and/or immunohistochemistry may 
be performed on these tissue samples to assess potential associations with these biomarkers 
relevant to pathways associated with STS, the mechanism of action of olaratumab, or 
doxorubicin, and/or cancer-related conditions, and may also be used for related research 
methods. The paraffin-embedded blocks will be sectioned and sent back to the site.  Slides will 
not be returned.
Tissue samples will be stored for a maximum of 15 years after the last patient visit for the study; 
any samples remaining at that time will be destroyed.
10.4.3. Samples for Immunogenicity Research
Blood samples for immunogenicity testing will be collected to determine antibody production 
against olaratumab.  To interpret the results of immunogenicity, blood samples will be collected 
at the same time points as the blood samples designated to measure the serum concentrations of 
olaratumab (as noted in Section 10.4.4).
In the event of an olaratumab/placebo IRR, unscheduled blood samples will be collected for 
additional immunogenicity analysis.  These additional samples will be collected as close as 
possible to the onset of the event, at the point of resolution from the event, and 30 days (± 3 
days) after onset of the event (as noted in Attachment 7).
Immunogenicity will be assessed by a validated assay designed to detect anti-drug antibodies in 
the presence of the olaratumab.  Antibodies may be further characterized and/or evaluated for 
their ability to neutralize the activity of olaratumab.  The serum samples collected for 
immunogenicity testing will be stored at a facility designated by the Sponsor.
Immunogenicity information that would unblind the study will not be reported to investigative 
sites or blinded personnel until the study has been unblinded.
Samples may be stored for a maximum of 15 years following last patient visit for the trial at a 
facility selected by the Sponsor to enable further analysis of immune responses to olaratumab.  
The duration allows the Sponsor to respond to regulatory requests related to olaratumab.

I5B-MC-JGDJ(d) Clinical Protocol
Page 69
LY3012207
10.4.4. Samples for Drug Concentration Measurements 
Pharmacokinetics
At the visits and times specified in the Pharmacokinetic, Immunogenicity, and 
Pharmacodynamic Sampling Schedule (Attachment 7), venous blood samples will be collected
for all patients randomized in the study.  These samples will be used to determine the serum
concentrations of olaratumab and plasma concentrations of doxorubicin.
Serum concentrations of olaratumab will be assayed using a validated enzyme-linked 
immunosorbent assay (ELISA) method.  Doxorubicin concentrations in plasma will be analyzed 
using a validated liquid chromatography with tandem mass spectrometry (LC/MS/MS) assay.
Instructions for the collection and handling of blood samples will be provided by the sponsor.  
It is preferred that the blood samples be obtained from a peripheral location.  Blood samples will 
be allowed from central access devices, but a sample drawn from a central catheter of any type 
for PK must take precautions to prevent obtaining a dilute sample.  If multiple samples are 
obtained centrally, the PK sample should be the last specimen drawn to reduce the potential for a 
diluted or improperly drawn sample.  The actual date and time (24-hour clock time) of each 
sampling will be recorded. Up to a maximum of 5 additional samples may be drawn at different 
time points during the study if warranted (for example, for safety assessment) and agreed upon 
between both the investigator and Lilly (refer to Attachment 7 for time points).  In the event of 
an IRR, unscheduled blood samples will be collected to determine serum olaratumab
concentrations, as described in Section 10.4.3.
These samples will be analyzed at a laboratory designated by the sponsor.  The serum samples 
for PK will be stored at a facility designated by the Sponsor.  The remaining sample materials 
collected for PK may be pooled and used for exploratory metabolism and other exploratory 
PK/pharmacodynamic work as deemed appropriate.
Drug concentration information that would unblind the study will not be reported to investigative 
sites or blinded personnel until the study has been unblinded.
Bioanalytical samples collected to measure olaratumab and doxorubicin concentration will be 
retained for a maximum of 1 year following last patient visit for the study.
10.5. Appropriateness of Measurements
The measures used to assess safety and efficacy in this study are consistent with those used in 
most conventional oncology trials.

I5B-MC-JGDJ(d) Clinical Protocol
Page 70
LY3012207
11. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the following:

Provide instructional material to the study sites, as appropriate

Sponsor start-up training to instruct the investigators and study coordinators.  This 
session will give instruction on the protocol, the completion of the eCRFs, and study 
procedures.

Make periodic visits to the study site

Be available for consultation and stay in contact with the study site personnel by mail, 
telephone, and/or fax

Review and evaluate eCRF data and use standard computer edits to detect errors in data 
collection

Conduct a quality review of the database
In addition, Lilly or its representatives will periodically check a sample of the patient data 
recorded against source documents at the study site.  The study may be audited by Lilly or its 
representatives, and/or regulatory agencies at any time.  Investigators will be given notice before 
an audit occurs.
To ensure the safety of participants in the study, and to ensure accurate, complete, and reliable 
data, the investigator will keep records of laboratory tests, clinical notes, and patient medical 
records in the patient files as original source documents for the study.  If requested, the 
investigator will provide Lilly, applicable regulatory agencies, and applicable ERBs with direct 
access to original source documents.
11.1. Data Capture System
An electronic data capture system will be used in this trial.  The site maintains a separate source 
for the data entered by the site into the Sponsor-provided electronic data capture system.
Case report form data will be encoded and stored in a clinical trial database.  Data managed by a 
central vendor, such as laboratory test data or ECG data, will be stored electronically in the 
central vendor’s database system.  Data will subsequently be transferred from the central vendor 
to the Lilly generic labs system.
Any data for which the paper documentation provided by the patient will serve as the source 
document will be identified and documented by each site in that site’s study file.  Paper 
documentation provided by the patient may include, for example, a paper diary to collect PRO 
measures (for example, a rating scale), a daily dosing schedule, or an event diary.
Data from complaint forms submitted to Lilly will be encoded and stored in the global product 
complaint management system.

I5B-MC-JGDJ(d) Clinical Protocol
Page 71
LY3012207
12. Sample Size and Statistical Methods
12.1. Determination of Sample Size
The primary objective of this trial is to compare doxorubicin plus olaratumab versus doxorubicin 
plus placebo with respect to OS in 2 populations:
(1) Patients with advanced or metastatic STS not amenable to treatment with surgery or 
radiotherapy with curative intent (referred to below as the ITT population)
(2) Patients with advanced or metastatic LMS not amenable to treatment with surgery or 
radiotherapy with curative intent
Population (1) will be analyzed for efficacy among all randomized study patients (the ITT 
population).  Population (2) will be analyzed as the subset of randomized patients with LMS.  
The study will be considered a positive study if either the ITT or LMS populations (or both)
show a statistically significant improvement in OS with the regimen of doxorubicin plus 
olaratumab.
The study will enroll 460 patients in 1:1 randomization (230 patients in the investigational arm
and 230 patients in the control arm).  Enrollment will be conducted so that approximately 
200 patients with LMS and 260 patients with other (non-LMS) histology will be randomized.  
The final analysis will occur only when both a minimum of 131 OS events have been observed 
in randomized patients with LMS, and a minimum of 322 OS events have been observed in 
randomized patients overall.
The statistical analysis will be conducted using a statistical testing plan according to the 
graphical method of Maurer and Bretz (2013) so as to control the overall type I error rate at 
0.025 (one-sided) or equivalently, 0.05 (two-sided).  The graphical approach can be 
characterized by first defining a set of pre-specified null hypotheses that are organized 
graphically by providing initial alphas for each hypothesis and weights for each edge of the 
graph which will determine the propagation of α through the entire hypothesis testing scheme.
The graph is shown in Figure JGDJ.3.
The hypotheses are;
Primary objectives: 
H11: OS in the LMS population
H12: OS in the ITT population
Secondary objectives: H2: PFS in the ITT population
H3: ORR in the ITT population
Initially the overall one-sided alpha of 0.025 is split between the primary objectives of OS in the 
LMS population (H11) and OS in the ITT population (H12), with H11 tested at a one-sided 
α1=0.005 and H12 tested at a one-sided α2=0.02. Zero alpha is initially assigned to the other 
hypotheses.

I5B-MC-JGDJ(d) Clinical Protocol
Page 72
LY3012207
The initial weights for each edge of the graph are shown in Figure JGDJ.3. The weight of the 
line from H11 to H12 is 1 indicating that H12 receives all of the alpha allotted to H11 if H11 is 
rejected, and similarly, the weight of the line from H12 to H11 is 1- ε, where ε is set equal to 0.001, 
indicating that H11 receives virtually all of the alpha allotted to H 12 if H12 is rejected.
Assigning ε=0.001 initially focuses virtually all the alpha on the primary endpoints. The 
iterative process of subsequent updating of the graph and redistribution of α is described in more 
detail in the SAP and is repeated until no further hypotheses can be rejected.
Abbreviations:  ITT = intention-to-treat; LMS = leiomyosarcoma; ORR = overall 
response rate; OS = overall survival; PFS = progression-free survival.  
ε is set equal to 0.001.
Figure JGDJ.3.
Graphical representation of testing sequence.
The power and associated sample sizes for the hypotheses that form the primary objective are 
based on the initial allocation of alpha. The total of 131 OS events at the final analysis in the 
LMS subpopulation provides 80% statistical power for a one-sided log-rank test at a 0.005 alpha 
level, assuming the true OS HR in LMS patients is 0.55. The total of 322 OS events at the final 
analysis in the ITT population provides 80% statistical power for a one-sided log-rank test at a 
0.02 significance level, assuming the true OS HR in STS patients is 0.723.
There is one interim analysis for efficacy planned for this study. This analysis will be performed 
in order to provide the IDMC and regulatory authorities an opportunity to review interim safety 
and efficacy data together.  There will be no formal statistical hypotheses tested at the interim for 
primary and secondary efficacy outcomes. There will be no alpha-spending associated with the 

I5B-MC-JGDJ(d) Clinical Protocol
Page 73
LY3012207
interim analysis; study follow-up and data collection will continue as planned until the final 
analysis regardless of the nature of the interim efficacy results.  Only the IDMC and regulatory 
authorities will be allowed access to unblinded interim data. This single interim efficacy 
analysis is planned to occur after 194 OS events (60% of the final OS events) have been 
observed in the ITT population.
12.2. Statistical and Analytical Plans
12.2.1. General Considerations
Statistical analysis of this study will be the responsibility of Lilly or its designee.
All tests of treatment effects will be conducted at a 2-sided alpha level of 0.05, unless otherwise 
stated.  All CIs will be given at a 2-sided 95% level, unless otherwise stated.
Any change to the data analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol. Before unblinding of the aggregate 
database, minor modifications or clarifications to the data analysis methods may be described 
and justified in the SAP. Any other change to the data analysis methods described in the 
protocol, and the justification for making the change, will be described in the clinical study 
report.
If study data violate key statistical assumptions of an analysis method, alternative statistical 
methods may be used.
Additional exploratory analyses of the data will be conducted as deemed appropriate.
12.2.1.1. Analysis Populations
The following populations will be defined for this study:
Intent-to-Treat population: will include all randomized patients. The ITT analysis of 
efficacy data will consider allocation of patients to treatment groups as randomized, and not 
by actual treatment received. This population will be used for baseline, efficacy, and health 
outcome analyses.  A key subset of the ITT population is the LMS population (randomized 
patients with LMS).  Unless otherwise indicated, all efficacy analyses will be performed for 
both the full ITT population and the LMS population.
Safety population: will include all randomized patients who received any quantity of study 
treatment, regardless of their eligibility for the study. The safety evaluation will be 
performed based on the actual study treatment a patient has received, regardless of the arm to 
which he or she was randomized. The safety population will be used for all dosing/exposure, 
adverse events, and resource utilization analyses.
12.2.2. Patient Disposition
A detailed description of patient disposition will be provided.  It will include a summary of the 
number and percentage of patients entered into the study, enrolled in the study, and treated as 

I5B-MC-JGDJ(d) Clinical Protocol
Page 74
LY3012207
well as number and percentage of patients completing the study, or discontinuing (overall and by 
reason for discontinuation).  A summary of all major protocol deviations will be provided.
12.2.3. Patient Characteristics
Description of patient characteristics at baseline, such as patient demographics, baseline disease 
characteristics, preexisting conditions, and prior therapies will be reported using descriptive 
statistics.
12.2.4. Concomitant Therapy
Concomitant medications will be summarized for the safety population. 
12.2.4.1. Postdiscontinuation Therapy
The numbers and percentages of patients reporting postdiscontinuation therapies will be 
provided overall, by type of therapy (surgery, radiotherapy, or systemic therapy), and by drug 
name, for the ITT population.
12.2.5. Treatment Compliance
The number of dose omissions, reductions, delays, number of cycles received, and dose intensity 
will be summarized for all treated patients per treatment arm.
12.2.6. Primary Outcome and Methodology
The analysis of OS at the interim and final analysis time points will be based on the stratified 
log-rank test, stratified by the randomization strata, excluding region; that is, number of prior 
systemic therapies for advanced/metastatic disease (0 versus ≥1), histological tumor type 
(leiomyosarcoma versus liposarcoma versus undifferentiated pleomorphic versus other STS 
types) and ECOG PS (0 versus 1). Region (North America versus Europe versus ROW) is 
included in the randomization so as to ensure balance between treatments within regions for 
subgroup analysis, but is not included as a stratification factor in the primary analysis as 
including it could result in small or empty strata due to the resulting increase in the number of 
strata from 16 to 48.
Overall survival curves, the median with 95% CI and survival rates at various time points for 
each treatment group will be estimated using Kaplan-Meier method (Kaplan and Meier 1958).  
The HR will be estimated using a stratified Cox regression model, stratified by randomization 
strata.
A single interim analysis is planned for efficacy as described in Section 12.1.  
12.2.7. Other Analyses of Efficacy
12.2.7.1. Progression-Free Survival
A precise definition of events and censoring for PFS will be defined in the SAP.  Progression-
free survival will be analyzed using the Kaplan-Meier method, and compared based on a log-

I5B-MC-JGDJ(d) Clinical Protocol
Page 75
LY3012207
rank test, stratified by the same stratification factors used in the analysis of the primary endpoint
OS.
Progression-free survival will be compared between the 2 treatment groups based on log-rank 
test, stratified by stratification factors.  Progression-free survival curves, the median with 95% CI 
and survival rates at various time points for each treatment group will be estimated using 
Kaplan-Meier method (Kaplan and Meier 1958).  The HR will be estimated using a stratified 
Cox regression model, stratified by randomization strata.
12.2.7.2. Additional Efficacy Analyses
Additional analyses of the measures defined in Section 10.1.4, as well as any other pre-planned 
efficacy analyses will be defined in the SAP.
12.2.8. Pharmacokinetic and Immunogenicity Analyses
Pharmacokinetics:
Pharmacokinetics analyses will be conducted on all patients who have received at least 1 dose of 
study treatment and have had PK samples collected.
Mean population PK parameters for olaratumab in serum (clearance, volume of distribution, and 
half-life) and inter-individual PK variability will be computed for this study using nonlinear 
mixed-effect modelling implemented in 
in order to describe the average dose-
concentration relationship in the target population.  Covariate effects (such as age, weight and 
sex) on the PK parameters of olaratumab in serum will also be investigated.
PK data collected for doxorubicin will be analyzed using descriptive methods.
If warranted by the data, PK/PD analyses using OS, PFS, and/or other appropriate clinical 
endpoints will also be conducted to characterize the exposure-response relationship in this study.  
The PK and PK/PD analyses will be reported as separate standalone reports for this study.
The version of any software used for the analysis will be documented, and the program will meet 
Lilly requirements of software validation.  It is possible that other validated equivalent PK 
software programs may be utilized if appropriate, warranted, and approved by global PK 
management.
Immunogenicity: 
Incidence of anti-olaratumab antibodies will be tabulated.  The potential impact of 
immunogenicity on olaratumab exposure will be evaluated in the population PK modeling 
exercises where immunogenicity will be evaluated as a covariate.  In addition, graphical 
assessments will be conducted, as appropriate, to compare drug exposure between ADA negative 
and ADA positive patients at correspondent visits, or before and after ADA development for 
patients who developed ADA.  However, for patients who test positive for anti-drug antibodies 
(ADA), their ADA titers will be listed over time and associated PK information (for example, 
plasma concentration) will be listed in subsequent cycles for each patient.

I5B-MC-JGDJ(d) Clinical Protocol
Page 76
LY3012207
In the event of an IRR, the immunogenicity and olaratumab serum concentrations will be 
tabulated.
12.2.9. Translational Research Analyses
Biomarker assay results will be summarized and correlated with clinical outcomes.
12.2.10.
Analyses of Patient-Reported Outcomes (PROs)
Patient-reported outcomes are measured through the following:

mBPI-sf (Brief Pain Inventory [Short Form] Modified)

EORTC QLQ-C30 (The European Organization for Research and Treatment of Cancer 
Quality of Life Questionnaire Core 30)

EQ-5D-5L (EuroQol 5-Dimension 5-Level)
For each instrument (mBPI-sf, EORTC QLQ-C30, and EQ-5D-5L), percentage compliance will 
be calculated as the number of completed assessments divided by the number of expected 
assessments (that is, patients still on study and alive). Percentage compliance and reasons for 
non-compliance will be summarized by treatment arm and time point.
Data will be separately summarized by treatment and time point using descriptive statistics. The 
main efficacy measure for the pain endpoint will be the time to first worsening of the mBPI-sf 
“worst pain” score. Time to first worsening in pain will be described using the method of Kaplan 
and Meier and analyses will be made between the 2 arms by a log-rank test.  “Worsening” will 
be defined as either a “worst pain” increase of >2 points postbaseline (Farrar et al. 2001; 
Rowbotham 2001) or an analgesic drug class increase of >1 level.  However, other approaches to 
defining clinically meaningful worsening in pain might be considered.  Further details will be 
provided in the SAP.
Additionally, time to first worsening of QLQ-C30 scale scores (see Section 10.2) will be 
analyzed using Kaplan-Meier and Cox methods. Further statistical analysis to be performed for 
PROs will be defined and detailed in the SAP.
12.2.11.
Safety Analyses
All safety summaries and analyses will be based upon the safety population as defined in 
Section 12.2.1, unless otherwise indicated, and include:

Adverse events (AE) will be summarized by MedDRA® System Organ Class/preferred 
term, classified from verbatim terms.  The incidence and percentage of patients with at 
least one occurrence of a preferred term will be included, according to the most severe 
NCI-CTCAE Version 4.0 grade.  Causality (relationship to study drug), action taken, and 
outcome will be summarized separately.  Duration of AE will be determined and included 
in the listings.

Study drug exposure will be summarized for each arm with following variables: number 
of infusion, number of cycles, duration of therapy, cumulative dose, dose intensity and 
relative dose intensity.

I5B-MC-JGDJ(d) Clinical Protocol
Page 77
LY3012207

Laboratory results will be classified according to the NCI-CTCAE, Version 4.0.  
Incidence of laboratory abnormalities will be summarized.

Hospitalizations due to AEs, transfusions, and vital signs will be summarized.
12.2.12.
Subgroup Analyses
Subgroup analyses of PFS and OS will be performed and will be detailed in the SAP.
12.2.13.
Interim Analyses
A limited number of pre-identified individuals may gain access to the limited unblinded data, as 
specified in the unblinding plan, prior to final database lock, in order to initiate the final 
population pharmacokinetic/pharmacodynamic model development processes for final ana lyses.  
Information that may unblind the study during the analyses will not be reported to study sites or 
blinded study team until the study has been unblinded.
An independent data monitoring committee (iDMC) will be established to conduct safety 
reviews.  The membership, roles, and responsibilities of the iDMC are defined in the iDMC 
Charter (that is, a separate iDMC charter document).
There will be no prespecified rules for stopping or modifying the trial due to safety concerns.  
The iDMC members will review unblinded interim safety data to determine whether there are 
sufficient safety concerns to justify modifying the study or the termination of study treatment 
and/or enrollment.
Only the iDMC is authorized to evaluate unblinded safety analyses.  Study sites will receive 
information about interim results ONLY if they need to know for the safety of their patients.
Unblinding details are provided in the blinding section of the protocol (Section 9.5).
The iDMC safety reviews will be performed for all randomized patients. The first iDMC 
meeting to review interim data will occur when approximately 80 patients (approximately 
40 patients from each arm) have received 2 cycles of treatment or discontinued all study 
treatment due to any reasons prior to Day 8 in Cycle 2. Subsequent iDMC meetings will occur
approximately every 6 months thereafter. Enrollment and treatment will continue during the 
iDMC safety assessments.  In the event a safety signal is detected, additional meetings may 
occur as needed. Details as to the process and communication plan will be provided in the 
iDMC Charter.
Interim PK analyses of the approximately 80 patients (approximately 40 patients from each arm) 
that will accompany the iDMC safety review will be performed by a Lilly PK scientist
independent from the study team.  These data will be provided to the iDMC upon request.
Interim efficacy analysis will be performed by the iDMC as described in Section 12.1. The
iDMC Charter (a separate document) will provide detailed guidance for the conduct of the 
interim analyses. 

I5B-MC-JGDJ(d) Clinical Protocol
Page 78
LY3012207
13. Informed Consent, Ethical Review, and Regulatory 
Considerations
13.1. Informed Consent
The investigator is responsible for ensuring that the patient understands the potential risks and 
benefits of participating in the study, including answering any questions the patient may have 
throughout the study and sharing in a timely manner any new information that may be relevant to 
the patient’s willingness to continue his or her participation in the trial.
The ICF will be used to explain the potential risks and benefits of study participation to the 
patient in simple terms before the patient is entered into the study, and to document that the 
patient is satisfied with his or her understanding of the risks and benefits of participating in the 
study and desires to participate in the study.
The investigator is responsible for ensuring that informed consent is given by each patient or, 
where permitted by local law or regulation, by the patient's legal representative.  This includes 
obtaining the appropriate signatures and dates on the ICF prior to the performance of any 
protocol procedures and prior to the administration of study treatments.
13.2. Ethical Review
Lilly or its representatives must approve all ICFs before they are used at the investigative sites.  
All ICFs must be compliant with the ICH guideline on GCP.
Documentation of ERB/IRB approval of the protocol and the ICF must be provided to Lilly
before the study may begin at the investigative sites. 
The study site’s IRB/ERBs should be provided with the following:

The current IB and updates during the course of the study

The ICF

Relevant curricula vitae
13.3. Regulatory Considerations
This study will be conducted in accordance with:

Consensus ethics principles derived from international ethics guidelines, including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences 
(CIOMS) International Ethical Guidelines 

ICH GCP Guideline (E6)

ICH Guideline, Clinical Investigation of Medicinal Products in the Pediatric Population 
(E11)

Applicable laws and regulations.
The investigator or designee will promptly submit the protocol to applicable ERBs/IRBs.
Some of the obligations of Lilly will be assigned to a TPO.

I5B-MC-JGDJ(d) Clinical Protocol
Page 79
LY3012207
An identification code assigned by the investigator to each patient will be used in lieu of the 
patient’s name to protect the patient’s identity when reporting AEs and/or other trial-related data.
13.3.1. Country-Specific Protocol Addenda
Revisions to the protocol are made to comply with local law and regulatory requirements and to 
address feedback received from competent authority reviews.  Where applicable, these changes 
are outlined in a country-specific protocol addendum associated with this protocol.  Participating 
investigators or their designee will promptly submit the country-specific protocol addendum to 
applicable ERBs/IRBs in accordance with their local procedures.  After reading the addendum, 
each investigator will sign the protocol addendum signature page, send a copy of the signed page 
to a Lilly representative, and subsequently comply with any local requirements contained in the 
relevant addendum.
13.3.2. Investigator Information
Physicians with a specialty in medical oncology with a specialty in STS will participate as 
investigators in this clinical trial.
13.3.3. Protocol Signatures
The Sponsor’s responsible medical officer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately describes the planned design and conduct of the 
study.
After reading the protocol, each principal investigator will sign the protocol signature page and 
send a copy of the signed page to a Lilly representative.
13.3.4. Final Report Signature
The clinical study report coordinating investigator will sign the final clinical study report for this 
study, indicating agreement that, to the best of his or her knowledge, the report accurately 
describes the conduct and results of the study. 
The Lilly responsible medical officer and statistician will sign/approve the final clinical study 
report for this study, confirming that, to the best of his or her knowledge, the report accurately 
describes the conduct and results of the study.

I5B-MC-JGDJ(d) Clinical Protocol
Page 80
LY3012207
14. References
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, 
Fleishman SB, de Haes JCJM, Kaasa S, Klee MC, Osoba D, Razavi D, Rofe PB, Schraub S, 
Sneeuw KCA, Sullivan M, Takeda F.The European Organisation for Research and Treatment 
of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in 
oncology. J Natl Cancer Inst. 1993;85:365-376.
[ACS] American Cancer Society. Cancer Facts and Figures. 2014. Available from URL: 
http://www.cancer.org/acs/groups/cid/documents/webcontent/003138-pdf.pdf
Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, 
Version 4.0, DCTD, NCI, NIH, DHHS. 2009. Publish date: 29 May 2009.
Cleeland CS. Pain assessment in cancer. In: Osoba D(ed). Effect of Cancer on Quality of Life, 
Chapter 21. CRC Press, Boca Raton FL, 1991.
Cockcroft DW, Gault MD. Prediction of creatinine clearance from serum creatinine. Nephron. 
1976;16:31-41.
Cox DR. Regression models and life-tables. J Royal Stat Soc Ser B. 1972;74(2):187-220.
D’Angelo SP, Tap WD, Schwartz GK, Carvajal RD. Sarcoma immunotherapy: past approaches 
and future directions. Sarcoma. 2014;2014:391967.
Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire 
toassess pain in cancer and other diseases. Pain. 1983;17(2):197-210.
Eisenhauer EA, Therasse P, Bogaert J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, 
Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. 
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). 
Eur J Cancer. 2009;45(2) 228-247.
[ESMO] European Society for Medical Oncology. Soft tissue and visceral sarcomas: ESMO 
Clinical Practice Guidelines for diagnosis, treatment and follow-up. The ESMO / European 
Sarcoma Network Working Group. Ann Oncol. 2014;25(Suppl 3):iii102–iii112.
Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in 
chronic pain intensity measured on an 11-point numerical pain rating scale. Pain.
2001;94(2):149-158.
Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the 
EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual (3rd Edition). 
Published by: European Organisation for Research and Treatment of Cancer, Brussels 2001.
Ger LP, Ho ST, Sun WZ, Wang MS, Cleeland CS. Validation of the Brief Pain Inventory in a 
Taiwanese population. J Pain Symptom Manage. 1999;18(5):316-322.
Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D, Bonsel G, Badia X. 
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). 
Qual Life Res. 2011;20(10):1727-1736.
Janssen MF, Birnie E, Haagsma JA, Bonsel GJ. Comparing the standard EQ-5D three-level 
system with a five-level version. Value in Health. 2008;11(2):274-284.

I5B-MC-JGDJ(d) Clinical Protocol
Page 81
LY3012207
Jones RL. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
Expert Rev Cardiovasc Ther. 2008;6(10):1311-1317.
Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, 
Whelan J, Hohenberger P, Krarup-Hansen A, Alcindor T, Marreaud S, Litière S, Hermans C, 
Fisher C, Hogendoorn PCW, dei Tos AP, Winette T. A Doxorubicin alone versus intensified 
doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue 
sarcoma: a randomised controlled phase 3 trial. The Lancet Oncology, 2014;15(4):415-423.
Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. J Amer Stat Assoc. 
1958;53:457-481.
Linch M, Miah AB, Thway K, Judson IR, Benson C. Systemic treatment of soft-tissue sarcoma -
gold standard and novel therapies. Nature Reviews Clinical Oncology 2014:11;187–202.
Maurer W, Bretz F. Multiple testing in group sequential trials using graphical approaches. Stat 
Biopharmaceut Res. 2013;5(4):311-320.
McMillan SC, Tittle M, Hagan S, Laughlin J. Management of pain and pain-related symptoms 
in hospitalized veterans with cancer. Cancer Nurs 2000;23(5):327-336.
[NCCN 2011] National Comprehensive Cancer Network. Clinical Practice Guidelines in 
Oncology. Soft Tissue Sarcoma. V1. 2011. Available at www.nccn.org.
[NCCN 2014] National Comprehensive Cancer Network. Guidelines v 2.2014 Myeloid Growth 
Factors. Available from URL: http://williams.medicine.wisc.edu/myeloid_growth.pdf.Oken 
MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and 
response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5:649-655.
Rowbotham MC. What is a "clinically meaningful" reduction in pain? Pain. 2001;94(2):131-132.
Schöffski P, Cornillie J, Wozniak A, Lia H, Hompes D. Soft Tissue Sarcoma: An Update on 
Systemic Treatment Options for Patients with Advanced Disease. Oncol Res Treat
2014;37:355–362.
Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, 
moderate or severe? Grading pain severity by its interference with function. Pain.
1995;61:277–284.
Shah GD, Loizos N, Youssoufian H, Schwartz JD, Rowinsky EK. Rationale for the development 
of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the 
platelet-derived growth factor receptor alpha. Cancer. 2010;116(4 Suppl):1018-1026.
Sharma S, Takyar S, Manson SC, Powell S, Penel N. Efficacy and safety of pharmacological 
interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a 
systemic review. BMC Cancer. 2013;13:385.
Shi Q, Wang XS, Mendoza TR, Pandya KJ, Cleeland CS. Assessing Persistent Cancer Pain: A
Comparison of Current Pain Ratings and Pain Recalled from the Past Week. Journal of Pain 
and Symptom Management. 2009;37(2):168-174.
Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, Lehman B, Benjamin EJ. 
Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the 
Framingham Heart Study). Am J Cardiol. 1999;83(6):897-902.

I5B-MC-JGDJ(d) Clinical Protocol
Page 82
LY3012207
Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, 
Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, 
Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, 
Wolff AC. 2006 update of recommendations for the use of white blood cell growth factors: an 
evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187-3205.
Stone AA, Broderick JE, Shiffman SS, Schwartz JE. Understanding recall of weekly pain from a
momentary assessment perspective: Absolute agreement, between- and within-person
consistency, and judged change in weekly pain. Pain. 2004;107(1-2):61-69.

I5B-MC-JGDJ(d) Clinical Protocol
Page 83
LY3012207
Attachment 1.
Protocol JGDJ Study Schedule

I5B-MC-JGDJ(d) Clinical Protocol 
 
Page 84 
LY3012207 
Study Schedule, Protocol I5B-MC-JGDJ 
Perform procedures as indicated.  All screening/baseline evaluations are performed within 14 days prior to randomization, unless 
otherwise specified.  Upon completion of all screening/baseline evaluations to confirm a patient’s eligibility, the site will register the 
patient by the IWRS. 
Baseline Schedule 
 
 
Study Period 
Baseline 
 
 
 
Cycle 
BL
 
 
 
Visit 
0
 
 
 
Duration 
Up to 14 days 
(except where noted) 
 
 
 
Relative Day from Randomization 
≤14
≤7
 
Procedure 
Category 
Protocol 
Sections 
Procedure 
 
Comments 
Study Entry/ 
Enrollment 
7 
13.1 
Informed Consent 
X (within 28 days 
of randomization) 
Written informed consent must be obtained prior to any study-specific screening 
evaluations.  For screening purposes, required assessments performed prior to the 
date of consent may be used provided they are noted exceptions.  
7.1, 7.2, 
9.3 
Inclusion/Exclusion Evaluation and IWRS 
 
X 
The patient will be randomized via IWRS after meeting inclusion/exclusion 
criteria.  After randomization, patients should receive their first dose of treatment 
within 72 hours (3 days) whenever possible. 
Medical 
History 
10.3.1 
Medical History 
X 
Any preexisting and pretreatment toxicity (treatment or disease related) should be 
documented and recorded as part of the pretreatment medical history.  Disease 
characteristics at initial diagnosis and at study entry will be collected. 
All adverse events must be recorded after signing the informed consent. 
7 
Demography 
X 
Date of birth, sex, and race/ethnicity will be collected at baseline. 
7 
Prior Treatment Therapies of Underlying Disease 
X 
Prior treatment includes any treatment for underlying disease, including 
maintenance therapy.  Start and stop dates should be documented as well.  
Previous therapy must be completed ≥ 4 weeks (28 days) prior to randomization. 
Physical 
Examination 
7 
Physical Examination 
 
X
Physical examination at baseline includes height, weight, and BSA measurement.  
7.1 
Att. 4 
ECOG Performance Status 
 
X 
Refer to Attachment 4 for details. 
7 
Vital signs 
 
X
Vital signs include blood pressure, pulse, and temperature.
Concomitant 
Medications 
9.6 
Concomitant Medications 
X (within 30 days 
of C1D1) 
Concomitant medications will be recorded, including any taken within 30 days 
prior to start of study treatment. 
 
 
 
 
 
 
7.1 
Att. 2 
Hematology 
X 
Screening evaluations done within 7 days prior to randomization do not have to be 
repeated.  
7.1 
Att. 2 
Serum Chemistry  
X 
Screening evaluations done within 7 days prior to randomization do not have to be 
repeated.   
7.1 
Att. 2 
Coagulation Profile  
X 
Screening evaluations done within 7 days prior to randomization do not have to be 
repeated.   

I5B-MC-JGDJ(d) Clinical Protocol
Page 85
LY3012207
Baseline Schedule
Study Period
Baseline
Cycle
BL
Visit
0
Duration
Up to 14 days
(except where noted)
Relative Day from Randomization
≤14
≤7
Procedure 
Category
Protocol 
Sections
Procedure
Comments
Lab/
Diagnostic 
Tests
Att. 2
Urinalysis 
X
Screening evaluations done within 7 days prior to randomization do not have to be 
repeated. Includes a routine urinalysis (UA), and if clinically indicated a 
microscopic analysis.  If routine analysis indicates ≥2+ proteinuria, then a 24-hour 
urine must be collected and must demonstrate ≤1000 mg of protein in 24 hours or 
a urine protein/creatinine ratio must be ≤1 in a spot urine test, prior to proceeding 
to treatment.
7.1
Att. 2
Pregnancy Test 
X
Serum β-HCG pregnancy test (women of childbearing potential only) within 
7 days prior to randomization.  If the serum pregnancy test performed for 
inclusion purposes is positive, confirm by repeating and performing a urine 
pregnancy test. The results of this test will not be collected on the eCRF.
7.1
Att. 2
Follicle-stimulating Hormone (FSH) 
X
Performed only at screening in menopausal women that have experienced 
spontaneous amenorrhea for 6 to 12 months.  To be done for women only when 
needed to confirm postmenopausal status.
10.4.2.3
Att. 7
Mandatory Tumor Tissue 
X (within 28 days
of randomization)
Mandatory archived tumor tissue or tumor tissue from biopsy (if adequate 
archived samples are unavailable) for biomarkers and tumor type (refer to 
Section 10.4.2.3 for details).
10.3.2.1
ECG (local)
X (within 28 days
of randomization)
A single 12-lead ECG is to be obtained within 28 days prior to randomization
(refer to Section 10.3.2.1 for details).
10.3.2.2
Echocardiogram or MUGA scan
X (within 28 days
of randomization)
Within 28 days prior to randomization (refer to Section 10.3.2.2 for details).
Efficacy
Assessment
8.1.1
10.1.1
Att. 6
Imaging Studies (CT/MRI)
Tumor Assessments (according to RECIST v1.1)
X (within 28 days
of randomization)
Within 28 days prior to randomization (refer to Section 10.1.1 and Section 8.1.1
for details).
Patient Disposition
X
At the time that the patient is discontinued from Study Participation, information 
regarding the patient status will be collected.
Abbreviations:  β-HCG = beta human chorionic gonadotropin; BL = baseline; BSA = body surface area; C1D1 = Cycle 1 Day 1; CT = computed tomography; CTCAE = Common Terminology Criteria 
for Adverse Events; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; eCRF = electronic case report form; FFPE = formalin-fixed paraffin embedded; FSH = follicle-
stimulating hormone; IWRS = interactive web-response system; MRI = magnetic resonance imaging; MUGA = multigated acquisition; PRO = patient-reported outcome; RECIST = Response Evaluation 
Criteria In Solid Tumors; v = version.

I5B-MC-JGDJ(d) Clinical Protocol
Page 86
LY3012207
Study Schedule, Protocol I5B-MC-JGDJ
Perform procedures as indicated.
Treatment Period Schedule
Study Period
Treatment Period
Cycle (21-day cycle ± 3 days)
1-8
9+
Relative Day within Cycle 
(± 3 days)
1a
8a
1a
8a
Procedure 
Category
Protocol 
Section
Procedure
Comments
Physical 
Examination
10.3.1
Physical Examination
X
X
X
X
Physical examination during treatment period includes weight and BSA 
measurement.  Patients should be weighed on D1 and D8 of each cycle
and BSA calculated.
Att. 4
ECOG Performance Status
X
X
Complete prior to treatment infusion. 
10.3.1
Vital signs
X
X
X
X
Vital signs include blood pressure, pulse, and temperature.
During the Observation Period (initial 2 cycles), collect vital signs : 1)
within 15 minutes (+5 minutes) prior to olaratumab/placebo infusion, 2)
within 1 hour (+5 minutes) after completion of the olaratumab/placebo 
infusion, and 3) within 1 hour (+5 minutes) after completion of the 
doxorubicin infusion if applicable.  
Thereafter (Cycles 3+), obtain vital signs: 1) within 15 minutes (+5 
minutes) prior to olaratumab/placebo infusion and 2) within 1 hour (+5 
minutes) after completion of the doxorubicin infusion if applicable.
Lab/
Diagnostic Tests
Att. 2
Hematology 
X
X
X
X
Laboratory assessments may be done within 3 days prior to D1 and D8 of 
each cycle.  See Attachment 2 for details.
Att. 2
Serum Chemistry 
X
X
Laboratory assessments may be done within 3 days prior to D1 of each 
cycle.  See Attachment 2 for details.
Att. 2
Coagulation Profile 
X
X
Laboratory assessments may be done within 3 days prior to D1 every 
other cycle or as clinically indicated.  See Attachment 2 for details.
Att. 2
Pregnancy Test 
X
X
Serum or urine pregnancy test on D1 of every cycle or per local practice 
(whichever is of shorter duration).  If the pregnancy test performed on D1 
of the cycle is positive, confirm with a serum pregnancy test (pregnancy 
test results are not recorded on the eCRF).
10.4.4
PK Samples
See Attachment 7 for specific time points
Whole blood samples collected.
10.4.3
Immunogenicity Samples
See Attachment 7 for specific time points
Whole blood samples collected.  If a patient experiences an infusion-
related reaction (IRR) to olaratumab, blood samples for immunogenicity 
and PK analysis will be taken at the following time points:  (1) as soon as 
possible after the onset of the IRR, (2) at the resolution of the IRR, and 
(3) 30 (± 3 days) days after onset of the IRR event.

I5B-MC-JGDJ(d) Clinical Protocol
Page 87
LY3012207
Treatment Period Schedule
Study Period
Treatment Period
Cycle (21-day cycle ± 3 days)
1-8
9+
Relative Day within Cycle 
(± 3 days)
1a
8a
1a
8a
Procedure 
Category
Protocol 
Section
Procedure
Comments
10.4.2.2
Pharmacogenetic (DNA) Whole 
Blood Sample
See Attachment 7 for specific time points.
Whole blood sample collected.  It is highly recommended to draw the 
whole blood sample prior to the first dose (C1D1 at predose); however, it 
can be collected later during the study if necessary.
10.4.2.1
Plasma sample for biomarkers
See Attachment 7 for time points.
Plasma sample collected.
10.3.2.1
ECG 
X
X
After C9
q3m
year 1, 
q6m 
year 2, 
annually 
there-
after
Twelve-lead ECGs are to be performed on Day 1 of Cycle 1 to Cycle 9. 
After Cycle 9, perform ECGs every 3 months (±2 weeks) the first year, 
every 6 months (± 2weeks) the second year, and annually (±2 weeks) 
thereafter. Perform more frequently, if clinically indicated.
Patients who stop doxorubicin prior to Cycle 8 will undergo the same 
cardiac monitoring frequency described above.
10.3.2.2
Echocardiogram or MUGA
X 
C5, C7, 
and C9
X
After C9
q3m
year 1, 
q6m 
year 2, 
annually 
there-
after
Echocardiograms or MUGA scans are to be performed within 7 days 
prior to start of treatment in Cycles 5, 7, and 9.  After Cycle 9 (for 
patients with resting LVEF 50%), perform echocardiograms or MUGA 
scans every 3 months (±2 weeks) the first year, every 6 months (±2 
weeks) the second year, and annually (±2 weeks) thereafter.  For patients 
with LVEF 50% or other cardiac dysfunction,  perform more frequently, 
if clinically indicated.
Patients who stop doxorubicin prior to Cycle 8 will undergo the same 
cardiac monitoring frequency described above.
Health Outcomes
10.2
PRO Assessments (mBPI-sf, 
EORTC QLQ C30, EQ-5D-5L)
X
X
The Patient Reported Outcome (PRO) measures will be collected on 
Day 1 of every cycle.
Efficacy
Assessment
8.1.1
10.1.1
Att. 6
Imaging Studies (CT/MRI)
Tumor Assessments (according to 
RECIST v1.1)
X
X
Imaging studies and tumor assessments are be obtained every 6 weeks 
(±7 days), irrespective of treatment cycles as calculated from 
randomization, until documented progression for patients with CR, PR, 
or SD, and/or for patients who have discontinued study treatment due to 
toxicity or reasons other than PD. Refer to Section 10.1.1 and Section 
8.1.1 for details.
Adverse Events 
Collection/
CTCAE Grading
10.3.1
Toxicity Assessment
X
X
X
X
All AEs considered at least possibly-related to study treatment will be 
followed until resolution, stabilization, return to baseline, or until deemed 
irreversible.
Concomitant 
Therapy
9.6
Concomitant Medications
X
X
X
X
Concomitant medications will be recorded throughout the treatment 
period, including those taken during the 30 days after the last dose of all 
study treatment.

I5B-MC-JGDJ(d) Clinical Protocol
Page 88
LY3012207
Treatment Period Schedule
Study Period
Treatment Period
Cycle (21-day cycle ± 3 days)
1-8
9+
Relative Day within Cycle 
(± 3 days)
1a
8a
1a
8a
Procedure 
Category
Protocol 
Section
Procedure
Comments
Premedication
9.1.1
Administer dexrazoxane prior to 
doxorubicin
X
Dexrazoxane is recommended for all patients receiving 5 or more cycles 
of doxorubicin.
9.1.1
Administer premedication prior to 
olaratumab or placebo treatment 
X
X
X
X
Premedicate all patients with the following medications (or equivalent): a
histamine H1 antagonist (eg, diphenhydramine) and dexamethasone  
intravenously 30–60 minutes prior to the olaratumab/placebo doses on 
Days 1 and 8 of Cycle 1.  For subsequent cycles, premedicate all patients 
with a histamine H1 antagonist (eg, diphenhydramine) intravenously 30-
60 minutes prior to each dose of olaratumab or placebo. 
Study Treatment
9.2.1
Administer olaratumab or placebo
X
X
X
X
Administer until PD, unacceptable toxicity, death, or other withdrawal 
criteria are met.  No crossover will be permitted.
9.2.2
Administer doxorubicin
X
Administered to all patients for the first 8 cycles (unless previous 
unacceptable toxicity).
Patient Disposition
At the time that the patient is discontinued from any component of the 
study treatment or Study Participation, information regarding the patient 
status will be collected.
a
Study procedures will be performed prior to study drug administration, except where noted (such as vital signs).  In case of dose interruption, these evaluations will also be done at minimum 
frequency every 21 days (±3 days).
Abbreviations:  BSA = body surface area; C1D1 = Cycle 1 Day 1; CT = computed tomography; CTCAE = Common Terminology Criteria for Adverse Events; D = Day; D/C = discontinuation; 
ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; eCRF = electronic case report form; IRR = infusion-related reaction; MRI = magnetic resonance imaging; PD = progressive 
disease; q3c = every 3 cycles; RECIST = Response Evaluation Criteria in Solid Tumors.

I5B-MC-JGDJ(d) Clinical Protocol
Page 89
LY3012207
Study Schedule, Protocol I5B-MC-JGDJ
Perform procedures as indicated.
Post-Treatment Discontinuation Schedule
Study Period
Post-discontinuation Follow-Up
Short-Term Follow-Up
Long-Term Follow-Up
Visit
801
802-8XX
Duration
30 ± 7 days
See footnote for duration
Procedure 
Category
Protocol 
Section
Procedure
Comments
Physical 
Examination 
10.3.1
Physical examination
X
Physical examination will include weight.
Att. 4
ECOG performance status
X
10.3.1
Vital signs
X
Includes blood pressure, pulse and temperature.
Lab/
Diagnostic 
Tests
Att. 2
Hematology 
X
See Attachment 2 for details.
Att. 2
Serum chemistry 
X
See Attachment 2 for details.
Att. 2
Coagulation profile
X
See Attachment 2 for details.
Att. 2
Urinalysis
X
Includes a routine urinalysis (UA), and if clinically indicated a microscopic 
analysis.  If urine dipstick or routine analysis indicates proteinuria ≥2+, a 
24-hour urine collection or urine protein/creatinine ration in spot urine test (to 
assess protein) must be obtained.
Att. 2
Pregnancy test
X
Serum or urine pregnancy test.  If the pregnancy test is positive, confirm with 
a serum pregnancy test (pregnancy test results are not recorded on the eCRF).
Additional pregnancy tests may be done after short-term follow-up if required 
by local regulation.
10.3.2.1
ECG
X
X
Twelve-lead ECGs are to be performed for all patients at the short–term 
follow-up.  
After the patient has stopped receiving doxorubicin and throughout the long-
term follow-up, ECGs are to be performed every 3 months (±2 weeks) the first 
year, every 6 months (±2 weeks) the second year, then annually (±2 weeks) 
thereafter as long as the patient is alive and has not withdrawn consent to
follow-up. Perform more frequently if clinically indicated.
10.3.2.2
Echocardiogram or MUGA
X
X
Echocardiogram or MUGA scans are to be performed for all patients at the 
short-term follow-up. 
After the patient has stopped receiving doxorubicin and throughout the long-
term follow-up, (for patients with resting LVEF 50%) perform 
echocardiogram or MUGA scans every 3 months (±2 weeks) the first year, 
every 6 months(±2 weeks) the second year, then annually (±2 weeks)  
thereafter as long as the patient is alive and has not withdrawn consent to 
follow-up. For patients with LVEF 50% or other cardiac dysfunction,  
perform more frequently, if clinically indicated.
10.4.4
PK sample
X
See Attachment 7.

I5B-MC-JGDJ(d) Clinical Protocol
Page 90
LY3012207
Study Period
Post-discontinuation Follow-Up
Short-Term Follow-Up
Long-Term Follow-Up
Visit
801
802-8XX
Duration
30 ± 7 days
See footnote for duration
Procedure 
Category
Protocol 
Section
Procedure
Comments
10.4.3
Immunogenicity sample
X
See Attachment 7.  In addition, if a patient experiences an IRR to 
olaratumab/placebo, blood samples for immunogenicity and PK analysis will 
be taken at the short-term follow-up after the IRR.
10.4.2.1
Plasma sample for biomarkers
X
See Attachment 7.
Health 
Outcomes
10.2
PRO Assessments (mBPI-sf, 
EORTC QLQ C30, EQ-5D-
5L)
X
X
The Patient Reported Outcome (PRO) measures will be collected at the 30-day 
short term follow-up visit.
A full due diligence will be taken to collect PRO measures during long-term 
follow-up (every 6 weeks [±7 days] until PD, thereafter every 3 months [±2 
weeks] for the first year, every 6 months (±2 weeks) the second year, then 
annually [±2 weeks] thereafter until the patient’s death or overall study 
completion).
Efficacy 
Assessments
10.1.1
Att. 6
Imaging/Tumor Assessments 
(according to RECIST v1.1)
X (if applicable)
X
For patients who discontinue study treatment for any reason without 
objectively measured PD, imaging studies and tumor assessments are be 
obtained every 6 weeks (±7 days), irrespective of treatment cycles as 
calculated from randomization, until documented progression.
8.1.2
Survival Information,All 
Subsequent Anti-Cancer 
Treatments, and Associated 
Disease Progression Date
X
For patients that discontinue study treatment after objectively measured PD 
the following information will be collected every 2 months (±7 days) for the 
first 2 years, then every 6 months (±14 days) until the patient’s death, or 
overall study completion:  details on all subsequent anticancer treatment 
(start/stop dates and treatments administered; first post-study treatment disease 
progression date; and survival status.
Adverse Events 
Collection/
CTCAE 
Grading
10.3.1
Toxicity assessment
X
X
All AEs considered at least possibly-related to study treatment will be 
followed until resolution, stabilization, return to baseline, or until deemed 
irreversible.  After the 30-day short-term follow-up visit, only new and 
ongoing SAEs deemed related to study treatment will be collected.
Concomitant 
Medication 
Notation
9.6
Concomitant medications
X
Patient Disposition
X
X
At the time that the patient is discontinued from Study Participation, 
information regarding the patient status will be collected.
Abbreviations:  AE = adverse event; CT = computed tomography; CTCAE = Common Terminology Criteria for Adverse Events; ECG = electrocardiogram; eCRF = electronic case report form; 
ECOG = Eastern Cooperative Oncology Group; PD = progressive disease; PRO = patient-reported outcome; QoL = quality of life; RECIST = Response Evaluation Criteria in Solid Tumors; 
SAE = serious adverse event.
Short-term follow-up begins the day after the patient and the investigator agree that the patient will no longer continue study treatment and lasts approximately 30 days (±7 days).  The short-term 
follow-up visit occurs at or near the end of the short-term follow-up period (±7 days). The date of this agreement is to be reported on the eCRF as the Date of Discontinuation from study treatment.
Long-term follow-up: begins the day after the patient completes short-term follow-up

Follow-up for progression: Patients that discontinue study treatment for reasons other than progression will be followed every 6 weeks (±7 days) until PD.

Follow-up for survival:  Patients will be followed every 2 months (±7 days) for the first 2 years, then every 6 months (±14 days) until the patient’s death or overall study completion.

I5B-MC-JGDJ(d) Clinical Protocol
Page 91
LY3012207
Study Schedule, Protocol I5B-MC-JGDJ
Perform procedures as indicated.
Continued Access Period Schedule
Study Period
Continued Access 
Treatment Period
Continued Access 
Follow-Up Period
Cycle
X-Y
Follow-Up
Visit
501-5XX
901
Duration
1
30 ± 7 days
Procedure 
Category
Protocol 
Section
Procedure
Comments
Adverse Events 
Collection/CTC
AE Grading
10.3.1
Toxicity assessment
X
X
All AEs/SAEs will be followed for up to 30 days after the patient 
and investigator agree that the patient will no longer continue 
study treatment.
Concomitant 
Therapy
9.6
Concomitant Medications 
X
Concomitant medications will be recorded throughout the 
treatment period, including those taken during the 30 days after 
the last dose of all study treatment.
Lab/Diagnostic 
Tests
Att. 7
Immunogenicity/Pharmacokinetics
X
X
If a patient experiences an IRR to olaratumab during the 
Continued Access Period, blood samples for immunogenicity 
and PK analysis will be taken at the following time points:  (1) 
as soon as possible after the onset of the IRR, (2) at the 
resolution of the IRR, and (3) 30 days (±3 days) after the IRR.
Premedications
9.1.1
Administer premedication prior to 
olaratumab treatment
X
Premedicate all patients with a histamine H1 antagonist (eg, 
diphenhydramine) intravenously 30-60 minutes prior to each 
dose of olaratumab. 
Study 
Treatment
9.2.1
Administer olaratumab
X
Administer until evidence of progressive disease (PD), 
unacceptable toxicity, death, or other withdrawal criteria are met.
Abbreviations:  AEs = adverse events; CTCAE = Common Terminology Criteria for Adverse Events; eCRF = electronic case report form; IRR = infusion-related reaction; PK = pharmacokinetics; 
SAE = serious adverse events.
Continued access follow-up begins the day after the patient and the investigator agree that the patient will no longer continue study treatment in the continued access period, and lasts until the 
continued-access follow-up visit is completed, approximately 30 days (±7 days) later.

I5B-MC-JGDJ(d) Clinical Protocol
Page 92
LY3012207
Attachment 2.
Protocol JGDJ Clinical Laboratory Tests
All laboratory evaluations are to be performed within 14 days prior to randomization or study 
drug administration, unless otherwise specified (refer to Attachment 1).  Eligibility for inclusion 
in this clinical trial will be based on local clinical laboratory results (not transcribed onto 
eCRFs); duplicate samples will be submitted to the central laboratory.  For patient and study site 
convenience and safety, treatment decisions may be based upon results of tests performed 
locally.  If local laboratory tests are used for this purpose, then a duplicate specimen must be 
submitted to the central laboratory. Discrepancies between local and central laboratory that may 
have an impact on eligibility or treatment decisions will not be considered protocol deviations.  
On-study clinical laboratory tests assayed for patient safety (such as hematology, serum 
chemistry, coagulation, and pregnancy tests) are to be collected prior to study treatment.

I5B-MC-JGDJ(d) Clinical Protocol
Page 93
LY3012207
Clinical Laboratory Tests
Hematologya,b
Clinical Chemistrya,b
Hemoglobin
Serum Concentrations of the following:
Hematocrit
Sodium
Erythrocyte count (RBC)
Potassium
Mean cell volume
Total bilirubin
Mean cell hemoglobin concentration
Alkaline phosphatase
Leukocytes (WBC)
Alanine aminotransferase (ALT)
Neutrophils
Aspartate aminotransferase (AST)
Lymphocytes
Gammaglutamyl transferase
Monocytes
Blood urea nitrogen (BUN)
Eosinophils
Creatinine
Basophils
Uric acid
Platelets
Calcium
Glucose, random
Coagulation Testa
Albumin
Prothrombin time (PT or INR)
Total protein
Partial thromboplastin time (PTT or aPTT)
Chloride
Bicarbonate
Urinalysisa,c
Direct bilirubin
Specific gravity
pH
Pregnancy testa,e
Protein
Glucose
Follicle-stimulating hormone (FSH)a,f
Ketones
Blood
Exploratory Biomarker Testsd
Urine leukocyte esterase
Refer to Section 10.4.2
Otherd
Immunogenicity samples
PK samples
Abbreviations:  aPTT = activated partial thromboplastin time; CRP = clinical research physician; INR = international normalized 
ratio; PK = pharmacokinetic; WOCBP = women of childbearing potential
a
Assayed by local or investigator-designated laboratory
b
Duplicate samples will also be assayed by Sponsor-designated laboratory.
c
If urinary protein is ≥2+ at evaluations, a 24-hour urine collection (to assess protein) must be collected or urine 
protein/creatinine ratio in spot urine test must be conducted. Urine protein creatinine ratio of spot urine is an estimation of 
the 24-hour urine protein excretion – a UPC ratio of 1 is roughly equivalent to a 24-hour urine protein of 1000 mg. UPC ratio 
is calculated using one of the following formulae:
     A) [urine protein]/[urine creatinine] – if both protein and creatinine are reported in mg/dL
     B) [(urine protein) x 0.088]/[urine creatinine] – if urine creatinine is reported in mmol/L.
d
Assayed by a Sponsor-designated (central) laboratory.  Refer to Attachment 7.
e
Serum pregnancy test will be performed at screening in females of childbearing potential only (if the baseline serum test is 
positive, a repeat serum and urine pregnancy test will be done; if those results are inconclusive, the investigator is to consult 
with the Lilly CRP regarding if dosing should occur and which follow-up laboratory tests are performed).  While on-study, 
serum or urine pregnancy tests will be performed in females of childbearing potential only on Day 1 of every cycle or per 
local practice (whichever is of shorter duration) and at short-term follow-up visit.  If the serum pregnancy test performed for 
inclusion purposes is positive confirm by repeating the serum and performing a urine pregnancy test.  If the pregnancy test 
performed on Day 1 of each cycle is positive, confirm with a serum pregnancy test.
f
Performed only at screening in menopausal women that have experienced spontaneous amenorrhea for 6 to 12 months. To be 
done for women only when needed to confirm postmenopausal status.

I5B-MC-JGDJ(d) Clinical Protocol
Page 94
LY3012207
Attachment 3.
Protocol JGDJ Hepatic Monitoring Tests 
for Treatment-Emergent Abnormality
Selected tests may be obtained in the event of a treatment-emergent hepatic abnormality and may 
be required in follow up with patients in consultation with the Lilly clinical research physician.
Hepatic Monitoring Tests
Hepatic Hematologya
Haptoglobina
Hemoglobin
Hematocrit
Hepatic Coagulationa
RBC
Prothrombin Time
WBC
Prothrombin Time, INR
Neutrophils
Lymphocytes
Hepatic Serologiesa,b
Monocytes
Hepatitis A antibody, total
Eosinophils
Hepatitis A antibody, IgM
Basophils
Hepatitis B surface antigen
Platelets
Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistrya
Hepatitis C antibody
Total bilirubin
Hepatitis E antibody, IgG
Direct bilirubin
Hepatitis E antibody, IgM
Alkaline phosphatase
ALT
Anti-nuclear antibodya
AST
GGT
CPK 
Anti-smooth muscle antibodya
Abbreviations:  ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatine phosphokinase; 
GGT = gamma-glutamyl transferase; IgG =immunoglobin G; IgM = immunoglobin M; INR = international 
normalized ratio; RBC = red blood cell; WBC = white blood cell.
a
Assayed by Lilly-designated laboratory.
b
Reflex/confirmation dependent on regulatory requirements and/or testing availability.

I5B-MC-JGDJ(d) Clinical Protocol
Page 95
LY3012207
Attachment 4.
Protocol JGDJ ECOG Performance Status
ECOG Performance Status
Activity Status
Description
0
Fully active, able to carry on all pre-disease performance without 
restriction
1
Restricted in physically strenuous activity but ambulatory and able to 
carry out work of a light or sedentary nature, e.g., light house work, 
office work
2
Ambulatory and capable of all selfcare but unable to carry out any 
work activities. Up and about more than 50% of waking hours
3
Capable of only limited selfcare, confined to bed or chair more than 
50% of waking hours
4
Completely disabled. Cannot carry on any selfcare. Totally confined 
to bed or chair
5
Dead.
Source:  Oken et al. 1982.

I5B-MC-JGDJ(d) Clinical Protocol
Page 96
LY3012207
Attachment 5.
Protocol JGDJ Creatinine Clearance 
Formula
Note:  This formula is to be used for calculating creatinine clearance (CrCl) from local 
laboratory results only.  
For serum creatinine 
concentration in mg/dL:
CrCl =
(mL/min) 
(140 – agea) (wt)    0.85 (if female), or 1.0 (if male)
72 serum creatinine (mg/dL)
For serum creatinine concentration in mol/L:
CrCl  =
(mL/min)
(140 – agea) (wt)  0.85 (if female), or 1.0 (if male)
0.81 serum creatinine (mol/L)
a age in years, weight (wt) in kilograms.
Reference:  Cockcroft and Gault 1976.

I5B-MC-JGDJ(d) Clinical Protocol
Page 97
LY3012207
Attachment 6.
Protocol JGDJ RECIST Criteria 1.1
Response and progression will be evaluated in this study using the international criteria proposed 
by the New Response Evaluation Criteria in Solid Tumors (RECIST): Revised RECIST 
Guideline (version 1.1; Eisenhauer et al. 2009).  
Measurability of Tumor at Baseline
Tumor lesions/lymph nodes will be categorized at baseline as measurable or nonmeasurable.  
Measurable disease is defined by the presence of at least 1 measurable lesion.
Measurable 
Tumor lesions:  Measured in at least 1 dimension (longest diameter in the plane of measurement 
is to be recorded) with a minimum size of:

10 mm by computed tomography (CT) or magnetic resonance imaging (MRI) 
scan (slice thickness 5 mm) 

10 mm caliper measurement by clinical exam (non-measurable lesions if cannot 
be accurately measured with calipers)

20 mm by chest X-ray.
Malignant lymph nodes:  To be considered pathologically enlarged and measurable, a lymph 
node must be 15 mm in short axis when assessed by CT scan (CT scan thickness recommended 
to be 5 mm).
Nonmeasurable 
All other lesions, including small lesions (longest diameter <10 mm or pathological lymph nodes 
with 10 to <15 mm short axis) as well as truly nonmeasurable lesions.  Lesions considered truly 
non-measurable include:  leptomeningeal disease, ascites, pleural/pericardial effusions, 
lymphangitis cutis/pulmonis, inflammatory breast disease, lymphangitis involvement of skin or 
lung, abdominal masses/abdominal organomegaly identified by physical exam that is not 
measurable by reproducible imaging techniques.
Special Considerations for Lesion Measurability
Bone lesions:  

Bone scan, PET scan or plain films are not considered adequate imaging 
techniques to measure bone lesions.

Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue
components, that can be evaluated by cross sectional imaging techniques such as 
CT or MRI, can be considered measurable lesions if the soft tissue component 
meets the definition of measurability.

Blastic bone lesions are non-measurable.

I5B-MC-JGDJ(d) Clinical Protocol
Page 98
LY3012207
Cystic lesions:  

Simple cysts should not be considered as malignant lesions (neither 
measurable nor nonmeasurable) 

Cystic lesions thought to represent cystic metastases can be considered as 
measurable lesions, if they meet the definition of measurability.  If noncystic 
lesions are presented in the same patients, these are preferred for selection as 
target lesions.
Lesions with Prior Local Treatment:

Tumor lesions situated at a previously irradiated area, or in an area subjected to other 
loco-regional therapy, are non-measurable unless there has been demonstrated 
progression in the lesion.  
Baseline Documentation of Target and Non-Target Lesion
Target Lesions
When more than 1 measurable lesion is present at baseline, all lesions up to a maximum of 5 
lesions total (and a maximum of 2 lesions per organ) representative of all involved organs should 
be identified as target lesions and will be recorded and measured at baseline. Non-nodal Target 
lesions should be selected on the basis of their size (lesions with the longest diameter), be 
representative of all involved organs, and can be reproduced in repeated measurements.  
Measurable lymph nodes are target lesions if they meet the criteria of a short axis of 15 mm by 
CT scan.  All measurements are to be recorded in the case record form (CRF) in millimeters (or 
decimal fractions of centimeters [cm]).
Nontarget Lesions
All other lesions (or sites of disease) are identified as nontarget lesions (chosen based on their 
representativeness of involved organs and the ability to be reproduced in repeated measurements) 
and should be recorded at baseline.  Measurement of these lesions are not required but should be 
followed as ‘present,’ ‘absent,’ or in rare cases ‘unequivocal progression.’  In addition, it is 
possible to record multiple nontarget lesions involving the same organ as a single item on the 
CRF (for example, multiple liver metastases recorded as 1 liver lesion).
Lymph nodes with short axis 10 mm but <15 mm should be considered nontarget lesions.  
Nodes that have a short axis <10 mm are considered nonpathological and are not recorded or 
followed.
Specifications by Methods of Measurement
All measurements should be recorded in metric notation, using a ruler or calipers if clinically 
assessed.  All baseline evaluations should be performed as closely as possible to the beginning of 
treatment and never more than 4 weeks before the beginning of the treatment.
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow-up.  Imaging-based evaluation is 

I5B-MC-JGDJ(d) Clinical Protocol
Page 99
LY3012207
should always be done rather than clinical examination unless the lesion(s) being followed 
cannot be imaged but are assessed by clinical exam.  
An adequate volume of a suitable contrast agent should be given so that the metastases are 
demonstrated to best effect and a consistent method is used on subsequent examinations for any 
given patient.  If prior to enrollment it is known a patient is not able to undergo CT scans with IV 
contrast due to allergy or renal insufficiency, the decision as to whether a non-contrast CT or 
MRI (with or without IV contrast) should be used to evaluate the patient at baseline and follow-
up should be guided by the tumor type under investigation and the anatomic location of the 
disease.
Clinical Lesions:  Clinical lesions will only be considered measurable when they are superficial 
and 10 mm diameter as assessed using calipers (for example, skin nodules).  For the case of 
skin lesions, documentation by color photography, including a ruler to estimate the size of the 
lesion is recommended.  When lesions can be evaluated by both clinical exam and imaging, 
imaging evaluation should be undertaken since it is more objective and may be reviewed at the 
end of the study.
Chest X-ray:  Chest CT is preferred over chest X-ray when progression is an important endpoint.  
Lesions on chest X-ray may be considered measurable if they are clearly defined and surrounded 
by aerated lung.
CT and MRI:  CT scan is the best currently available and reproducible method to measure lesions 
selected for response assessment.  Measurability of lesions on CT scan is based on the 
assumption that CT slice thickness is 5 mm.  When CT scan have slice thickness >5 mm, the 
minimum size for a measurable lesion should be twice the slice thickness.  MRI is also 
acceptable in certain situations (for example, for body scans).  If there is concern about radiation 
exposure at CT, MRI may be used instead of CT in selected instances.  
Ultrasound:  Ultrasound should not be used to measure lesion size.  Ultrasound examinations 
cannot be reproduced in their entirety for independent review at a later date and, because they are 
operator dependent, it cannot be guaranteed that the same technique and measurements will be 
taken from one assessment to the next.  If new lesions are identified by ultrasound in the course 
of the study, confirmation by CT or MRI is advised.
Endoscopy, Laparoscopy:  The utilization of these techniques for objective tumor evaluation is 
not advised.  However, such techniques can be useful to confirm complete pathological response 
when biopsies are obtained or to determine relapse in trials where recurrence following complete 
response or surgical resection is an endpoint.
Tumor Markers:  Tumor markers alone cannot be used to assess tumor response.  If markers are 
initially above the upper normal limit, they must normalize for a patient to be considered in 
complete response (CR).  Specific guidelines for both prostate-specific antigen (PSA) response 
(in recurrent prostate cancer) and CA-125 response (in recurrent ovarian cancer) have been 
published.  

I5B-MC-JGDJ(d) Clinical Protocol
Page 100
LY3012207
Cytology, Histology:  These techniques can be used to differentiate between partial responses 
(PR) and complete response (CR) in rare cases if required by protocol (for example, residual 
lesions in tumor types such as germ cell tumors, where known residual benign tumors can 
remain).  When effusions are known to be a potential adverse effect of treatment (for example, 
with certain taxane compounds or angiogenesis inhibitors), the cytological confirmation of the 
neoplastic origin of any effusion that appears or worsens during treatment can be considered if 
the measurable tumor has met criteria for response or stable disease (SD) in order to differentiate 
between response (or SD) and progressive disease (PD). 
Pet Scan (FDG-PET, PET CT):  PET is not recommended for lesion assessment. If a new lesion 
is found by PET, another assessment must be done by CT, unless the PET CT is of diagnostic 
quality.  If CT is done to confirm the results of the earlier PET scan, the date of progression must 
be reported as the earlier date of the PET scan. 
Bone Scan:  If lesions measured by bone scan are reported at baseline, it is necessary to repeat 
the bone scan when trying to identify a complete response (CR) or partial response (PR) in target 
disease or when progression in bone is suspected. 
Response Criteria
Evaluation of Target Lesions 
Complete Response (CR):  Disappearance of all target lesions.  Any pathological lymph nodes 
(whether target or non-target) must have reduction in short axis to <10 mm.  Tumor marker 
results must have normalized.
Partial Response (PR):  At least a 30% decrease in the sum of diameter of target lesions, taking 
as reference the baseline sum diameters.
Progressive Disease (PD):  At least a 20% increase in the sum of the diameters of target lesions, 
taking as reference the smallest sum on study (including the baseline sum if that is the smallest).  
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase 
of at least 5 mm.  The appearance of 1 or more new lesions is also considered progression.
For equivocal findings of progression (for example, very small and uncertain new lesions; cystic 
changes or necrosis in existing lesions), treatment may continue until the next scheduled 
assessment.  If at the next scheduled assessment, progression is confirmed, the date of 
progression should be the earlier date when progression was suspected.
Stable Disease (SD):  Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum diameters while on study.
Not Evaluable:  When an incomplete radiologic assessment of target lesions is performed or 
there is a change in the method of measurement from baseline that impacts the ability to make a 
reliable evaluation of response. 
Evaluation of Nontarget Lesions
Complete Response:  Disappearance of all nontarget lesions and normalization of tumor marker 
level.  All lymph nodes must be non-pathological or normal in size (<10mm short axis).

I5B-MC-JGDJ(d) Clinical Protocol
Page 101
LY3012207
Non-CR/ non-PD:  Persistence of 1 or more nontarget lesions and/or maintenance of tumor 
marker level above the normal limits.
Progressive Disease:  Unequivocal progression of existing nontarget lesions.  The appearance of 
1 or more new lesions is also considered progression.
Not Evaluable: When a change in method of measurement from baseline occurs and impacts the 
ability to make a reliable evaluation of response.
Evaluation of Best Overall Response
The best overall response is the best response recorded from the start of the study treatment until 
the earliest of objective progression or start of new anticancer therapy, taking into account any 
requirement for confirmation.  The patient’s best overall response assignment will depend on the 
findings of both target and nontarget disease and will also take into consideration the appearance 
of new lesions.  The Best Overall Response will be calculated via an algorithm using the 
assessment responses provided by the investigator over the course of the trial.  
Time Point Response
It is assumed that at each protocol-specified time point, a response assessment occurs.  (When no 
imaging/measurement is done at all at a particular time point, the patient is not evaluable (NE) at 
that time point.)  Table 1 provides a summary of the overall response status calculation at each 
time point for patients who have measurable disease at baseline.
Table 1.
Time Point Response: Patients with Target (Nontarget) Disease
Target Lesions
Non-Target Lesions
New Lesions
Overall Response
CR
CR
No
CR
CR
Non-CR/non-PD
No
PR
CR
Not evaluated
No
PR
PR
Non-PD or not all evaluated
No
PR
SD
Non-PD or not all evaluated
No
SD
Not all evaluated
Non-PD
No
NE
PD
Any
Yes or No
PD
Any
PD
Yes or No
PD
Any
Any
Yes
PD
Abbreviations:  CR = complete response; PR = partial response; SD = stable disease.; PD = progressive disease; 
NE = inevaluable. 
Table 2 is to be used when patients have nonmeasurable disease only.

I5B-MC-JGDJ(d) Clinical Protocol
Page 102
LY3012207
Table 2.
Time Point Response: Patients with Nontarget Disease Only
Nontarget Lesions
New Lesions
Overall Response
CR
No
CR
Non-CR/non-PD
No
Non-CR/non-PDa
Not all evaluated
No
NE
Unequivocal PD
Yes or No
PD
Any
Yes
PD
Abbreviations:  CR = complete response; PD = progressive disease ; NE = inevaluable.
a
non-CR/non-PD is preferred over SD for nontarget disease. 
Frequency of Tumor Re-Evaluation
A baseline tumor evaluation must be performed within 4 weeks before patient begins study 
treatment. Frequency of tumor re-evaluation while on and adapted to treatment should be 
protocol-specific and adapted to the type and schedule of treatment.  In the context of Phase 2 
studies where the beneficial effect therapy is not known, follow-up every 6-8 weeks is 
reasonable.  Normally, all target and non-target sites are evaluated at each assessment using the 
same method.  However, bone scans may need to be repeated only when CR is identified in 
target disease or when progression in bone is suspected.  
Confirmatory Measurement/Duration of Response
Confirmation:
The main goal of confirmation of objective response in clinical trials is to avoid overestimating 
the response rate observed. 
In randomized trial (Phase 2 or 3) or studies where SD or progression is the primary endpoints, 
confirmation of response is not required.  
In the case of SD, follow-up measurements must have met the SD criteria at least once after start 
of treatment at a minimum interval not less than 5 weeks measured from randomization..
Duration of Overall Response
The duration of overall response is measured from the time measurement criteria are first met for 
CR or PR (whichever is first recorded) until the first date that disease is recurrent or objective 
progression is observed (taking as reference for PD the smallest measurements recorded on 
study).
The duration of overall CR is measured from the time measurement criteria are first met for CR 
until the first date that recurrent disease is objectively documented.
Duration of Stable Disease
Stable disease is measured from the start of the treatment (in randomized trials, from date of 
randomization) until the criteria for objective progression are met, taking as reference the 
smallest sum on study (if the baseline sum is the smallest, that is the reference for calculation of 
PD).  

I5B-MC-JGDJ(d) Clinical Protocol
Page 103
LY3012207
Independent Review of Response and Progression
When objective response (CR + PR) is the primary end point, and when key drug development 
decisions are based on the observation of a minimum number of responders, it is recommended 
that all claimed responses be reviewed by an expert(s) independent of the study.  If the study is a 
randomized trial, ideally reviewers should be blinded to treatment assignment.  

I5B-MC-JGDJ(d) Clinical Protocol
Page 104
LY3012207
Attachment 7.
Protocol JGDJ Pharmacokinetic, 
Immunogenicity, and Translational Research Sampling 
Schedule
It is essential that the exact infusion start and stop times (actual clock readings), as well as 
infusion parameters (such as, total dose infused and if intended dose was given) are recorded.  
The exact time of collection of each venous blood sample will be based on the clock used to 
record infusion times.  It is essential that the pharmacokinetic blood samples not be withdrawn 
from the same site as the drug infusion.
For samples collected within the first 24 hours of study drug administration, sample collection 
times may vary ±10% or as specified in the PK sampling schedule.  

I5B-MC-JGDJ(d) Clinical Protocol
Page 105
LY3012207
Pharmacokinetic and Immunogenicity Sampling Schedule
Sample 
Number
Cycle
Day
Sampling Time
Olaratumab/
Placebo PKa
Doxorubicin 
PKb
IGc
IG/PK 
(IRR)d
1
1
1
Predose
X
X
X
2
Within 5 min post olaratumab/placebo infusion
X
3
8
Prior to olaratumab/placebo infusione
X
X
4
Within 5 min post olaratumab/placebo infusion
X
5
2
1
Prior to olaratumab/placebo infusione
X
6
Within 5 min post doxorubicin infusion
X
X
7
8
Prior to olaratumab/placebo infusione
X
X
8
Within 5 min post olaratumab/placebo infusion
X
9
3
1
Prior to olaratumab/placebo infusione
X
X
10
4
1
Prior to olaratumab/placebo infusion
X
X
11
Within 5 min post doxorubicin infusion
X
X
12
8
Prior to olaratumab/placebo infusione
X
13
Within 5 min post olaratumab/placebo infusion
X
14
5
1
Prior to olaratumab/placebo infusione
X
X
15
6
1
Within 5 min post doxorubicin infusion
X
16
7
1
Prior to olaratumab/placebo infusione
X
X
17
8
1
Within 5 min post doxorubicin infusion
X
18
9 and then 
every other 
cycle
1
Prior to olaratumab/placebo infusione
X
X
801
30-day 
follow-up 
visit
--
Anytime
X
X
Abbreviation:  PK = pharmacokinetic; IG = Immunogenicity; IRR = infusion-related reaction.
a
Samples of approximately 3 mL of whole blood will be drawn into plastic tubes without anticoagulant for measurement of 
olaratumab in serum.
b
Samples of approximately 3 mL of whole blood will be drawn into plastic tubes with anticoagulant for measurement of 
doxorubicin in plasma.
c
For the immunogenicity assay, approximately 6 mL of whole blood will be drawn into plastic tubes without anticoagulant to 
generate serum samples.
d
For any unscheduled blood draws due to IRRs, approximately 4 mL of whole blood will be drawn into plastic tubes without 
anticoagulant to generate serum samples. If a patient experiences an IRR to olaratumab/placebo, blood samples for 
immunogenicity and PK analysis will be taken at the following time points:  (1) as soon as possible after the onset of the IRR, 
(2) at the resolution of the IRR, and (3) 30 days (±3 days) after the IRR.
e
Pretreatment PK samples may be collected up to 60 minutes prior to the olaratumab infusion and must be prior to 
administering any premedication.
Translational Research Sampling Schedule
Sample 
Number
Cycle
Day
Sampling Time
Plasma for 
Biomarkersa
Whole 
bloodb
Tumor 
Tissuec
1
1
1
Predose
X
X
X
10
3
1
Prior to olaratumab/placebo infusiond
X
801
30-day follow-up 
visit
Anytime
X
a
Refer to Section 10.4.2.1 for details on whole blood for plasma collection.
b
Refer to Section 10.4.2.2 for details on whole blood for DNA collection.  It is highly recommended to draw the whole blood 
sample prior to the first dose (Cycle 1 Day 1 at predose); however, it can be collected later during the study if necessary.
c
Refer to Section 10.4.2.3 for details on tumor tissue collection.
d
Pretreatment samples may be collected up to 60 minutes prior to the olaratumab infusion.

I5B-MC-JGDJ(d) Clinical Protocol
Page 106
LY3012207
Attachment 8.
Protocol JGDJ CYP3A4, CYP2D6, and 
P-gp Inhibitors and Inducers of Doxorubicin
CYP3A4 Inducers
Strong CYP3A4 Inhibitors
Moderate CYP3A4 Inhibitors
Aminoglutethimide
Clarithromycin 
Amiodarone
Bosentan
Chloramphenicol
Amprenavir
Carbamazepine
Cobicistat 
Aprepitanta
Efavirenz (in liver only)
Conivaptan
Atazanavir
Fosphenytoin 
Cremophor EL
Cimetidine
Nafcillin
Cyclosporine 
Ciprofloxacin
Nevirapine
Delavirdine
Clotrimazole
Oxcarbazepine
Diclofenac
Darunavir
Pentobarbital
Diltiazem 
Darunavir and ritonavir
Phenobarbital
Elvitegravir and ritonavir
Desipramine
Phenytoin
Enoxacin
Doxycycline
Primidone
Fosamprenavir
Dronedarone
Rifabutin
Grapefruit juice, starfruit, Seville orange
Efavirenz
Rifampin
Indinavir
Erythromycin
Rifapentine
Indinavir and ritonavir
FK1706
St. John's wort
Itraconazole 
Fluconazole 
Ketoconazole 
Fluvoxamine
Lopinavir and ritonavir
Haloperidol
Mibefradil
Imatinib
Miconazole
Metronidazole
Nefazodone  
Norfloxacin
Nelfinavir 
Protease inhibitors
Nicardipine
Quinidine
Posaconazole 
Schisandra sphenanthera extract
Quinidine
Sertraline
Ritonavir 
Tetracycline
Saquinavir 
Tofisopam
Telithromycin
Verapamil
Theophylline 
Troleandomycin 
Voriconazole 
a
Aprepitant is allowed when given according to local practice and institutional guidelines and if no alternative
anti-emetic is recommended.

I5B-MC-JGDJ(d) Clinical Protocol
Page 107
LY3012207
CYP2D6 Inducers
CYP2D6 Inhibitors
P-glycoprotein 1 (P-gp) Inhibitors
Rifampin
Amiodarone
Amiodarone
Celecoxib
Azithromycin
Chloroquine
Captopril
Chlorpromazine
Clarithromycin
Cimetidine
Cyclosporine
Citalopram
Piperine
Clomipramine
Quercetin
Codeine
Quinidine
Deiavirdine
Quinine
Desipramine
Reserpine
Dextroprpoxyphene
Ritonavir
Diltiazem
Tariquidar
Doxorubicin
Verapamil
Entacapone (high dose)
Fluoxetine
Fluphenazine
Fluvaxamine
Haloperidol
Labetalol
Lobeline
Lomustine
Methadone
Mibefradil
Moclobemide
Nortuloxeline
Paroxetine
Perphenazine
Propafenone
Quinacrine
Quinidine
Ranitadine (ranitidine, Zantac)
Risperidone (weak)
Ritonavir
Serindole
Sertraline (weak)
Thioridazine
Valproic acid
Venlafaxine (weak)
Vinblastine
Vincristine
Vinorelbine
Yohimbine

I5B-MC-JGDJ(d) Clinical Protocol
Page 108
LY3012207
Attachment 9.
Protocol JGDJ Amendment (d) Summary
A Randomized, Double-Blind, Placebo-Controlled, Phase 
3 Trial of Doxorubicin plus Olaratumab versus 
Doxorubicin plus Placebo in Patients with Advanced or 
Metastatic Soft Tissue Sarcoma
Overview
Protocol I5B-MC-JGDJ, A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of 
Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or 
Metastatic Soft Tissue Sarcoma, has been amended.  The new protocol is indicated by 
Amendment (d) and will be used to conduct the study in place of any preceding version of the 
protocol.
The overall changes and rationale for the changes made to this protocol are as follows:
1) Inclusion criterion [10] was updated to allow patients receiving anticoagulants to 
participate in the study.
2) Inclusion criterion [13] was updated to be consistent with the doxorubicin prescribing 
information.
3) Long-term follow-up for survival and patient reported outcomes were updated so that the 
collection of this information is concurrent with the collection of ECG data during long-
term follow-up.
4) Dosing information was clarified for those instances where infusion times at the maximal 
rate is longer than 60 minutes.
5) Clarification of dose delays, modifications, and discontinuations based on hemoglobin 
levels and nonhematologic toxicity have been made.
6) The method of reporting infusion-related reactions was clarified.
7) The language for the efficacy interim analysis has been updated to state that only the 
IDMC and regulatory authorities will have access to the unblinded results.  Therefore, 
there will be no alpha-spending associated with this interim analysis.
8) Urine analysis (UA) has been removed from the beginning of each cycle, since it is no 
longer needed in this setting. Previously, primary purpose for the UA was to determine 
the presence of significant proteinuria. Proteinuria as a side effect is no longer 
considered to be related to olaratumab. Urine Analysis will continue to be obtained at 
baseline and at V801 including urine protein studies if needed.
9) Language added to allow use of urine protein creatinine ratio or a 24-hour urine protein 
excretion.  Urine protein creatinine ratio of spot urine is an estimation of the 24-hour 
urine protein excretion – a UPC ratio of 1 is roughly equivalent to a 24-hour urine protein 
of 1000 mg.  UPC ratio is calculated using one of the following formulae:
a)
[urine protein]/[urine creatinine] – if both protein and creatinine are reported in 
mg/dL

I5B-MC-JGDJ(d) Clinical Protocol
Page 109
LY3012207
b) [(urine protein) x 0.088]/[urine creatinine] – if urine creatinine is reported in mmol/L.  
The spot urine test has been preferred by some investigators rather than the 24-hour 
urine collection.
10) Other edits for clarity and consistency were made.

I5B-MC-JGDJ(d) Clinical Protocol
Page 110
LY3012207
Revised Protocol Sections
Note:
Deletions have been identified by strikethroughs.
Additions have been identified by the use of underscore.
2. Synopsis
Clinical Protocol Synopsis:  Study I5B-MC-JGDJ
Criteria for Evaluation:
Patient-Reported Outcomes (PROs):  Pain will be assessed with the Brief Pain Inventory Short Form Modified 
[mBPI-sf], HRQoL will be assessed with The European Organization for Research and Treatment of Cancer Quality 
of Life Questionnaire Core 30 version 3.0 [EORTC QLQ-C30] and health state will be assessed with the 
EuroQol 5-Dimension 5-Level [EQ-5D-5L].  Patients will complete the instruments on Day 1 of every cycle and at 
the 30-day short-term follow-up visit.  A full due diligence will be taken to collect PRO measures during long-term 
follow-up (every 6 weeks [±7 days] until PD, thereafter every 32 months [±2 weeks7 days] for the first 2 years, then 
every 6 months [±2 weeks14 days] the second year, then annually [±2 weeks] thereafter until the patient’s death or 
overall study completion).
Statistical Methods:
The primary objective of this study is to compare doxorubicin plus olaratumab (investigational arm) versus 
doxorubicin plus placebo (control arm) with respect to OS in 2 populations:
(1)
Patients with advanced or metastatic STS not amenable to treatment with surgery or radiotherapy with 
curative intent (referred to below as the ITT population)
(2)
Patients with advanced or metastatic LMS not amenable to treatment with surgery or radiotherapy with 
curative intent
The study will be considered positive if either the ITT or LMS populations (or both) show a statistically significant 
improvement in OS.
Investigative sites will screen approximately 600 patients to enroll 460 patients in 1:1 randomization (230 patients in 
the investigational arm and 230 patients in the control arm).  Enrollment will be conducted so that approximately 
200 patients with LMS and 260 patients with other (non-leiomyosarcoma) histology will be randomized.  The final 
analysis will occur only after both a minimum of 131 OS events have been observed in randomized patients with 
LMS, and a minimum of 322 OS events have been observed in randomized patients overall.
The statistical analysis will be conducted using a statistical testing plan according to the graphical method of Maurer 
and Bretz (2013).  Under this testing scheme, the primary analysis for OS can be tested in both the LMS population 
and in the full ITT population, splitting and sharing alpha so as to control the family-wise type 1 error rate across 
these 2 populations, across interim and final analyses, and also across a prespecified sequence of endpoints (OS and 
selected secondary endpoints).
The Lan-DeMets form of the O’Brien-Fleming alpha-spending function will be applied for OS and each selected 
secondary endpoint.
The final total of 131 OS events in the LMS population provides 80% statistical power for a one-sided log-rank test 
at a 0.005 alpha level, assuming the true OS hazard ratio (HR) in LMS patients is 0.55.
The final total of 322 OS events in the ITT population provides 80% statistical power for a one-sided log-rank test at 
a 0.02 significance level, assuming the true OS HR in STS patients is 0.723.
An interim efficacy analysis for OS is planned after 194 OS events (60% of the final OS events) have been observed
in the ITT population.  Time to event analyses at the interim and final analysis time points will be based on the 
stratified log-rank test, stratified by the randomization strata:  number of prior systemic therapies for 
advanced/metastatic disease (0 versus ≥1), histological tumor type (leiomyosarcoma versus liposarcoma versus 
undifferentiated pleomorphic versus other STS types), and ECOG PS (0 versus 1).  The exact testing boundaries will
depend on the exact number of events and will be determined using an O’Brien-Fleming alpha spending function.  
OS survival curves, the median with 95% CI and survival rates at various time points for each treatment group will 
be estimated using Kaplan-Meier method (Kaplan and Meier 1958).  The HR will be estimated using a stratified Cox 

I5B-MC-JGDJ(d) Clinical Protocol
Page 111
LY3012207
regression model, stratified by randomization strata).  All randomized patients, according to the ITT principle, will 
be included in the analysis of this endpoint.
The interim analysis will be performed by an independent Data Monitoring Committee (iDMC).  The iDMC Charter 
(a separate document) will provide detailed guidance for the conduct of the interim analysis and describe the process 
for recommending changes to the trial in the event that interim OS results are statistically significant.  In the event of 
a statistically significant interim result for OS, investigative sites will be informed that the study has met its primary 
objective and thus confirmed the efficacy of olaratumab in combination with doxorubicin.  It is recommended that 
any patients currently receiving study treatment at the time of a positive interim result should continue his/her study 
treatment as originally planned.
5.4.
Rationale for Amendments
5.4.1. Rationale for Amendment (a)
The rationale for amendment (a) was based on feedback received from global regulatory 
authorities and compliance with local regulatory requirements for submissions.  Major changes 
for amendment (a) included the following:  

Leiomyosarcoma (LMS) was added as a specific population to be tested within the 
primary objective, and is now co-primary with the STS (ITT) population.

Pleomorphic was added to the stratifications factors

Due to regional/institutional differences dexrazoxane dosing was modified

PFS2 was added to the efficacy endpoints

Cardiovascular monitoring was increased

Gatekeeping methods have been included for OS, PFS, ORR, and DoR

Grade 1 liposarcoma patients are now included under certain conditions

The olaratumab dosing regimen was modified

Management of infusion-related reactions was modified

Single interim analysis will be performed based on 60% of overall OS events (194) in the 
ITT population and 72 events from the LMS

Analysis of OS will be based on the stratified log-rank test analyzed by the randomization 
strata, excluding region.
5.4.2. Rationale for Amendment (b)
The rationale for amendment (b) was based on global regulatory authority feedback, regulatory 
guidance and compliance with local regulatory requirements for submissions.  Additional 
changes were made by the sponsor to address issues of subject safety and to improve the 
efficiency of study implementation and conduct.  Major changes for amendment (b) included the 
following:  

Exclusion criteria were deleted

Grade 4 nonhematologic toxicity as related to study therapy is now considered a basis for 
study drug discontinuation

Duration of Response was deleted from secondary objectives.

O’Brien-Fleming alpha spending will now be used for all efficacy boundaries

bisphosphonate osteoclast inhibitors are now allowed, denosumab is still not permited.

I5B-MC-JGDJ(d) Clinical Protocol
Page 112
LY3012207
5.4.3. Rationale for Amendment (c)
The rationale for amendment (c) was based on global regulatory authority feedback, regulatory 
guidance and compliance with local regulatory requirements for submissions.  Additional 
changes were made by the sponsor to address issues of subject safety and to improve the 
efficiency of study implementation and conduct.  Major changes for amendment (c) included the 
following:  

Germany was directed to refer to Addendum (7)
5.4.4. Rationale for Amendment (d)
The rationale for amendment (d) was to increase subject safety and to improve the efficiency of 
study implementation and conduct.  Major changes for amendment (d) included the following:  

Patients receiving anticoagulants are now eligible to participate

Long-term follow-up for survival and patient reported outcome collection were updated 
so that these events are concurrent with the collection of ECG data

Efficacy interim stopping rules were removed from the protocol plan, as the intention is 
to continue the study until the final analysis with the sponsor remaining blinded to 
aggregate data by study arm until the final analysis.

Urine protein creatinine ratio of spot urine can now be used in place of 24-hour urine 
protein excretion
See Attachment 9 for more details.
7.1 Inclusion Criteria
[10] The patient has adequate hematologic, organ, and coagulation function within 2 weeks 
(14 days) prior to randomization:

Absolute neutrophil count (ANC) ≥1.5 x 109/L.  Granulocyte colony-stimulating 
factor (G-CSF) cannot be administered within 2 weeks (14 days) prior to 
randomization.

Platelet count ≥100 x 109/L

Hemoglobin ≥9.0 g/dL.  No transfusions are allowed within 2 weeks (14 days) 
prior to randomization.

The creatinine clearance is ≥45 mL/min (refer to Attachment 5 for the 
Cockcroft-Gault formula)

Proteinuria ≤1000 mg in 24 hours (if routine urinalysis indicates ≥2+ proteinuria)

Total bilirubin below upper limit of normal (ULN) (except for patients with 
Gilbert’s Syndrome, who must have a total bilirubin <3 mg/dL)

Alanine aminotransferase/aspartate aminotransferase (AST/ALT) ≤3.0 × ULN; if 
the liver has tumor involvement, AST and ALT ≤5.0 × ULN are acceptable.

I5B-MC-JGDJ(d) Clinical Protocol
Page 113
LY3012207

The patient has an adequate coagulation function as defined by International 
Normalized Ratio (INR) or prothrombin time (PT) ≤1.5 x ULN, and partial 
thromboplastin time (PTT or aPTT) ≤1.5 x ULN if not receiving anticoagulation 
therapy. For patients receiving anticoagulants, exceptions to these coagulation 
parameters are allowed if they are within the intended or expected range for their 
therapeutic use. Patients must have no history of active bleeding (defined as 
within 14 days of first dose of study drug) or pathological condition that carries a 
high risk of bleeding (for example, tumor involving major vessels or known 
esophageal varices).
[13] Females of child-bearing potential and males and must agree to use highly effective 
contraceptive precautions during the trial and up to 63 months following the last dose 
of study drug.  A highly effective method of birth control is defined as one that results 
in a low failure rate (that is, <1% per year) when used consistently and correctly, such 
as implants, injectables, combined oral contraceptives, some intrauterine contraceptive 
devices (IUDs), sexual abstinence, or a vasectomized partner.
7.2 Exclusion Criteria
[29] The patient has a known investigator-assessed active fungal, bacterial, or viral infection 
including human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis 
(screening is not required).  
8.1 Summary of Study Design
Terms used to describe the periods during the study are defined below:

Baseline:  begins when the ICF is signed (study entry) and ends at the first study 
treatment (or at discontinuation, if no treatment is given).

Study Period:  begins at the first study treatment and ends at study completion.
o
Study Treatment Period:  begins at the first study treatment and ends when the 
patient and the investigator agree that the patient will no longer continue study 
treatment.  The date of this agreement is to be reported on the electronic case 
report form (eCRF) as the Date of Discontinuation from study treatment.
o
Post discontinuation Follow-Up:  begins the day after the patient and the 
investigator agree that the patient will no longer continue study treatment.

Short-term follow-up begins the day after the patient and the investigator 
agree that the patient will no longer continue study treatment and lasts 
approximately 30 days (±7 days).  The short-term follow-up visit occurs at 
or near the end of the short-term follow-up period (±7 days).

Long-term follow-up begins the day after short-term follow-up is 
completed.
Follow-up for progression - Patients that discontinue study 
treatment for reasons other than progression will be assessed for 
progression every 6 weeks (±7 days) until PD.

I5B-MC-JGDJ(d) Clinical Protocol
Page 114
LY3012207
Follow-up for survival - Patients will be followed every 23 months 
(±2 weeks7 days) for the first 2 years, then every 6 months (±2 
weeks14 days) the second year, then annually [±2 weeks] 
thereafter until the patient’s death or overall study completion.

Continued Access Period:  begins after study completion and ends at the end of trial.  
During the continued access period, patients on study treatment who continue to 
experience clinical benefit and no undue risks may continue to receive olaratumab 
treatment until one of the criteria for discontinuation is met.  The continued access period 
includes continued access follow-up.  Refer to Section 8.1.4 for more details.
o
Continued access follow-up:  begins the day after the patient and the investigator 
agree that the patient will no longer continue treatment in the continued access 
period and lasts approximately 30 days (±7 days).  The continued access 
follow-up visit occurs at or near the end of the continued access follow-up period.
9.2.1. Olaratumab/Placebo
Please refer to the pharmacy manual for olaratumab/placebo dosing solution for infusion.
Prepared Olaratumab/Placebo Dosing Solution for Infusion:  Chemical and physical in-use 
stability for the prepared olaratumab/placebo dosing solution has been demonstrated for up to 
24 hours below 25ºC (77ºF) in the concentration range of 1.2 mg/mL to 6.4 mg/mL.  It is 
recommended that the prepared dosing solution be used immediately in order to minimize the 
risk of microbial contamination.  If not used immediately, the prepared olaratumab/placebo 
dosing solution must be stored under refrigeration at 2ºC to 8ºC (36ºF-46ºF) for duration not to 
exceed 24 hours.  If the prepared solution is held at room temperature (below 25ºC [77ºF]), it 
must be used within 8 hours.  Do not freeze and/or shake prepared olaratumab/placebo dosing 
solution for infusion.
Aseptic technique is to be used when preparing and handling olaratumab/placebo.  Patients are to 
receive loading dose of 20 mg/kg on Days 1 and 8 in Cycle 1, followed by 15 mg/kg of 
olaratumab/placebo on Days 1 and 8 of each 21-day in subsequent treatment cycle administered 
as an IV infusion.  On the days that both olaratumab/placebo and doxorubicin (or doxorubicin 
with dexrazoxane) are administered, olaratumab/placebo will be administered prior to 
doxorubicin (or dexrazoxane with doxorubicin).  The dose of olaratumab/placebo is dependent 
upon the patient’s body weight.  Actual body weight will be used for dose calculation.  
Subsequent doses of olaratumab/placebo must be recalculated if there is a 10% change 
(increase or decrease) in body weight; subsequent doses may also be recalculated if there is a 
<10% change in body weight from prior dose and it is considered clinically relevant by the 
treating investigator.
Olaratumab/placebo is compatible with commonly used infusion containers.  Refer to the IB or 
pharmacy manual for detailed information.
Olaratumab concentration of below 1.2 mg/ml in prepared dose should be avoided due to 
dilution of excipients, which are important in maintaining stability.

I5B-MC-JGDJ(d) Clinical Protocol
Page 115
LY3012207
The dose of olaratumab/placebo will be aseptically withdrawn from the vial and transferred to a 
sterile infusion bag or an evacuated glass container.    To prepare the dose, a sufficient quantity 
of sterile normal saline (0.9% weight/volume) solution should be added (or removed in the case 
of a prefilled container such as AVIVA) to make the total volume 250 mL.  The container should 
be gently inverted to ensure adequate mixing.
In some cases, the volume of infusion solution required may exceed the 250 mL scenario 
described here to keep the infusion solution concentration within the desired range stated 
above. This situation may be more likely with the required loading dose of 20 mg/kg given in 
Cycle 1, but may also apply to any subsequent cycle depending on the patient’s body weight. In 
case of dose volumes 250 mL, an empty 500-mL container of acceptable material of 
construction can be used without addition of any normal saline.  A pre-filled container (filled 
with 0.9% normal saline) of 250 mL size can be used as long as the material of construction is 
acceptable and the concentration of olaratumab in prepared dose remains within 1.2 mg/mL to 
6.4 mg/mL.
The dose should be infused over approximately 60 minutes.  The infusion rate should not exceed 
25 mg/min.  Infusion durations longer than 60 minutes are permitted in specific circumstances 
(that is, for patients with higher body weight for whom the upper limit of infusion rate is limited 
or in the setting of prior olaratumab/placebo Grade 1-2 IRR); the infusion duration must always 
be accurately recorded.
The infusion set must be flushed immediately postinfusion of dose with sterile normal saline to 
ensure delivery of the calculated dose.
9.4.1.1. Dose Delays, Modifications, and Discontinuations
After treatment has been initiated, in order to start the next cycle the following criteria must be 
fulfilled:

ANC ≥1.0 × 103/µL (1000/µL; ≥1.0 × 109/L) 
Note that in order to administer single-agent olaratumab/placebo on Day 8, ANC must be 
750/µL; 0.75 × 109/L.  If the ANC is 750/µL, the Day 8 administration of 
olaratumab/placebo may be delayed for a maximum of 7 days.  If the ANC level has not 
increased to 750/µL within 7 days, then the Day 8 olaratumab/placebo dose in that cycle 
should be skipped and dosing resumed on Day 1 of the following cycle if criteria for 
dosing are met.  If all dosing criteria are met, a delay or omission of the Day 8 
olaratumab/placebo dose should not result in a delay of the Day 1 olaratumab/placebo 
dose of the following cycle. 

Platelets ≥100 × 103/µL (100,000/µL; ≥100 × 109/L)

Hemoglobin ≥89 g/dL

Creatinine clearance ≥45 mL/min (refer to Attachment 5 for the Cockcroft-Gault 
formula)

Proteinuria ≤1000 mg in 24 hours (if routine urinalysis indicates ≥2+ proteinuria)

I5B-MC-JGDJ(d) Clinical Protocol
Page 116
LY3012207

Total bilirubin below ULN.  In patients with Gilbert’s syndrome, total bilirubin should be 
3 mg/dL. 

AST and ALT ≤3.0 x ULN, or ≤5 x ULN if the transaminase elevation is due to liver 
metastases

Nonhematologic toxicityOlaratumab/Placebo related AE’s that are NCI-CTCAE, v4.0 
Grade <2 or equivalent severity to baseline must be less than Grade 2, except for those 
not deemed clinically significant by the investigator, or electrolyte abnormalities (for 
example, potassium, magnesium, phosphate).
9.4.1.1.1.1. Infusion Related Reactions
Symptoms occurring during or following infusion of investigational therapy may also be defined 
according to AE categories such as allergic reaction, anaphylaxis, or cytokine release syndrome 
(NCI-CTCAE version 4.0 section “Immune system disorders”). In the setting of symptoms or 
signs occurring during or following infusion of investigational therapy, investigators are 
encouraged to use the AE terms that best describe the event, “infusion-related reaction” and 
mark “yes” or “no” for hypersensitivity/IRR event flagany additional terms (including those not 
listed here) that best describe the event.
9.4.1.1.1.2. Hematologic Toxicity
Table JGDJ.2.
General Guidelines for Olaratumab/Placebo Dose Modification Due 
To Hematologic Toxicity Deemed Related To Olaratumab/Placebo
Toxicity
Required Dose Modification
Neutropenia
  ANC Grade 1-3
No dose modification required
  ANC <500 cells/µL (Grade 4)
No treatment administered; treatment cycle delayed
  At retreatment:
  If  ≥Grade 3 neutropenic fever/infection has 
occurred
Withhold dose until ANC is 1000 cells/uL or higher; 
reduce dose to 12 mg/kg (15 mg/kg if toxicity occurs 
during Cycle 1).
  If Grade 4 neutropenia lasting longer than 1 week 
has occurred
Withhold dose until ANC is 1000 cells/uL or higher; 
reduce dose to 12mg/kg (15 mg/kg if toxicity occurs 
during Cycle 1).
  Grade 4 ANC without fever/infection
Retreatment with olaratumab/placebo at full dose at 
investigator’s discretion with recommended use of 
prophylactic G-CSFs
  Second incidence of either:  
  1) ≥Grade 3 neutropenic fever/infection
  2) Grade 4 neutropenia lasting longer than 1 week
Second dose reduction to 10 mg/kg
Thrombocytopenia
  Platelets <100,000 cells/µL 
No treatment administered; treatment delayed until 
resolved to ≥100,000 cells/ µL
Anemia

I5B-MC-JGDJ(d) Clinical Protocol
Page 117
LY3012207
  Hemoglobin <89 gm/dL 
No treatment administered; treatment delayed until 
resolved to ≥8 gm/dL≤Grade 1
Abbreviations:  ANC = absolute neutrophil count; G-CSFs = granulocyte colony-stimulating factors.
10.2. Patient-Reported Outcomes/Resource Utilization
Patient-reported pain will be assessed using the mBPI-sf (Cleeland et al. 1991).  Health related 
Quality of Life will be assessed with the EORTC QLQ-C30 (Aaronson et al. 1993).  Health 
status will be assessed using the EQ-5D-5L (Janssen et al. 2008).  The PRO measures will be 
collected on Day 1 of every cycle and at the 30-day short term follow-up visit.  A full due 
diligence will be taken to collect PRO measures during long-term follow-up (every 6 weeks 
[±7 days] until PD, thereafter every 23 months [±2 weeks7 days] for the first 2 years, then every 
6 months [±2 weeks14 days] the second year, then annually [±2 weeks] thereafter until the 
patient’s death or overall study completion).
12.1. Determination of Sample Size
AnThere is one interim analysis is for efficacy planned for this study.  This analysis will be 
performed in order to provide the IDMC and regulatory authorities an opportunity to review 
interim safety and efficacy data together.  There will be no formal statistical hypotheses tested at 
the interim for primary and secondary efficacy outcomes.  There will be no alpha-spending 
associated with the interim analysis; study follow-up and data collection will continue as planned 
until the final analysis regardless of the nature of the interim efficacy results.  Only the IDMC 
and regulatory authorities will be allowed access to unblinded interim data. The hypothesis has 
its own alpha-spending function. The Lan-DeMets form of the O’Brien-Fleming alpha-spending 
function will be used in testing each of the hypotheses. This A single interim efficacy analysis is
planned to occur after 194 OS events (60% of the final OS events) have been observed in the ITT 
population.  Planned timing and approximate nominal significance levels based on the initial 
graph and corresponding approximate OS HR boundaries for the  interim analysis and the final 
analysis are as follows (using EAST® 6.3):

Interim analysis:
o
ITT population:  194 events, one-sided alpha = 0.00267, corresponding 
approximately to an HR < 0.669
o
LMS population: 72 events, one-sided alpha = 0.00015, corresponding 
approximately to an HR < 0.427

Final Analysis:
o
ITT population:  322 events, one-sided alpha = 0.01915, corresponding 
approximately to an HR < 0.794
o
LMS population:  131 events, one-sided alpha = 0.00495, corresponding 
approximately to an HR < 0.637
The number of events shown above for the LMS population at the interim analysis is an 
estimated value, not a required number for performing the analysis.  However, the final analysis 
will occur only after 131 LMS OS events and 322 ITT OS events have been observed.

I5B-MC-JGDJ(d) Clinical Protocol
Page 118
LY3012207
12.2.6. Primary Outcome and Methodology
A single interim analysis is planned for efficacy as described in Section 12.1.  The interim 
analysis boundaries and nominal alpha levels will be calculated at the time of conducting interim 
and final analyses, with efficacy boundaries and alpha values following O’Brien-Fleming alpha-
spending functions. The boundaries presented in Section 12.1 are approximate; actual boundaries 
will depend on the exact timing of the analyses.
12.2.13. Interim Analysis
A limited number of pre-identified individuals may gain access to the limited unblinded data, as 
specified in the unblinding plan, prior to an interim or final database lock, in order to initiate the 
final population pharmacokinetic/pharmacodynamic model development processes for interim or 
final analyses.  Information that may unblind the study during the analyses will not be reported 
to study sites or blinded study team until the study has been unblinded.
An independent data monitoring committee (iDMC) will be established to conduct safety 
reviews.  The membership, roles, and responsibilities of the iDMC are defined in the iDMC 
Charter (that is, a separate iDMC charter document).
There will be no prespecified rules for stopping or modifying the trial due to safety concerns.  
The iDMC members will review unblinded interim safety data to determine whether there are 
sufficient safety concerns to justify modifying the study or the termination of study treatment 
and/or enrollment.
Only the iDMC is authorized to evaluate unblinded safety analyses.  Study sites will receive 
information about interim results ONLY if they need to know for the safety of their patients.
Unblinding details are provided in the blinding section of the protocol (Section 9.5).
The iDMC safety reviews will be performed for all randomized patients.  The first iDMC 
meeting to review interim data will occur when approximately 80 patients (approximately 
40 patients from each arm) have received 2 cycles of treatment or discontinued all study 
treatment due to any reasons prior to Day 8 in Cycle 2.  Subsequent iDMC meetings will occur 
approximately every 6 months thereafter.  Enrollment and treatment will continue during the 
iDMC safety assessments.  In the event a safety signal is detected, additional meetings may 
occur as needed.  Details as to the process and communication plan will be provided in the 
iDMC Charter.
Interim PK analyses of the approximately 80 patients (approximately 40 patients from each arm) 
that will accompany the iDMC safety review will be performed by a Lilly PK scientist
independent from the study team.  These data will be provided to the iDMC upon request.
Interim efficacy analysis will be performed by an theiDMC as described in Section 12.1. The 
iDMC Charter (a separate document) will provide detailed guidance for the conduct of the 
interim analyses. and describe the process for recommending changes to the trial in the event 
that interim OS results are statistically significant.  In the event of a statistically significant 
interim result for OS according to the specifications of Section 12.2.1 and the iDMC Charter, 

I5B-MC-JGDJ(d) Clinical Protocol
Page 119
LY3012207
investigative sites will be informed that the study has met its primary objective and thus 
confirmed the efficacy of olaratumab in combination with doxorubicin.  It is recommended that 
any patients currently receiving study treatment at the time of a positive interim result should 
continue his/her study treatment as originally planned.  This recommendation is appropriate 
given that any positive interim result will not support the use of olaratumab in patients who have 
(currently or previously) received treatment with single-agent doxorubicin. 

I5B-MC-JGDJ(d) Clinical Protocol 
Page 120 
LY3012207 
Attachment 1. Protocol JGDJ Study Schedule 
Study Schedule, Protocol I5B-MC-JGDJ 
Perform procedures as indicated. 
Baseline Schedule 
 
 
Study Period 
Baseline 
 
 
 
Cycle 
BL
 
 
 
Visit 
0
 
 
 
Duration 
Up to 14 days 
(except where noted) 
 
 
 
Relative Day from Randomization 
≤14
≤7
 
Procedure 
Category 
Protocol 
Sections 
Procedure 
 
Comments 
 
 
 
 
 
 
 
Lab/ 
Diagnostic 
Tests 
Att.2 
Urinalysis  
X 
Screening evaluations done within 7 days prior to randomization do not have to be 
repeated.  Includes a routine urinalysis (UA), and if clinically indicated a 
microscopic analysis.  If routine analysis indicates ≥2+ proteinuria, then a 24-hour 
urine must be collected and must demonstrate ≤1000 mg of protein in 24 hours or 
a urine protein/creatinine ratio must be ≤1 in a spot urine test, prior to proceeding 
to treatment..  
Efficacy 
Assessment 
8.1.1 
10.1.1 
Att. 6 
Imaging Studies (CT/MRI) 
Tumor Assessments (according to RECIST v1.1) 
X (within 28 days 
of randomization) 
Within 28 days prior to randomization (refer to Section 10.1.1 and Section 8.1.1 
for details). 
 
 
 

I5B-MC-JGDJ(d) Clinical Protocol
Page 121
LY3012207
Treatment Period Schedule
Study Period
Treatment Period
Cycle (21-day cycle ± 3 days)
1-8
9+
Relative Day within Cycle 
(± 3 days)
1a
8a
1a
8a
Procedure 
Category
Protocol 
Section
Procedure
Comments
Physical 
Examination
10.3.1
Vital signs
X
X
X
X
Vital signs include blood pressure, pulse, and temperature.
During the Observation Period (initial 2 cycles), collect vital signs 3 
times: 1) within 15 minutes (+5 minutes) prior to olaratumab/placebo 
infusion, 2) within 1 hour (+5 minutes) after completion of the 
olaratumab/placebo infusion, and 3) within 1 hour (+5 minutes) after 
completion of the doxorubicin infusion if applicable.  
Thereafter (Cycles 3+), obtain vital signs 2 times: 1) within 15 minutes 
(+5 minutes) prior to olaratumab/placebo infusion and 2) within 1 hour 
(+5 minutes) after completion of the doxorubicin infusion if applicable.
Lab/
Diagnostic Tests
Att.2
Coagulation Profile 
X
X
Laboratory assessments may be done within 3 days prior to Perform on 
D1 every other cycle or as clinically indicated.  See Attachment 2 for 
details.
Att.2
Urinalysis
X
X
Laboratory assessments may be done within 3 days prior to D1 of every 
other cycle or as clinically indicated.  Includes a routine urinalysis (UA), 
and if clinically indicated a microscopic analysis.  If routine analysis 
indicates 2+ proteinuria, then a 24-hour urine must be collected and 
must demonstrate ≤1000 mg of protein in 24 hours (up to 3 business days 
is allowed if the weekend).
Efficacy
Assessment
8.1.1
10.1.1
Att. 6
Imaging Studies (CT/MRI)
Tumor Assessments (according to 
RECIST v1.1)
X
X
Imaging studies and tumor assessments are be obtained every 6 weeks 
(±7 days), irrespective of treatment cycles as calculated from 
randomization, until documented progression for patients with CR, PR, 
or SD, and/or for patients who have discontinued study treatment due to 
toxicity or reasons other than PD.  Refer to Section 10.1.1 and Section 
8.1.1 for details.

I5B-MC-JGDJ(d) Clinical Protocol
Page 122
LY3012207
Study Schedule, Protocol I5B-MC-JGDJ
Perform procedures as indicated.
Post-Treatment Discontinuation Schedule
Study Period
Post-discontinuation Follow-Up
Short-Term Follow-Up
Long-Term Follow-Up
Visit
801
802-8XX
Duration
30 ± 7 days
See footnote for duration
Procedure 
Category
Protocol 
Section
Procedure
Comments
Lab/
Diagnostic 
Tests
Att.2
Urinalysis
X
Includes a routine urinalysis (UA), and if clinically indicated a microscopic 
analysis.  If urine dipstick or routine analysis indicates proteinuria ≥2+, a 
24-hour urine collection or urine protein/creatinine ration in spot urine test (to 
assess protein) must be obtained.
Health 
Outcomes
10.2
PRO Assessments (mBPI-sf, 
EORTC QLQ C30, EQ-5D-
5L)
X
X
The Patient Reported Outcome (PRO) measures will be collected at the 30-day 
short term follow-up visit.
A full due diligence will be taken to collect PRO measures during long-term 
follow-up (every 6 weeks [±7 days] until PD, thereafter every 32 months [±2 
weeks7 days] for the first 2 years, then every 6 months (±2 weeks14 days) the 
second year, then annually [±2 weeks] thereafter until the patient’s death or 
overall study completion).
Attachment 2. Protocol JGDJ Clinical Laboratory Tests
Clinical Laboratory Tests
c
If urinary protein is ≥2+ at evaluations, a 24-hour urine collection (to assess protein) must be collected or urine protein/creatinine ratio in spot urine test must be conducted. and 
must be ≤1000 mg of protein in 24 hours (up to 3 business days is allowed if the weekend). Urine protein creatinine ratio of spot urine is an estimation of the 24-hour urine 
protein excretion – a UPC ratio of 1 is roughly equivalent to a 24-hour urine protein of 1000 mg. UPC ratio is calculated using one of the following formulae:
     A) [urine protein]/[urine creatinine] – if both protein and creatinine are reported in mg/dL
      B) [(urine protein) x 0.088]/[urine creatinine] – if urine creatinine is reported in mmol/L.